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Acute myeloid leukaemia (AML), also known as acute myelogenous leukaemia is a cancer of the 
myeloid line of blood cells, characterized by the rapid proliferation of abnormal myeloid cells 
accumulating in the bone marrow that interfere with normal haematopoiesis. Although AML is a 
relatively rare disease, which accounts for almost 1% of cancer deaths in the United Kingdom and 1.2% 
of cancer deaths in the United States, it is the most common acute leukaemia; primarily affecting adults, 
and its incidence is known to increase with age.  
To date, there is still very little understood about the risk factors for the development of AML beyond 
the onset of old age. However, some key pre-existing haematological disorders such as myelodysplastic 
syndrome (MDS) and myeloproliferative neoplasms (MPN) are now known to have a relatively high 
incidence of developing AML (15-52% and 7% respectively). In recent years, there have been great 
strides made towards understanding some of the major genetic changes that occur in AML. Normal 
haematopoiesis is strictly regulated by the HOX family of transcription factors which have been shown 
to play a key role in the development of cancer when elevated in the normal peripheral blood 
mononuclear cells (PBMCs) of the elderly. Together with its known role as an oncogene in AML, and 
a predictor of survival in this disease, it is suggested that HOXA9 expression in PBMCs could be a 
predictive marker of non-therapy related AML. 
This study suggests that elevated HOXA9 expression is indeed a predictive marker for AML 
development and attempts to shine a light on the progression of AML from pre-leukemic diseases such 
as MDS and MPN as well as offering a possible solution which may be used as a therapeutic drug either 
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1.1 The evolution of cancer  
Cancer is a family of genetic diseases resulting from uncontrolled cell division and tissue invasion 
(metastasis). The inability to regulate cell proliferation and an increase in metastasis is caused by 
alterations in the genome and/or epigenome of cancer cells. Over time, somatically acquired 
abnormalities in DNA sequences can lead to alterations in the cancer cell genome. Somatic mutations 
according to their contribution to cancer development can be divided into driver or passenger mutations. 
Driver mutations possess growth advantages to cancer cells and are often positively selected during the 
evolution of the cancer. These mutations tend to cause clonal expansion of cancer cells. However, 
passenger mutations are present in the cancer genome as a by-product of cancer cell development and 
therefore do not often contribute to the development of cancer, although may be associated with a clonal 
expansion, usually caused by driver mutations (Alberts et al., 2002, Hanahan and Weinberg, 2000, 
Futreal et al., 2001, Stratton et al., 2009, Berdasco and Esteller, 2010).  
There is a growing body of evidence from recent studies of epigenetic mechanisms in cancer that 
highlights evidence supporting the idea that cancer is not solely a consequence of genetic alteration of 
the cancer-critical genes. Cancer cells have a different epigenome compared to their normal cell 
counterparts. For example, hypo-methylation of cancer cells has been one of the first epigenetic 
alterations found in human cancers (Berdasco and Esteller, 2010). The development of cancer is a multi-
step process that requires the accumulation of different mutations during the lifetime of any cancer 
patient. During cancer, cells acquire genetic alterations that progressively transform previously normal 
cells into more malignant ones (Figure 1.1) (Alberts et al., 2002, Hanahan and Weinberg, 2000, Stratton 
et al., 2009). Cancers however, can be classified into various types according to their original cell: 
carcinoma (epithelial cell), glioma (glial brain cell), sarcoma (mesenchymal cell), lymphoma and 
leukaemia (bone marrow and blood cells), mesothelioma (mesothelial cells that cover the peritoneal 
and pleural cavities), choriocarcinoma (placenta), and germinoma (germ cell of the testes or 
ovary)(Alberts et al., 2002).   
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1.2 Cancer critical genes  
These include all genes whose mutations eventually contribute to the tumorigenicity of the cell. Mutated 
genes however are divided into two categories according to their function. Cancer risks arise either from 
the activation or the inactivation of cancer-critical genes. Genes of the first category, where a gain-of-
function mutation may drive a cell towards cancer are also called proto-oncogenes; where their mutant 
forms are known as oncogenes. Genes of the second category, where a loss-of-function mutation 
impacts normal cellular mechanisms, are defined as tumour suppressor genes (Alberts et al., 2002, Frei 
and Antman, 2003).  
 
Figure 1.1 A schematic diagram depicting somatic mutations that occur from a fertilized egg to a single 
cell within a cancer. Mutations accumulate due to the intrinsic mutation rate during normal cell 
division and the formation of mutations due to exogenous mutagens. Passenger mutations may be 
acquired as the cell lineage is phenotypically normal, however, driver mutations cause a clonal 
expansion and resistance to chemotherapy (Stratton et al., 2009).  
 
1.3 Discovery of oncogenes  
In the 1960s research had discovered that some animal cancers were caused by viruses. This led to the 
discovery of the very first oncogene from the Rous Sarcoma Virus (RSV) called v-src (the viral 
oncogenes are called v-oncogenes) in 1970. The studies around the RSV revealed that RSV did not 
require v-src gene for its replication. After this however, studies began to show that v-src was 
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homologous to a host cellular gene (c-src) widely conserved in eukaryotic species. Studies from other 
transforming retroviruses from other species have since then led to the discovery of different retroviral 
oncogenes. These retroviral oncogenes are copies of normal cellular genes, the proto-oncogenes, that 
are captured from the genome of the host through a process known as retroviral transduction (Frei and 
Antman, 2003, Duesberg and Canaani, 1970, Martin, 1970). 
 
1.4 Function of oncogenes  
Proto-oncogenes encode proteins that control cell proliferation or apoptosis. They are activated to 
become oncogenes by alteration of their structure or amplification of genes. The activated oncogenes, 
capable of inducing neoplastic phenotypes, can be divided into six groups based on function and 
biochemical characteristics of the protein products of their normal counterparts (proto-oncogene): 
chromatin remodelers, growth factors, transcription factors, growth factor receptors, signal transducers 
and apoptosis regulators (Frei and Antman, 2003, Croce, 2008). 
 
1.5 Activation of oncogenes 
Oncogenes are activated by specific genetic alterations that generally involve a gain of function. This 
is often mediated through three main genetic mechanisms in human neoplasms: (1) mutation, (2) gene 
amplification, and (3) chromosome rearrangements. Some of these changes may lead to changes in the 
structure of the proto-oncogene or lead to the deregulation of expression (Holland-Frei 2003). Various 
mutations occur, base substitutions, deletions, and insertions for example, activate proto-oncogenes 
through alterations in the structure of their encoded proteins. Alterations, usually impact critical 
regulatory regions of a specific protein and may often enhance the transforming activity of the mutated 
protein (Bishop, 1991). Point mutations in key codons, are frequently detected in the RAS family of 
proto-oncogenes. RAS encodes a specific protein that remains in the active state, leading to a continuous 
signal induction. The signal transduction however, is responsible for inducing continuous cell growth 
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(Rodenhuis and Slebos, 1992). Cancer cells contain several copies of structurally normal oncogenes. 
An increased copy of any of these specific genes due to some genomic changes is called gene 
amplification, initially discovered in tumour cells, which acquires a resistance to anti-growth 
treatments. The process of gene amplification often creates chromosomal abnormalities, double-minute 
chromosomes (DMs) and homogeneously staining regions (HSRs) (Frei and Antman, 2003, Keung et 
al., 1997). High frequency of DMs and HSRs in human tumours suggests the amplification of specific 
proto-oncogenes may be a common occurrence in cancer malignancies. Studies have recently shown 
that three proto-oncogene families including MYC, ERBB, and RAS are often found amplified in many 
human tumours (Keung et al., 1997).  
Chromosomal rearrangements are a lot more common in haematological malignancies than solid 
tumours. Cytogenetic abnormalities consist mainly of chromosomal translocations. Chromosomal 
rearrangements have been shown to increase or deregulate transcription of oncogenes or proto-
oncogenes by transcriptional activation of proto-oncogenes or the creation of fusion genes. 
Transcriptional activation for example, occurs when a proto-oncogene is moved adjacent to an 
immunoglobulin or T-cell receptor gene. In doing so, the regulatory elements of the immunoglobulin 
or T-cell receptor locus may control the transcription of the proto-oncogene (Frei and Antman, 2003). 
For example, the t(8;14)(q24;q32) translocation found in Burkitt lymphoma is to date one of the most 
studied examples of proto-oncogene activation. This chromosomal rearrangement occurs when the c-
Myc gene controls regulatory elements of the immunoglobulin heavy chain locus (Siebert et al., 1998, 
Aspland et al., 2001). Gene fusions may often form chimeric transcription factors, like the E2A/PBX1 
fusion protein found in childhood pre-B-cell ALL is a t(1;19)(q23;p13) translocation (Aspland et al., 
2001).  
 
1.6 Tumour-suppressor genes  
The discovery of many oncogenes has fuelled the idea that different classes of genes must exist to elicit 
tumour-preventing functions. Somatic cell fusion and chromosomal segregation experiments have 
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confirmed the existence of genes involved in tumour suppression (Stanbridge EJ, 1976). Over the years 
many tumour suppressor genes have been identified. Interestingly, these prototypic tumour suppressor 
genes were thought to be recessive and follow the “two-hit hypothesis” proposed by A.G. Knudson 
(Knudson, 1971).  This then, well-respected hypothesis that implies that biallelic gene inactivation is in 
fact required before an effect is observed in cancer cells (Knudson, 1971) has been a little outdated. 
Further studies have shown however, that not all tumour suppressor genes follow this well-known 
hypothesis. Other tumour suppressors are haplo-insufficient for tumour progression; meaning that the 
inactivation of a single tumour suppressor gene by mutation, deletion or methylation-mediated 
transcriptional silencing may give a selective advantage during tumorigenesis. For example: 
inactivation of single alleles of genes encoding PREP1, p53, TGF, 27KIP1 and DMP1 can be sufficient 
to predispose mice to tumour development (Krimpenfort et al., 2001, Balmain et al., 2003). Over 30 
tumour suppressors have been identified all of which appear to control a broad range of critical yet 
highly conserved normal cellular functions, including: signal transduction, cell differentiation, cell 
cycle checkpoint control, apoptosis, control of genomic integrity, repair of DNA damage and adhesion, 
and angiogenesis. These functions can be deregulated in cancer cells (Balmain et al., 2003). For this 
reason, tumour suppressor genes are generally divided into gatekeepers, caretakers and landscapers 
based on primary functions (Macleod, 2000). This “Gatekeeper” term was first proposed in an attempt 
to explain the role of adenomatous polyposis coli tumour suppressor gene, consistently found mutated 
in colorectal tumorigenesis. Gatekeeper genes encode proteins that act directly to inhibit tumour growth 
by either suppressing proliferation, inducing apoptosis or by promoting differentiation. Since the loss 
of function of these genes is the rate-limiting event in tumorigenesis, restoration of their function 
suppresses neoplasia. Individuals who may have a hereditary mutation in one of the two alleles of a 
gatekeeper gene are predisposed to neoplasia (Macleod, 2000).  
“Caretaker” genes have been shown to help maintain genomic stability by encoding proteins in DNA 
repair and mitotic checkpoint pathways like MLH1, BRCA1, MYH, and XPA. These genes indirectly 
suppress cell proliferation ensuring the integrity of DNA. Caretaker genes do not directly contribute to 
the development of cancer; however, their loss of function increases the DNA mutation rate, raising the 
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probability that gatekeeper gene function will be altered. Cancer risk is not easily quantified although 
research into overall survival (OS) with drug treatments are currently one of the best ways to quantify 
this. These alterations increase cancer development risk from 5 to 50-fold (Macleod, 2000). The 
products of the third class of tumour suppressor genes named the “landscapers”, act by modulating their 
microenvironment and the microenvironment of the tumour cells. These genes are known to regulate 
extracellular matrix proteins, cell surface receptors, adhesion proteins and secreted growth factors. Loss 
of function mutations of landscapers can generate an abnormal microenvironment prompting the 
neoplastic transformation of the adjacent epithelia (Macleod, 2000).  
 
1.7 The hallmarks of cancer 
18 years ago, Hanahan and Weinberg (2000) described the six “Hallmarks of Cancer” which at that 
time provided a logical framework summarizing and understanding several decades of research 
dedicated to cancer. These six common traits or “Hallmarks” that are thought to govern the 
transformation of normal cells to cancer cells, are essential for cells to acquire a cancer phenotype in a 
multi-step process (Hanahan and Weinberg, 2011). In 2011, two emerging hallmarks were added to this 
list due to the conceptual progress in research in the last decade. The complexity of upwards of 100 
different types of human cancers often arises from disruption of the distinct regulatory circuits of cells 
that govern normal cell proliferation and homeostasis. Hanahan and Weinberg proposed that this 
complexity can often be explained by a small number of common traits between most, if not perhaps 
all types of human tumours (Figure 1.2)(Hanahan and Weinberg, 2011).   
 
1.7.1 Sustaining proliferative signals  
Tumours arise from unconstrained proliferation of cells that harbour either oncogenic activating or 
tumour suppressor inactivating mutations. Therefore, uncontrolled proliferation is the most 
fundamental feature of cancer development (Cheng et al., 2005). Normal cells require mitogenic growth 
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signals to evolve from a quiescent state and enter a proliferation state. Growth-promoting signals that 
are released from cells are transmitted through transmembrane receptors to their neighbouring cells. 
Cell proliferation relies on the important availability of growth promoting signals with normal cells 
stopping proliferation in the absence of these signals. Cancer cells may develop a few ways when 
growing and proliferating independent of the absence of exogenous mitogenic signals (Hanahan and 
Weinberg, 2011) as seen in Figure: 1.2. Some cancer cells, however, produce their own growth factors. 
The production of tumour growth factor and platelet-derived growth factor (PDGF) by sarcomas and 
glioblastomas, are two very important examples (Frei and Antman, 2003). They also stimulate normal 
cells that are present in the tumour microenvironment and produce growth factors (Cheng et al., 2005). 
Cell surface receptors that bind to the growth factors and transmit the growth signals inside cells are 
overexpressed in many cancers. The increase in the number of these receptors makes cancer cells 
hypersensitive to minimal amounts of the growth factor which would normally be unable to trigger 
proliferation (Frei and Antman, 2003). For example, HER2/NEU is overexpressed in stomach and 
mammary carcinomas. Structural alterations in the receptor may also lead to ligand-independent 
signalling and growth factor autonomy can be achieved by activation of components of signalling 
pathways that operate downstream of these receptors (Medema et al., 1993).   
 
Figure 1.2 A schematic diagram depicting the newest and updated version of “The Hallmarks of 
Cancer” (Hanahan and Weinberg, 2011). 
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1.7.2 The evasion of growth suppressors  
Cells have evolved mechanisms to control proliferation and tissue homeostasis by manipulating 
positively and negatively acting growth signals. Like the growth-promoting signals mentioned 
previously, the growth-inhibitory signals may be transmitted through transmembrane cell surface 
receptors. These signals act by blocking proliferation by either transiently forcing cells out of the 
proliferative state into the quiescent state or by preventing proliferative ability, which drives cells into 
a post-mitotic state like quiescence. Inactivation of tumour suppressors often conveys various 
capabilities to cancer cells to evade the anti-proliferative signals (Hanahan and Weinberg, 2000, 
Hanahan and Weinberg, 2011). RB (retinoblastoma-associated) and p53 proteins are typical examples 
of key tumour suppressors that control cell proliferation or activation of senescence and apoptosis 
programs. These tumour suppressor genes are frequently inactivated in cancer by loss of function 
mutations (Burkhart and Sage, 2008, Hupp et al., 1992, Sherr and McCormick, 2002).  
 
1.7.3 Resistance to cell death  
Normal tissues can maintain their homeostasis by balancing rates of cell proliferation and cell death. 
Programmed cell death or apoptosis, plays a major role in maintaining cell population in different 
tissues. Apoptosis may be triggered by either an extrinsic pathway mediated by cell surface death 
receptors bound by extracellular ligands, or by an intrinsic pathway mediated by the mitochondria. The 
second, is triggered in response to different extracellular and intracellular stresses, like: growth factor 
depletion, hypoxia, DNA damage and oncogene induction. The ability of transformed cancer cells to 
bypass this apoptotic barrier is widely known in the pathogenesis of cancer. Tumour cells may develop 
different strategies to escape apoptosis the most common of these is the loss of the p53 tumour 
suppressor, which increases expression of anti-apoptotic regulators and survival signals or down 
regulating the pro-apoptotic signals (Hanahan and Weinberg, 2011, Adams and Cory, 2007).  
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1.7.4 Enabling replicative immortality  
Normal cells have a finite capability of replication and therefore may be able to pass through a limited 
number of cell growth and division cycles. Mammalian cells whilst in culture, stop growing and go into 
senescence after around 60-70 doublings (Burkhart and Sage, 2008, Hupp et al., 1992, Sherr and 
McCormick, 2002). Some cells succeed and bypass this barrier, going into a crisis phase, involving 
apoptosis and karyotypic abnormalities. Rarely however, cells from a specific population in crisis 
acquire indefinite replicative potential. This immortalization is one of the characteristics of the tumour 
cells (Wright et al., 1989). In non-immortalized cells, telomeres responsible for protecting the ends of 
chromosomes progressively shorten with each cell division, often leading to the end-to-end fusions of 
chromosomes, karyotypic disarray, crisis and eventually cell death. Telomerase is responsible for 
maintaining telomeric DNA and is mainly absent in non-immortalized cells, however it is expressed at 
high level in a large proportion of immortalized cells including human cancer cells (Hanahan and 
Weinberg, 2000, Hanahan and Weinberg, 2011).  
 
1.7.5 Induction of angiogenesis  
The induction and sustaining of angiogenesis are crucial for the growth of all tumours. In the adult, 
angiogenesis is only transiently turned on due to physiological processes such as wound healing. 
However, in neoplastic growth an “angiogenic switch” can be activated and may remain permanently 
on, forcing the normal quiescent vasculature to generate new vessels and help expand tumour growth 
by supplying oxygen and nutrients. The activation of this angiogenic switch is mediated when changing 
the ratio of angiogenic inducers versus inhibitors. Vascular endothelial growth factor (VEGF) induces 
angiogenesis and can be over expressed in tumours compared to their normal tissue counterparts. 
Alternatively, the angiogenic inhibitor thrombospondin-1, can be positively regulated by p53 tumour 
suppressor protein, and is down regulated in tumours (Hanahan and Weinberg, 2000, Hanahan and 
Weinberg, 2011).   
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1.7.6 Invasion and metastasis  
Metastasis, the dissemination of cancer cells from a primary site to an adjacent or distant organ, which 
is the leading cause of death in patients with solid cancers. Invasion and metastasis are both multistep 
processes beginning with local invasion followed by intravasation of cancer cells in nearby vessels and 
circulation of these cells through the lymphatic and haematic systems (Figure 1.3). This often results in 
the extravasation of cancer cells to distant tissues and eventually with the formation of micro-metastatic 
lesions. At a molecular level, proteins involved in cell-to-cell and cell-to-matrix adhesion are important. 
E-cadherin is an important Ca(2+)-dependent cell-to-cell adhesion molecule and plays an important 
role as a key suppressor of metastasis. This protein along with various other adhesion molecules 
involved in cell-to-matrix adhesions is often down regulated in cells possessing invasive or metastatic 
capabilities (Hanahan and Weinberg, 2000, Hanahan and Weinberg, 2011).   
 
Figure 1.3 A schematic diagram depicting development of a ‘metastatic niche’ due to the interaction 
of some disseminated tumour cells with that of the bone marrow micro-environment. Evidence supports 
the hypothesis that tumour cell behaviour is often dependent on the surrounding micro-environment, 
suggesting that the micro-environment in distant tissues, like bone, may be essential for disseminated 
tumour cell (DTC) survival and metastatic growth (Shiozawa et al., 2011).  
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1.7.7 Reprogramming of energy metabolism  
During normoxic conditions, cells process glucose through glycolysis followed by oxidation of 
pyruvate in the mitochondria of the cells. In anaerobic conditions however, glycolysis occurs in the 
cytosol of the cell and is shortly followed by lactic acid fermentation. Malignant cells usually limit their 
energy metabolism to glycolysis, even when under normoxic conditions. This phenomenon is known 
as the Warburg-effect (Liberti and Locasale, 2016). To date there are several hypotheses to explain the 
Warburg-effect, for example mitochondrial damage, adaptation to hypoxic environments, and the 
shutdown of mitochondria due to their involvement in apoptosis. Glycolysis can provide most of the 
intermediates that are necessary to produce nucleosides and amino acids, facilitating biosynthesis of the 
macromolecules and organelles that are required for active cell proliferation. Cancer cells often switch 
metabolic pathways to anaerobic glycolysis and support the uncontrolled, continuous cell proliferation 
(Hanahan and Weinberg, 2011).  
 
1.7.8 Evading the immune system  
There is currently a lot of evidence suggesting that the immune system plays an important role in the 
recognition and eradication of malignant cells. The cancer immunosurveillance theory suggests that 
immune cells constantly monitor cells and tissues recognizing and eliminating continuously arising 
nascent transformed cells by immunoediting. Immunoediting is an important process, responsible for 
protecting the individual from cancer growth and development of tumour immunogenicity. 
Immunoediting is composed of three main phases: elimination, equilibrium, and escape. Although it 
has been observed that both innate and adaptive immune systems contribute to immunosurveillance, 
many tumours escape the immune barrier and drive immunological tolerances. This has the potential to 
lead to tumour progression by mimicking immune signalling pathways that impact the tumour 
microenvironment and activate immunosuppressive cells such as regulatory T (Treg) and myeloid-
derived suppressor cells (MDSCs) (Hanahan and Weinberg, 2011).   
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1.8 Transcription factors  
Transcription factors are sequence-specific DNA binding factors responsible for the regulation of the 
transcription of target genes in regulatory regions such as promoters or enhancers (Mitchell and Tjian, 
1989). Most of the 2600 proteins in our human genome containing DNA-binding domains are thought 
to act as transcription factors. Almost 10% of the protein-coding genes in our genome encode proteins 
which are known to be responsible for the regulation of transcription, making this family the single 
largest family of human proteins (Babu et al., 2004, Levine and Tjian, 2003). Multigene families of 
some transcription factors share common DNA-binding domains, for example: zinc finger, leucine-
zipper, helix-loop-helix and homeodomain motifs (Pabo and Sauer, 1992). Transcription factors often 
act in a complex binding to other proteins and operate as the final link in a signal transduction pathway 
that translates cellular signals by altering gene expression (Alberts 2002). However, proto-oncogene 
transcription factors were initially discovered from their retroviral homologs. Chromosomal 
translocations are often responsible for the activation of transcription factors in haematological and 
solid malignancies, for example proto-oncogenic transcription factors include HOXA9, MEIS1, PBX1, 
Erb, Ets, Fos, Jun, Myb, and c-Myc. Relevant to this work is the HOXA9 transcription factor known to 
cooperate with the MEIS1 transcription factor in the induction of AML (Kroon et al., 1998, Mamo et 
al., 2006, Thorsteinsdottir et al., 2001). Equally, E2A-PBX1 chimeric protein resulting from 
chromosomal translocation of the basic helix-loop-helix transcription factor E2A with the gene 
encoding the homeodomain protein PBX1 has been shown to cause pre-B cell acute lymphoblastic 
leukaemia (ALL) (Aspland et al., 2001).   
 
1.9 AML 
In the western world, acute myeloid leukaemia (AML) accounts for approximately 25% of all 
leukaemias in adults. According to the World Health Organisation (WHO) there is an incidence of 3.7 
per 100,000 people with a mortality rate of 2.7, rising to almost 18 per 100,000 people within the older 
age groups. Rarely diagnosed before 40 years of age, with newly diagnosed cases having a median age 
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of 65 (<65 years incidence 1.8 per 100.00, >65 years incidence 17 per 100.000). Complete remission 
can be achieved in 60%-80% of younger adults, however, treatment related mortality (TRM) can vary 
considerably, between 15% to 50%, and maintaining a balance between remission and TRM is vital. 
This is particularly relevant for those patients ages >60, who are more likely to show increased 
incidence of resistance to therapy and TRM. 
 
 
Table 1.1 A table depicting the current and simple classification of leukaemia. 
 
Acute myeloid leukaemia is a heterogeneous group of genetically and phenotypically aggressive 
disorders in which several acquired somatic genetic changes accumulate and result in differentiation 
blockage of human progenitor cells, increasing the self-renewal ability of cells and disturbing the 
normal regulation of proliferation (Fröhling et al., 2005). Non-random chromosomal alterations, such 
as balanced translocations, monosomies, trisomies, inversions and deletions have been found in the 
leukemic blasts in approximately 55% of AML patients. These chromosomal aberrations are essential 
in the classification of AML and in the past they have been considered to be the most crucial prognostic 
factor for cure rates, possibility of relapse, and overall survival (Estey and Döhner, 2006, Mrózek et al., 
2007). Recently, due to advances in molecular diagnosis, several gene alterations and specific 
dysregulation of gene expression has also been recognized. This has helped to clarify the numerous 
heterogeneities of AML subsets, particularly AML (Döhner and Döhner, 2008a) and furthered the 
understanding of the molecular mechanisms of leukaemogenesis. However, to date there is no current 
evidence for a direct molecular link between a person’s age and their risk of developing AML, although 
several age associated potential haematological factors have been identified. Interestingly, some of 
these include myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN), which like 
AML, are also classified by the WHO and are an extremely heterogeneous group of haematological 
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disorders.  MDS and MPN are clonal haematological disorders characterized by ineffective 
haematopoiesis, bone marrow dysplasia in MDS or hyperplasia in MPN, frequently progressing to AML 
15-52% and 7% respectively, incurring a poor prognosis. In MPN, Hematopoietic Stem Cell (HSC) 
dysregulation occurs due to failure of normal cytokine feedback or hypersensitivity. This often results 
in the production of excessive blood cells and involves the three main myeloid lineages; erythroid, 
megakaryocytic/platelet and granulocytic, predominantly affecting only one lineage (Döhner and 
Döhner, 2008a). In MDS however, several factors are believed to contribute to the molecular pathology 
of this disorder, including increased HSC apoptosis, defective stroma, altered response to cytokines and 
chromosomal abnormalities including deletions of chromosome 5q31–q32. HOXA9 and HOXA7 are 
both often linked to the status of HSC underlying MDS and AML, either through overexpression or 
reciprocal translocations (e.g. NUP98-HOXA9) although very little, if any profile of HOX expression 
has been explored for MPN (Estey and Döhner, 2006, Mrózek et al., 2007). 
 
 
1.10 Subtypes for AML 
The diagnosis and classification of AML since its discovery has proven challenging. In most cases, the 
presence of specific morphologic features such as auer rods or specific markers can distinguish AML 
from other leukaemias. In the absence of these features, diagnosis may be a little more difficult. The 
two most commonly used classifications to date are the French-American-British (FAB) system and 
the newer WHO system.  
 
The French American–British (FAB) classification system is divided into eight AML subtypes, M0 
through to M7, based on the type of cell from which the leukaemia has developed and the degree of 
maturity (Table 1.2). This is analysed by examining the appearance of the malignant cells via light 
microscopy and by using cytogenetics to then characterize any underlying chromosomal abnormalities. 
The subtypes have varying prognoses and responses to therapy. These eight FAB subtypes were 
proposed in 1976 (Bennett et al., 1976). FAB classification requires a blast percentage of at least 30% 
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in the bone marrow (BM) or the peripheral blood (PB) for diagnosis of AML (Amin et al., 2005). It is 
important that AML is differentiated from "pre-leukemic" conditions such as myelodysplastic 
syndrome or myeloproliferative neoplasm, that have very different treatment options.  
 
Type Name Cytogenetics Percentage 
M0 Acute myeloblastic leukaemia, minimally differentiated  5% 
M1 Acute myeloblastic leukaemia without granulocytic maturation  15% 
M2 Acute myeloblastic leukaemia, with granulocytic maturation T(8;21)(q22;q22), 
t(6;9) 
25% 
M3 Promyelocytic, or acute promyelocytic leukaemia (APL) t(15;17) 10% 
M4 Acute myelomonocytic leukaemia Inv(16)(p13q22) 
del(16q) 
20% 
M4eo Myelomonocytic with bone marrow eosinophilia inv(16), t(16;16) 5% 





M6 Acute erythroid leukaemia (M6a) (M6b)  5% 
M7 Acute megakaryoblastic leukaemia T(1;22) 5% 
Table 1.2 A table depicting the acute myeloid leukaemia classification according to the French-
American-British classification scheme. 
 
World Health Organisation (WHO): classification of acute myeloid leukaemia that was published in 
2008, aims to be more clinically useful and aims to produce more meaningful prognostic information 
than the FAB criteria. The WHO classification has various descriptive subcategories however, most of 
the clinically significant information of this WHO schema can be organised via categorization into one 
of the subtypes listed below (Table1.3). The WHO diagnosis of AML can be established by 
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demonstrating involvement in more than 20% of the blood and/or bone marrow by leukemic 
myeloblasts, except three best prognosis forms of AML that have recurrent genetic abnormalities 
(t(8;21), inv(16), and t(15;17)) of which the presence of genetic abnormality is now diagnostic 
irrespective of blast percentage (Harris et al., 1999, Foucar et al., 1982). The WHO  
 
 
Table 1.3 A table depicting the current acute myeloid leukaemia classification according to the WHO 
classification scheme (WHO 2008) 
 
1.11 Pathophysiology of AML 
The myeloblast is the malignant cell in AML which in haematopoiesis, is an immature precursor of 
myeloid white blood cells. Normally a myeloblast gradually matures into a mature white blood cell. 
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However, in AML, a single myeloblast accumulates genetic changes halting the cell in an immature 
state that prevents differentiation (Fialkow, 1976). This mutation alone does not cause leukaemia, 
however when a "differentiation arrest" happens in conjunction with other mutations that disrupts 
proliferation control, the result is an uncontrolled growth of immature cells leading to AML (Fialkow, 
1976). There has been a large diversity and heterogeneity of AML identified since leukemic 
transformation may occur at several different steps along the differentiation pathway (Bonnet and Dick, 
1997). Classification schemes for AML recognize the characteristics and behaviour of leukemic cells 




Figure 1.4 A schematic diagram depicting blood cell development, showing the steps a blood stem cell 
goes through to become either a red blood cell, platelet, or white blood cell. This also shows a lymphoid 




Cytogenetic abnormalities may be found in people with AML, with the types of chromosomal 
abnormalities usually have a prognostic significance (Abeloff and Martin 2004). Chromosomal 
translocations encode abnormal fusion proteins that are usually transcription factors whose altered 
properties may lead to "differentiation arrest" (Greer et al., 2004). For example, in acute promyelocytic 
leukaemia, the t(15;17) translocation mutation is responsible for producing a PML-RARα fusion protein 
known to bind to the retinoic acid receptor element in the promoters of several myeloid-specific genes 
inhibiting myeloid differentiation (Melnick and Licht, 1999). Clinical signs and symptoms of AML 
result from growth of leukemic clone cells, that tends to displace and interfere with the development of 
normal blood cells in the bone marrow (Martin 2004). Disturbances like these often lead to neutropenia, 
anaemia, and thrombocytopenia. Symptoms of AML are often due to low numbers of these normal 
blood elements. In some rare cases however, people with AML may develop a chloroma, or solid 
tumour made up of leukemic cells that form outside the bone marrow. This can cause symptoms 
depending on location (Dally et al., 2005). An extremely important pathophysiological mechanism of 
leukaemogenesis in AML is the epigenetic induction of dedifferentiation by some genetic mutations 
that may alter the function of epigenetic enzymes. Some examples of these include the DNA 
demethylase TET2 and the metabolic enzymes IDH1 and IDH2 (Molenaar et al., 2015), which may lead 
to the generation of a novel oncometabolite, D-2-hydroxyglutarate and inhibits activity of some 
epigenetic enzymes such as TET2 (Molenaar et al., 2014). The general hypothesis is that such 






Figure 1.5 A schematic diagram depicting the development of acute myeloid leukaemia both from either 
an abundance of myeloid stem cells and/or myeloid blast cells (Winslow 2007). 
 
 
1.12 AML and mutations 
There has been a widely accepted hypothesis based on data obtained from animal models and human 
diseases over recent years termed, “the two-hit model hypothesis”.  The idea behind this hypothesis is 
that there are two types of genetic changes that may occur and are known to be involved in AML 
emergence. Molecular mutations in AML are divided into classes. The first class, Class I consists of 
mutations that enhance proliferation signal transduction pathways and induce the proliferation of HSC’s 
or HPC’s and usually affect kinase signalling pathways, such as FLT3, KIT, NRAS/KRAS, 
RAS/MAPK and JAK/STAT mutations. These Class I mutations take place later on and cause disease 
progression. Class II mutations on the other hand, consist of target hematopoietic transcription factor 
genes that may lead to a block in myeloid differentiation and give the self-renewal ability of HPC’s. 
These mutations take place early on and initiate the AML disease (Döhner and Döhner, 2008b, 
Renneville et al., 2009, Betz and Hess, 2010). In fact, one set of the most affected transcription factors 
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are the HOX genes. Consequently, over-expression of HOX genes, which play significant roles in 
development of embryogenesis, organogenesis as well as normal differentiation of HPC’s, is a frequent 
characteristic of AML (Ferrando et al., 2003). Class I mutation mainly cause changes in kinase 
signalling pathways and this occurs in the later stage of AML, leading to disease progression. The class 
II mutations take place in the early stages causing initiation of AML disease. HOX genes are the main 
type of transcriptional factors mutated in AML (Figure 1.7) (Bloomfeild, Small, & Stock, 2006). 
 
 
Figure 1.6 A schematic diagram depicting both Class I (proliferation and survival) mutations and Class 
II (impaired differentiation) mutations that may lead to acute myeloid leukaemia. 
 
 
1.13 Current treatment  
The current curative treatment for AML starts with chemotherapy. The aim of the first cycle, induction 
chemotherapy, is to achieve complete remission (CR), defined as microscopical disappearance of 
cancer cells from blood and bone marrow (Dahlstrom et al., 2011). Following induction therapy, 
consolidation therapy is administered the aim of which is to eliminate any remaining leukemic cells 
(Dahlstrom et al., 2011). Approximately 71% of patients can achieve CR. Unfortunately however, many 
patients relapse, explaining why long-term survival remains as poor as 22–32% despite the high rate of 
CR (Vardiman et al., 2009). In addition to chemotherapy, some patients receive allogenic stem cell 
 33 
transplantation (Dahlstrom et al., 2011). Associated with this treatment is significant mortality and 
morbidity (Dahlstrom et al., 2011), making the choice of whether to proceed with a transplantation 
something to carefully consider. The risk of relapse, the availability of a matching donor and the overall 
general condition of the patient are considered (Dahlstrom et al., 2011). Knowledge of the genetic 
changes and the mechanisms behind AML has increased significantly (Vardiman et al., 2009), which 
is an important step towards the identification of new and more specific targets for therapy. However, 
the prognosis remains poor and there is still need for a better understanding of the mechanisms behind 
the disease and how these can be exploited to improve patient outcome.  
 
 
1.14 Myelodysplastic syndromes  
MDS or the myelodysplastic syndromes are a large group of clonal hematopoietic stem cell disorders 
previously classified as “pre-leukaemia” often characterized by ineffective haematopoiesis, peripheral 
blood cytopenias, dysplasia, and a propensity for the transformation to acute myeloid leukaemia. 
Patients who develop MDS often go on to develop severe anaemia and require blood transfusions. In 
some cases, the disease progresses and worsens and the patient may go on to develop cytopenias or a 
low blood count caused primarily by progressive bone marrow failure (Mufti et al., 2010). The overall 
outlook for patients with MDS often depends on the severity and type of the disease. Very often 
however, many live very normal life spans with the disease, and many are often asymptomatic for MDS 
until detected in a routine blood test. These MDS are all disorders of the HSCs in the bone marrow. 
Notably, in MDS, haematopoiesis is ineffective and disorderly with the number and quality of blood-
forming cells declining irreversibly, further impairing blood production.  
 
1.15 Myeloproliferative neoplasms 
Myeloproliferative neoplasms (MPN), previously myeloproliferative disorders, are diseases of the bone 
marrow from which excess cells are produced. In the more recent WHO classification of hematologic 
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malignancies, these diseases have been renamed from "myeloproliferative diseases" to 
"myeloproliferative neoplasms" (Tefferi et al., 2011, Vainchenker et al., 2011), better reflecting the 
underlying clonal genetic changes that are a very salient feature of this group of diseases giving a far 
more accurate description of the disease itself. These malignancies are often characterized by a clonal 
proliferation of one or more of the hematopoietic cell lineages, often in the bone marrow as well as the 
liver and spleen. The discovery of myeloproliferative disease/neoplasms came when they were first 
proposed in the 1950’s by the eminent haematologist William Dameshek (Dameshek, 1951). In contrast 
to myelodysplastic syndromes however, MPNs demonstrate a terminal myeloid cell expansion into the 
peripheral blood. In 2008, a revision of the WHO classification of MPNs. MPNs included: chronic 
myelogenous leukaemia (CML), chronic neutrophilic leukaemia, polycythemia vera (PV), primary 
myelofibrosis (PMF), essential thrombocythemia (ET), chronic eosinophilic leukaemia, mastocytosis, 
and unclassifiable MPNs. Overlap disorders between MDSs and MPNs are those chronic myeloid 
disorders unable to be classified as "classic" MPN or MDS. These include: chronic myelomonocytic 
leukaemia (CMML), atypical CML, juvenile myelomonocytic leukaemia, and unclassifiable 
MDS/MPN. Over the last few years work has been done to highlight a link between myeloproliferative 
neoplasms and their ability to evolve into MDS and most significantly for the work presented here into 
AML. Although this is true, the MPDs overall have a much better prognosis than both MDS and acute 
myeloid leukaemia.  MDS and other “pre-leukaemic” diseases will be discussed. 
 
1.16 HOX genes 
Homeobox-containing proteins are a highly expressed family of proteins, the genes of which encode 
DNA-binding transcription factors (Garcia-Fernandez, 2004). These genes have been extensively 
studied since they were first discovered in Drosophila as master regulators of the trunk and the tail 
during embryogenesis (Shah and Sukumar, 2010). Genetic duplication of HOX genes in Drosophila 
results in eight genes in a single cluster, while in mammals the genetic duplication produces 39 genes 
divided into four different chromosomes, HOXA, HOXB HOXC and HOXD (Rice and Licht, 2007). 
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The four paralogs or four clusters are produced because of the original gene in the first cluster. Within 
these clusters, the same paralogous group will show genetic homology and therefore has functional 
redundancy and high sequence similarity as seen in a more recent review, He et al., 2011a. HOX clusters 
are believed to have been derived from a single gene that produced tandem duplications (Ruddle et al., 
1994). Each cluster is approximately 100 Kb in length, found on different chromosomes, with HOXA 
at 7p15.3, HOXB at 17p21.3, HOXC at 12q13.3 and HOXD at 2q31 (Akam, 1989). HOX gene products, 
HOX proteins, primarily function as transcription factors that are essential in the patterning of the 
anterior and posterior axis during embryonic development but also help determine tissue fate (Garcia-
Fernandez, 2004).   
Mammalian genes have a notable homology with Drosophila melanogaster HOX-C genes. These genes 
are distributed between two gene complexes termed the Ant-C and BX-C. Many mammalian HOX genes 
(Paralogous groups 1-8) are like Ant-C genes. The others (9-13) are known as Abd-B Hox genes because 
of their similarity to the Abd-B genes of the BX-C complex (Phelan et al., 1995). The anterior-posterior 
expression of these HOX genes is a unique feature among developmental regulators, termed “HOX 
code” (Knittel et al., 1995). HOX code in mammals has four distinctive criteria: (1) Temporal 
distribution: which is that the expression of HOX genes is initiated from the 5’ to 3’ ends of the DNA. 
(2) spatial distribution: so that in terms of a 5’-3’ co-linear sequence of each single cluster, the 
expression of 5’end genes are caudal, whereas the expression of the 3’ end genes is labial. (3) posterior 
prevalence: that in the individual cluster itself, the function of these posterior gene products is dominant 
over the more anterior genes. (4) Overlapping expression: HOX genes form a nested expression pattern 
(He et al., 2011b). Typically, 3’ prime HOX genes are expressed in anterior tissue whilst 5’ prime tissue 
will be expressed in posterior tissue (Shah and Sukumar, 2010). HOX proteins play several other roles, 
including: cellular proliferation, differentiation as well as apoptosis and the ability to modulate cell-cell 
and cell-extracellular matrix interactions (Cillo et al., 2001). These functions highlight the importance 
of understanding the disruption of activated HOX genes implemented in the initiation, promotion and 




Figure 1.7 A schematic diagram depicting the HOX gene layout in Drosophila with only a single HOX 
cluster, containing 8 HOX genes, compared to the 39 seen in Humans. Separated into 4 clusters, it is 
believed that the additional HOX clusters arose from a single ancestral cluster like the one seen in 
Drosophila. Vertebrate HOX groups 1, 2, 4, 5, 6, 7, and 8 are very like drosophila labial (lab), 
proboscipedia (pb), deformed (Dfd), sex combs reduced (Scr), antennapedia (Antp), ultrabithorax 
(Ubx), and abdominal-A (Abd-A), respectively. The vertebrate HOX group 9-13 are strongly related to 
the Drosophila abdominal-A (Abd-A). The Drosophila however, is not seen to have a group 3 
corresponding HOX gene (Goodman, 2003).  
 
 
1.17 HOX genes and haematopoiesis 
HOX genes are key regulators of trunk and tail development during normal embryogenesis, as an 
important family of homeodomain-containing transcription factors as already discussed. However, 
DNA-binding site studies highlight the fact that HOX proteins have relatively limited selectivity and 
specificity, with co-factor interactions needed to increase both.  The co-factors associated with HOX 
genes also have crucial roles in development and haematopoiesis. For example, due to severe 
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hematopoietic defects, PBX1 null mice die during the embryonic stage and MEIS1-deficient mice are 
known to fail to generate megakaryocytes, resulting in severe haemorrhaging and fatality during the 
embryonic stage. HOX proteins 1–10 bind to PBX1, whereas HOX proteins 9–13 bind to MEIS1 
(Thorsteinsdottir et al., 2001) both key co-factors in this study. 
HOX genes are highly expressed in HSCs and progenitors with lineage and differentiation stage-
restricted patterns. In uncommitted hematopoietic cells HOXB3, HOXB4 and HOXA9 are highly 
expressed, on the other hand, HOXB8 and HOXA10 are expressed in myeloid committed cells. The 
different HOX clusters also have specific patterns of lineage-restricted expression, whereby HOXA 
genes are expressed in myeloid cells, HOXB genes in erythroid cells and HOXC genes in lymphoid 
cells. Interestingly, HOXD genes are not expressed in haematopoiesis despite having similar regulatory 
regions to the other clusters. The function of HOX genes in normal haematopoiesis has been widely 
studied using gene expression analysis and knock-in or knockout studies in HSCs and early 
hematopoietic progenitors. In general, overexpression of HOX genes leads to expansion of stem and 
progenitor cell populations together, through an increased proliferation with a block on differentiation. 
Overexpression of murine HOXB6, results in the expansion of murine HSCs and myeloid precursors, 
together with the inhibition of erythropoiesis and lymphopoiesis. Overexpression of murine HOXB3 
results in several haematological abnormalities, such as a block of B- and T-cell differentiation along 
with a delay in myeloid precursor proliferation. Other HOX genes are required for the maintenance of 
progenitor or stem cell status and promote self-renewal, especially HOXA9 and HOXB4. The former is 
the most preferentially expressed HOX gene in early hematopoietic progenitors and CD34þ HSCs and 
is downregulated during differentiation (Thorsteinsdottir et al., 2001).  
Interestingly however, the exception to the general prevalence of functional redundancy amongst the 
HOX gene family is HOXA9. HOXA9 is the most highly expressed member of the HOX family in HSCs. 
Although the mechanism by which HOX genes regulate haematopoiesis is not yet fully understood, 
genome-wide analyses after experimentally induced changes in HOX gene expression have identified 
some potential downstream targets. Amongst these are the HOX genes themselves, some of which have 
been shown to auto-activate their own expression or to cross regulate their neighbours, or their co-
factors. HOXA9, HOXA10 and HOXB4 are the most comprehensively studied genes in this respect 
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because of their key roles in normal haematopoiesis and leukaemia. It is particularly noteworthy that 
HOXA9 positively regulates the transcription of other HOX genes including HOXA7 and HOXA10 and 
its cofactors PBX3 and MEIS1 (Thorsteinsdottir et al., 2001). 
 
1.18 HOX over-expression in AML  
HOX genes have also been shown over the last decade to be indirectly involved in AML through 
chromosomal rearrangements that may involve some of their upstream regulators, such as MLL. MLL 
fusion proteins are known to constitute about 10% of therapy-related AML and just over 3% of de novo 
AML (Slany, 2009). There are almost 65 known translocation partner genes that are thought to fuse 
with the MLL N- terminus (Meyer et al., 2009). MLL positively regulates the transcription of HOX 
genes, maintaining their expression by directly binding to a proximal promoter region (Milne, Briggs 
et al. 2002). However, MLL fusion proteins activate HOX gene transcription far more efficiently than 
MLL alone (Liu et al., 2009, Slany, 2009), in particular the 5’ end members of the HOXA cluster with 
their co-activator MEIS1. Due to this, myeloid differentiation is blocked and proliferation is vastly 
enhanced (Marschalek, 2011). As well as this current proposed mechanism, it has been shown that 
MLL-AF9, just like NUP98-HOXA9, often leads to a block in erythroid/myeloid cell maturation and 
erythroid hyperplasia (Abdul-Nabi et al., 2010). Interestingly, studies have suggested that the MLL- Enl 
fusion protein seems to require HPXA7 and HOXA9 for efficient immortalization of haematopoietic 
stem cells (HPSCs) (Ayton and Cleary, 2003). Conversely, some studies have shown that the expression 
of HOXA genes is not necessary for MLL leukaemogenesis, but their expression may affect disease 
phenotype. For example, HOXA7 and HOXA9 have been shown to influence AML latency and 
phenotype; but are not essential to initiate MLL-Gas7-mediated leukaemogenesis (So et al., 2004). 
Suppression of HOXA9 expression in specific cells with a chimeric MLL-AF9 gene has been shown to 
reduce the survival of leukaemic cells and possibly changes the disease phenotype, without affecting 
AML initiation (Faber et al., 2009).  
The dysregulation of the CDZ gene family (another regulator of HOX genes), has also been shown to 
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progress the development of AML. The CDX2 protein is expressed in around 90% of AML cases but 
not in normal adult haematopoiesis, with CDX2-elevated expression often leading to AML with a very 
short latency period (Scholl et al., 2007). The CDX4 gene is expressed in just over 25% of AML cases, 
as well as being expressed in normal adult haematopoiesis. CDX4 being over-expressed in some murine 
BM can result in AML, with a long latency period (Bansal et al., 2006). Latency in relation to the CDX4 
gene is accelerated in mice through co-operation of MEIS1 resulting in the over-expression of several 
HOX genes including HOXA6, HOXA7, HOXA9, HOXB4, HOXB8 and HOXC6 (Bansal et al., 2006). 
CDX2 expression alone has been shown to be sufficient in driving the up-regulation of a set of HOX 
genes (Thoene et al., 2008), which demonstrates the importance of this CDX family in dysregulation 
of HOX genes during AML.  
Dysregulation of HOX gene expression is strongly associated with the nucleophosmin 1 (NPM1) 
mutation. This NPM1 protein is a chaperone protein that the cell uses to translocate between the nucleus 
and cytoplasm, even though its predominant localization is the nucleus (Rau and Brown, 2009). NPM1 
plays a critical role in biological processes, such as genomic stability, ribosome biogenesis, and cell 
cycle progression. In adult AML patients however, the NPM1 mutation appears to be one of the most 
common genetic mutations, which has been reported in just over 33% of all adult AML and in 45-55% 
of NK-AML cases (Luzi Falini, Mecucci et al., 2005). However, in paediatric AML, NPM1 mutations 
are far less common occurring in just less than 10% of cases, and in less than a quarter of the normal 
karyotype cases (Brown et al., 2007, Hollink et al., 2009). NPM1 relocation into the cytoplasm 
(NPMc+) occurs only in AML (Falini et al., 2009). This cellular relocation facilitates the up regulation 
of several HOX genes, of which some are very like those seen in AML initiated by an MLL chimeric 
gene fusion, although some are distinct. HOXA4, HOXA6, HOXA7, HOXA9, HOXB9 and MEIS1 are all 
over-expressed in both contexts, whereas HOXB2, HOXB3, HOXB5, HOXB6 and HOXD4 are up-
regulated in NPMc+ AML only (Mullighan et al., 2007). This will be discussed in a lot more detail 
throughout this study, however recent studies report activation of a humanized NPM1 allele leading to 
over-expression of HOXA5, HOXA7, HOXA9 and HOXA10, induction of HSC self-renewal and an 
increase in myelopoiesis (Vassiliou et al., 2011). The mechanism of the relationship between the NPM1 
 40 
mutation and the up regulation of HOX genes remains relatively unclear. A logical explanation for this 
may be that NPM1 is directly affecting the expression of HOX genes, or potentially, that mutations in 
NPM1 arrest the differentiation of early stage HPs in which HOX expression is up-regulated (Rau and 
Brown, 2009). 
 
HOX protein  Targets of transcriptional activation  Targets of transcriptional 
repression  
Species  
HOXA9/ Hoxa9  Pim1 (Hu, Passegué et al. 2007), ID2 
(Nagel, Venturini et al. 2010), CYBB 
(Bei, Lu et al. 2005), HOXA7, HOXA10, 
PBX3, MEIS1 (Faber, Krivtsov et al. 
2009). Bcl-2 (Brumatti, Salmanidis et al. 
2013), Flt3 (Gwin, Frank et al. 2010), 
Cerb1 and Pknox1 (Bei, Lu et al. 2005), 
Camk2d, Cdk6, Erg, Etv6, Foxp1, Gfi1, 
Kit, Lck, Lmo2, Myb and Sox4 (Huang, 
Sitwala et al. 2012).  
BIM (Nagel, Venturini et al. 
2010)/ Itfi1, Tlr4, Ccl3, 
Ccl4, Csf2rb, Ifngr1, 
Runx1, Cd28, Cd33 





c-Myb (Hess, Bittner et al. 2006).   Mouse  
   
NUP98-HOXA9  
  
HOXA7, HOXA9, MEIS1, PBX3, EVI1, 
MEF2C, FLT3 and KIT (Takeda, 
Goolsby et al. 2006).  
  Human  
   
HOXA10/ 
Hoxa10  
P21 (Bromleigh and Freedman 2000), 
DUSP4 (Wang, Lu et al. 2007), Itgb3 
CYBB (Eklund, Jalava et al. 
2000)/ Gata1 (Magnusson, 
Human/mouse  
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(Bei, Lu et al. 2007), Hlf (Magnusson, 
Brun et al. 2007), Tgfβ2 (Shah, Wang et 
al. 2011), Fgf2 (Shah, Bei et al. 2012), 
Dusp4 (Wang, Lu et al. 2007), Hoxa5 
(Magnusson, Brun et al. 2007), Cdx4 
(Bei, Huang et al. 2011).  
Brun et al. 2007)  
Nup-Hoxa10  Flt3, Prnp, Hlf and Jag2 (Palmqvist, 
Pineault et al. 2007).  
 Mouse  
HOXB4/ Hoxb4  MEIS1, DNTT, HLF, SOX4, RUNX2 
(Lee, Zhang et al. 2010), c-MYC (Pan 
and Simpson 2001), Hoxb2, Hoxb3 
(Satoh, Matsumura et al. 2004), Fra-1, 
JunB (Krosl and Sauvageau 2000).  
B220 and HMBS (Lee, 
Zhang et al. 2010), c-Myc 
(Satoh, Matsumura et al. 
2004).  
Human/mouse  
Table 1.4 A table listing the important mammalian HOX target genes (Alharbi et al., 2013).  
 
 
1.19 HOX gene upstream regulation 
Knock out models of HOX gene upstream regulators over the last decade have helped to define the role 
of HOX genes in normal haematopoiesis. Upstream regulators of HOX genes are thought to function as 
activators for HOX genes, such as MLL, and a family of CDX’s (CDX1, CDX2, CDX4), or potentially 
act as repressors, for example the PcG genes. These regulators play some crucial roles in development 
and haematopoiesis by regulating HOX genes (Schuettengruber et al., 2007, Jude et al., 2007, Liu et 
al., 2009, Ernst et al., 2004, Bansal et al., 2006). Studies have shown that MLL-deficient mice express 
a dramatic reduction in HSC’s and hematopoietic progenitors. Additionally, mice deficient in MLL 
exhibit a remarkable reduction in certain HOX genes, such as HOXA7/HOXA9, HOXA10, and other 
HOXB and HOXC genes (Ernst et al., 2004, McMahon et al., 2007, Jude et al., 2007, Gan et al., 2010). 
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Similarly, compound CDX-deficient mice have shown a dysregulation of the embryonic hematopoietic 
progenitors as well as impaired expression of certain HOX genes (Davidson and Zon, 2006, Wang et 
al., 2010). Most interestingly, CDX’s may act in a redundant manner and therefore many of their 
functions are conserved in embryonic haematopoiesis but may not always influence adult 
haematopoiesis (Wang et al., 2010, Lengerke et al., 2009, Koo et al., 2010). On the contrary however, 
the PcG genes (PRC1 and PRC2) are known to effectively suppress the expression of HOX genes 
(Beuchle et al., 2001, Schuettengruber et al., 2007, Simon, 2010). 
 
1.20 HOX gene dysregulation in ALL  
The dysregulation of HOX genes has also been identified in ALL including B- and T-progenitor ALL 
(B-ALL and T-ALL), especially when MLL translocations are involved. Human HOXA9, HOXA10 
and HOXC6, and their co-factor MEIS1 are up-regulated in both MLL-ENL T-ALL and MLL B-ALL 
(Ferrando et al., 2003). The human HOXA9 and MEIS1, and the murine HOXA5, HOXA9 and MEIS1 
were also shown to be up-regulated in MLL-AF4 B-ALL (Rozovskaia et al., 2001, Krivtsov et al., 2008). 
A common signature of MLL rearrangements in both AML and ALL has been the over-expression of 
HOXA genes including HOXA3, HOXA5, HOXA7, HOXA9 and HOXA10 (Zangenberg et al., 2009). 
Additionally, HOX genes are involved in translocations such as CALM-AF10 T-ALL, where human 
HOXA5, HOXA9, HOXA10 and MEIS1 are also over-expressed (Dik et al., 2005). HOXA proteins have 
been identified and shown to form chimeric fusion proteins with T-cell receptors in T-ALL, resulting 
in the global over-expression of HOXA genes (Soulier et al., 2005, Speleman et al., 2005). However, 
the aberrant expression of the CDX2 protein in ALL, which is an upstream regulator of HOX genes, is 
not correlated with HOX gene dysregulation (Thoene et al., 2009).  
 
1.21 Role of HOX genes in AML 
There are two primary mechanisms by which HOX genes are hypothesized to promote the 
transformation of myeloid progenitor cells in vivo. HOX genes are known to cause AML by forming 
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parts of new fusion proteins such as NUP98-HOX have been recently confirmed (Nakamura et al., 1996, 
Borrow et al., 1996). In addition, to this HOX genes may also indirectly lead to AML through their 
aberrant expression due to chromosomal rearrangements involving upstream regulators or co-factors, 
such as MEIS1 (Zangenberg et al., 2009). HOX genes are known to facilitate the initial transformation 
of fusion proteins, most notably with NUP98. NUP98 is a known member of the nuclear pore family. 
It is localized in the nuclear membrane and functions as a selective transporter for RNA and proteins 
between the nucleus and the cytoplasm. NUP98-HOX fusion proteins have been reported in AML and 
other leukaemias (Slape and Aplan, 2004). In AML, NUP98-HOXA9 is found to be a t(7;11)(p15;p15) 
positive translocation (Nakamura et al., 1996, Borrow et al., 1996). Eight other HOX genes have the 
ability to be fused with NUP98, including HOXA11 and HOXA13 (Fujino et al., 2002, Suzuki and 
Kuroiwa, 2002), HOXD11 and HOXD13 (Raza-Egilmez et al., 1998, Taketani et al., 2002b), and 
HOXC13 (Taketani et al., 2002a). To date, only abd-B clustered HOX genes have been shown to fuse 
with NUP98 in AML (Palmqvist et al., 2007). HOXB3 under an experimental expression has been 
reported to be a leukemogenic partner with NUP98 (Pineault et al., 2004), supporting its ability to be a 
fusion NUP98 partner although is not limited to abd-B clustered HOX genes. The potential explanation 
for the Abd-B clustered genes’ leukemogenic ability is that they have the ability to disturb hematopoietic 
differentiation (Pineault et al., 2004). HOXA9 is a key regulator of haematopoiesis and has been shown 
to behave as an oncogene in many types of leukaemia. It is unsurprising therefore that it activates the 
transcription genes known to regulate cell proliferation and survival. HOXA9 is known to directly 
activate the PIM1 gene (Hu et al. 2014). The product of this activation can then enhance proliferation 
by activating c-Myb and exerts anti-apoptotic effects by phosphorylating and inactivating the BAD 




Figure 1.8 A schematic diagram depicting the structures of AbdB HOX, NUP98 and the predictive 
fusion protein NUP98-HOX. (a) A general structure of AbdB HOX (9-13) proteins that have been 
reported to fuse with NUP98. (b) Structure of normal NUP98 protein. (c) Structure of predictive 
NUP98-HOX fusion protein. This fusion eliminates MD and RBD from AbdB and NUP98, respectively. 
Arrows represent breakpoints, MD: MEIS domain, PM: PBX motif, H: hexapeptide, HD: 
homeodomain, FG: phenylalanine-glycine, GLEBS: GLE2P-binding like motif, RBD: RNA-binding 
domain (Alharbi et al., 2013).  
 
HOXA9 directly activates the PIM1 gene, the product of which enhances c-Myb which has recently 
been identified as an indirect transcriptional target of HOXA9-MEIS1 mediating the transformation in 
Mll-Enl Leukaemia (Hu et al. 2014). HOXA9 has several other targets associated with tumorigenesis 
including the oncogene ID2, seen to be upregulated. BIM that encodes an apoptotic factor is 
downregulated in response to HOXA9. HOXA9 also activates the CYBB gene; encoding Gp91phox, a 
phagocyte respiratory burst oxidase protein expressed in differentiated myeloid cells (Thorsteinsdottir 
et al., 2001). Interestingly however, HOXA9 in mice has been shown to directly activates the 
transcription of the Flt3 gene, associated with the unfavourable prognosis of AML, and has also shown 
to regulate its own co-factor, MEIS1, by binding to both MEIS1’s upstream regulatory genes CERB1 
and PKNOX1 (Morgado et al., 2007). There is a list of proliferative genes that have been recently linked 
and identified as downstream targets for HOXA9 including; CAMK2D, CDK6, ERG, ETV6, FLT3, 
FOXP1, GFI1, KIT, LCK, LMO2, MYB and SOX66. Over 50% of AML cases over express HOXA9 
along with the co-factor already mentioned, MEIS1 (Morgado et al., 2007). This is thought to be a result 
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of some highly conserved evolutionary enhancers that function to promote self-renewal. These binding 
sites are also enriched for transcription factors such as PU1, C/EBPa and STAT5 that are mutated or 
otherwise activated in acute leukaemia. HOXA9 binding enhancers promotes CBP/P300 recruitment, 
histone acetylation and transcriptional activation of pro-proliferative genes while at other sites HOXA9 
binding is associated with repression (Rajala et al. 2013). A key area of study therefore is to try and 
validate how HOXA9 over-expression or mutation of associated transcription factors deregulates 
transcription and on identifying these, what might be the crucial targets for leukaemogenesis (Figure 
1.10).  
 
Figure 1.9 A schematic diagram depicting cell specific transcriptional programs involved in AML 
progression via MLL fusions and MLL PTD near HOXA9 and the ability for differentiation genes and 
pro-proliferation genes to be manipulated (Allis et al., 2010).  
 
 
1.22 HOX genes as prognostic markers  
The expression of HOX genes is an important prognostic factor in AML. Over-expression of HOX genes 
is now widely accepted as being closely associated with an unfavourable cytogenetic subset of AML. 
Among all 6817 genes investigated in AML patients, the single gene linked to the worst outcome and 
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relapse of disease, including short survival was HOXA9 (Golub et al., 1999). Equally, high expression 
of HOXA9 is associated with low CR rate (Li et al., 2013). Low HOXA9 expression on the other hand 
was found to be strongly correlated with the best outcome and response to therapy (Andreeff et al., 
2008). It is important to note at this point that low expression of HOXA4 and MEIS1 are also shown to 
be predictors of more favourable AML patient outcome (Zangenberg et al., 2009). High expression of 
HOXA7, HOXA9 and HOXA11 as well as the co-factor PBX3 are independent prognosis markers of 
adverse overall survival (OS) in abnormal karyotype AML (Li et al., 2012). The global increase in HOX 
expression appears to strongly reflect the outcome of disease, supporting the theory of functional 
redundancy between many HOX proteins. The highest levels of HOX can be seen in cases where an 
FLT3 mutation is present, and has unfavourable outcomes, in general HOX genes are expressed at very 
low levels only in the favourable subsets of AML.  
Studies have established the importance of HOX genes in the progression of AML, however, it is still 
unclear exactly what the functions of these genes are other than inhibiting differentiation and increasing 
cell proliferation. The inability to identify a precise mechanism for individual HOX genes may be due 
to the co-operative functional redundancy expressed by members of this family, meaning the 
knockdown of any single HOX gene is extremely difficult to interpret, but may also help to explain the 
contrast in gene knock-in and knockout results seen in some myeloma and solid malignancies by 
targeting the HOX proteins and antagonizing their interactions with the PBX co-factor using HXR9 (a 
peptide inhibitor) (Morgan et al., 2007, Shears et al., 2008, Plowright et al., 2009, Daniels et al., 2010, 
Morgan et al., 2010). PBX is known to bind to the PBX motif in HOX paralogous group 1-10. HOX-
PBX dimers have been shown to have an increased binding affinity and specificity for their target DNA 
sequences compared to isolated HOX monomers alone. HOX-PBX dimers are involved in the interaction 
of PBX to the conserved hexapeptide sequence WYPWMK found in the N terminal region to the 
homeodomain of HOX proteins from paralogous groups 1-10 responsible for the cooperative binding 
to DNA by PBX and HOX partners (Chang et al., 1995, Shen et al., 1997, Medina-Martínez and 
Ramírez-Solis, 2003). A novel peptide inhibitor, HXR9, expresses a sequence which mimics the HOX 
protein hexapeptide sequence responsible for PBX binding and therefore interferes with the DNA 
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binding of HOX-PBX. HXR9 has been shown to be extremely cytotoxic to cells, due to an increase in 
expression of c-Fos (Morgan et al., 2007, Shears et al., 2008, Plowright et al., 2009, Daniels et al., 
2010). Targeting this could be a useful approach in AML for addressing some of the redundant functions 
of HOX genes. Dysregulation of HOX genes is very common in many types of haematological 
malignancies, including AML (Ferrando et al., 2003), but also in some solid malignancies including 
lung (Abe et al., 2006, Plowright et al., 2009), renal (Shears et al., 2008), ovarian (Cheng et al., 2005, 
Morgan et al., 2010), and other cancers. Although it is well documented that over-expression of HOXA9 
in AML is a poor prognostic factor (Golub et al., 1999), HOX genes have a very clear oncogenic 
function in leukaemia (Eklund, 2007) with their over-expression in melanoma maintaining cell survival, 
by likely preventing c-Fos transcription (Morgan et al., 2007). 
 
1.23 HOXA9 
As mentioned already, out of all 6817 genes investigated in AML patients by a larger study, the single 
gene linked to the worst outcome and relapse of disease, including poor survival was HOXA9 (Golub 
et al., 1999), with high expression of HOXA9 associated with a low CR rate (Li et al., 2013) and low 
HOXA9 expression strongly correlated with the best outcome and response to therapy (Andreeff, 
Ruvolo et al. 2008). HOXA9 is necessary for maintaining leukemic transformation; however, the 
molecular mechanisms through which it promotes leukaemogenesis remain extremely elusive. Studies 
have helped establish that HOXA9 regulates downstream gene expression through binding at promoter 
distal enhancers along with a subset of cell-specific cofactor and collaborator proteins. Efforts are being 
made to identify the critical co-factors and target genes required for maintaining transformation in 
HOXA9-overexpressing leukaemia. With continued advances in understanding HOXA9-mediated 
transformation, and opportunity for developing novel therapeutics that would be applicable for greater 




Figure 1.10 A schematic diagram depicting tertiary structure of HOXA9 binding to DNA under x-ray 























Table 1.5 A table listing all HOXA9 interacting proteins and all HOXA9 target genes (LaRonde-
LeBlanc and Wolberger, 2003).  
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1.24 HOX-PBX targeting  
Over the last 20 years there has been a definitive change in the approach to cancer therapy from the use 
of untargeted chemotherapeutic agents to utilizing cancer-specific targeting drugs. As previously 
mentioned HOX proteins can act as dimers or trimers, bound to different co-factors in many different 
spatial arrangements. The co-factor of most interest here is pre-B-cell leukaemia homeobox (PBX). 
PBX is a family of transcriptions co-factors, which are members of the three-amino acid loop extension 
superclass of Homeobox proteins, known to bind with a large variety of HOX proteins. Exploiting the 
interaction between HOX and PBX binding which is mediated by a small tryptophan-containing motif 
which incorporates a highly conserved hexapeptide region, which can be located within the HOX 
protein itself, a hydrophobic pocket positioned in the PBX tertiary structure is responsible for this 
binding and became an area of keen interest. HXR9 is a synthetic peptide, designed by Professor 
Richard Morgan at The University of Bradford, formerly of The University of Surrey, which consists 
of a hexapeptide region and a small polyarginine sequence that can mimic this hexapeptide motif 
inhibiting HXR9’s ability to successfully bind to HOX proteins, therefore down-regulating some of their 
target genes. This 18-amino-acid peptide consisting of a previously identified hexapeptide sequence 
binds to PBX and nine C-terminal arginine residues (R9) facilitating cell entry into the cytoplasm and 
nucleus by facilitating binding to the extra cellular proteins heparan sulphate (Morgan et al., 2007). The 
N-terminal and C-terminal amino bonds are in a D-isomer conformation which has already been shown 
to extend the half-life of the peptide to 12h in human serum (Morgan et al, 2007). CXR9 is used as a 
control peptide which lacks the functional hexapeptide sequence including the R9 sequence.  
Since the discovery of HXR9, it has been shown to increase apoptosis in several cancers including 
myeloma, kidney, melanoma, non-small cell lung and ovarian cancer (Phelan et al., 1995, Chang et al., 
1995, Shanmugam et al., 1997, Piper et al., 1999, Morgan et al., 2000, Medina-Martínez and Ramírez-
Solis, 2003). HXR9 treatment causes a dramatic reduction in proliferation in tumour cells from multiple 
myeloma, ovarian, and melanoma both in vivo and in vitro (Phelan et al., 1995, Chang et al., 1995, 
Shanmugam et al., 1997, Piper et al., 1999, Morgan et al., 2000, Medina-Martínez and Ramírez-Solis, 
2003). It is important however, to note that as HXR9 exerts its ability by specifically binding to the 
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PBX family, only HOX proteins 1-10 use PBX as a co-factor. HOXA11, which is a tumour suppressor, 
is not affected. E4 is a 300 Dalton small molecule which is a mimic of HXR9 that could exert its 
cytotoxic effects on the cell, binding to PBX and blocking its ability to interact with HOX proteins. E4 
is lipophilic and passes through the phospholipid bilayer in a passive manner. HXR9 is a peptide and 
therefore it cannot be taken orally and must be administered intravenously or intratumorally for 
effective delivery to the target tumour (Figure 1.11).  
 
Figure 1.11 A schematic diagram depicting the competitive binding of HXR9, where HXR9 mimics the 
hexapeptide motif of HOX proteins binding to PBX, inhibiting its own ability to successfully bind to 
HOX proteins and down regulating some of their target genes (Morgan and Grey 2016). 
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1.25 Targeting HOX-PBX Dimers  
The widespread aberrant HOX protein expression in cancer, and the key pathways they exert influence 
over has provided much interest as potential therapeutic targets. Various independent groups have 
targeted individual HOX genes with siRNA and miRNA, to varying degrees of success. This therapeutic 
approach is neither seen as especial effective, mainly due to functional redundancy of HOX proteins, 
and the limited application of siRNAs and miRNAs in the clinical setting. An alternative approach is to 
target and inhibit the interaction between HOX and PBX proteins, disrupting HOX paralog groups’ 1-
10 functionality. This interaction is mediated by a small tryptophan-containing motif, which 
incorporates a highly conserved hexapeptide region located within the HOX protein. This hexapeptide 
motif binds to a hydrophobic pocket positioned in the PBX’s tertiary structure known as the PID 
(Laurent, 2008; Phelan, 1994; Morgan, 2000). A previous attempt at targeting this interaction with a 
small molecular inhibitor has been published, but with its dissociation constants (Kd) in the micromolar 
range, the experimental drug was abandoned (Jl, 2004). Independently an alternative approach was 
developed utilising a peptide- based drug named HXR9.  
 
1.26 Peptide therapies: HXR9, CXR9 and HTL00-1  
HXR9 is an 18 amino acid synthetic peptide consisting of a hexapeptide sequence connected to a short 
polyarginine sequence (Li, 2003; Errico, 2013). The hexapeptide motif mimics the same amino acid 
sequence found in HOX proteins, thus allowing it to bind to PBX1-4 and inhibiting its dimerization to 
HOX (Morgan, 2010). Figure 1.32 shows computer modelling of HOXA9-PBX1 inhibition by HXR9.  
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Figure 1.32 Computer modelling based on X-ray crystallography of HXR9 binding to PBX1 PID, 
inhibiting the dimerization with HOXA9 and HOXB1 (LaRonde-LeBlanc and Wolberger, 2003).  
The polyarginine repeat promotes the cellular uptake of HXR9, via endocytosis, by binding to the extra 
cellular protein heparin sulphate. HXR9 was initially proved to be cytotoxic on melanoma cell lines 
and primary melanoma tumour cells and was shown to reduce growth of B16F10 murine melanoma 
cells in an orthotropic model. Subsequent experiments have shown HXR9 to be cytotoxic in numerous 
cancers including myeloma, mesothelioma, meningioma, melanoma, prostate cancer, breast cancer, 
non-small cell lung cancer and ovarian cancer both in vitro and in vivo (Li, 2003; Errico, 2013; Morgan, 




1.28 Apoptosis resistance mechanisms 
Apoptosis can be triggered by intrinsic and extrinsic mechanisms, with cross-talk common, both leading 
to loss of mitochondrial membrane potential and the activation of the cysteine-aspartic acid proteases 
(caspase) cascade. The extrinsic apoptotic pathway is mediated by membrane death receptors such as, 
Fas receptor or tumour necrosis factor (TNF) receptor. Once a death factor has bound to its’ respective 
receptor, it causes a cascade reaction in which procaspases are cleaved to form their activated forms. 
These activated caspases cleave specific protein targets within the cell causing apoptosis. The intrinsic 
pathway is not dependent on external stimuli but rather stimuli from inside the cell. Cellular stress 
causes BH3 interacting-domain death agonist (BID) protein to translocate and bind to B-cell lymphoma 
2 associated X protein (Bax). This binding event causes a conformational change in Bax, which allows 
it to insert itself into the outer mitochondria membrane. Bax oligomerises (6-8 molecules) to produce 
its final form. This final form of Bax allows cytochrome C and procaspase 9 to be released from the 
mitochondria into the cytosol (Pastorino, 1999; Eskes, 1998). In the cytosol molecules of cytochrome 
C, procaspase 9 and apoptotic protease activating factor 1 (Apaf-1) bind together to form the wheel-
like complex known as apoptosome. The newly formed apoptosome triggers a caspase cascade reaction 
which ends with cell apoptosis. Members of the IAP family inhibit apoptosis by binding, and 
inactivating, caspases 3, 7 and 9 (Deveraux, 1999) During the release of cytochrome C from the 
mitochondria, two other proteins known as Smac and DIABLO are also liberated. Smac and DIABLO 
act as inhibitors to members of the inhibitor of apoptosis (IAP) family. B-cell lymphoma 2 (Bcl-2) and 
B-cell lymphoma-extra-large (Bcl-XL) can inhibit Bax and thus stop it from being inserted into the 
mitochondrial membrane. However, Bcl-2 and Bcl-XL can both are inhibited themselves by the 
inhibitor Bad. Figure 1.12 (de Vries, 2006) illustrates key proteins needed in the intrinsic and extrinsic 
apoptosis pathways. GBM tumours have been shown to have aberrant expression of key pro and anti-
apoptotic proteins either by direct activation/suppression or by inactivation of p53. Inactivation of P53 
has shown associated with an up-regulation of Bcl-2 and Bcl-XL leading to increased resistance to 
chemo and radiotherapy.  
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Figure 1.12 A schematic illustration of the intrinsic and extrinsic apoptosis pathway. Though apoptotic 
stimuli are a key difference, both pathways converge at the mitochondria leading to the release of 
cytochrome C and caspase cascade (de Vries, 2006).  
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Chapter 2: General Materials & 
Methods 
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2.1 Leukemic cell lines 
The human leukaemic cell lines have been key over the last decade in attempting to understand what is 
going on at a cytogenetic level with patients with AML and other leukaemia’s. These cell lines provide 
useful model systems to study various aspects of the disease including control of differentiation in 
human myelogenous leukaemia and, in a broader framework, the control of normal myeloid 
development. The AML cell lines used in this study represented various AML subtypes with these cell 
lines being both primary or secondary cell lines. Some of these primary AML cell lines derived from 
patients that had de novo mutations like KG-1, a cell line which is derived from patients with 
erythroleukaemia (Koeffler and Golde, 1978b, Koeffler and Golde, 1978a), HEL 92.1.7, an 
erythroleukaemia cell line (Martin and Papayannopoulou, 1982) and importantly, HL-60, a cell line that 
was initially obtained from acute promyelocytic leukaemia (APML) (Collins et al., 1978). Secondary 
AML cell lines are just as important as these cell lines are derived from patients that developed AML 
from pre-leukemic diseases such as MDS, chronic myeloid leukaemia (CML) or following previous 
treatment with chemotherapy, including K562, a CML cell in blast crisis (Lozzio and Lozzio, 1975) 
and KU812F, also a CML cell in blast crisis indicative of a poor prognosis (Lozzio and Lozzio, 1975, 
Kishi, 1985, Roche et al., 2004, Rücker et al., 2006, Weisberg et al., 2008).  
• HL-60: cells also known as human promyelocytic leukaemic cells are widely used for laboratory 
research on how specific kinds of blood cells are formed. HL-60 cells proliferate continuously in a 
suspension culture of nutrient and antibiotic chemicals. The doubling time of these cells is about 
36–48 hours. This cell line was derived from a 36-year-old woman with acute promyelocytic 
leukaemia at MD Anderson Cancer Centre (Gallagher et al., 1979). HL-60 cells are predominantly 
neutrophilic promyelocytic (Gallagher et al., 1979), with proliferation occurring through transferrin 
and insulin receptors, expressed on the cell surface. The requirement for insulin and transferrin is 
absolute, as HL-60 proliferation ceases if either of these compounds is removed from serum-free 
culture media (Breitman et al., 1980). With this cell line, differentiation to mature granulocytes is 
highly induced by compounds like dimethyl sulfoxide (DMSO), or RA. Other compounds like 1,25-
dihydroxyvitamin D3 and GM-CSF can also induce HL-60 cells to differentiate to monocytic, 
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macrophage-like and eosinophil phenotypes, respectively. The HL-60 cultured cell line provides a 
continuous source of human cells to study the molecular events of myeloid differentiation and the 
effects of physiologic, pharmacologic, and virologic elements of this process.  
 
• KG1: cells are derived from the bone marrow aspirate of a 59-year-old male Caucasian who was 
diagnosed with erythroleukaemia that happened to transform into acute myelogenous leukaemia. 
These cells form colonies in soft-agar in the presence of colony stimulating factor (CSF). KG-1 
cells appear to resemble acute myelogenous leukaemia and show considerable pleomorphism with 
a large predominance of myeloblasts and promyelocytes. However, a small percentage of these 
cells are mature granulocytes that have the occasional presence of macrophages and eosinophils. It 
is important to note, however, that they do not express surface IG or EBV antigens and lack specific 
markers for lymphocytic cells (Figure 3.1). 
 
• K562: cells are erythroleukaemia-like cells derived from a 53-year-old female chronic 
myelogenous leukaemia patient in blast crisis (Lozzio and Lozzio, 1975, Britten et al., 2002). This 
cell line, like most leukaemic cell lines is non-adherent and rounded. They are positive for the BCR-
ABL fusion gene, and bear proteomic resemblance to both undifferentiated granulocytes (Klein et 
al., 1976) and erythrocytes (Andersson et al., 1979). In culture these cells exhibit a lot less clumping 
than many other suspension cell lines, which is thought to be due to downregulation of cell surface 
adhesion molecules by the BCR-ABL gene (Jongen-Lavrencic et al., 2008). On the other hand, 
another study suggests that BCR-ABL over-expression could in fact increase cell adherence to cell 
culture plastic (Karimiani et al., 2014). K562 cells spontaneously develop characteristics that 
resemble early stage erythrocytes, granulocytes and monocytes (Lozzio, 1981) however are easily 
killed by natural killer cells (Lozzio, 1979) that lack the MHC complex required to inhibit NK 
activity (Figure 3.1). These cells also lack any trace of Esptein-Barr virus and other herpes viruses. 
In addition to the Philadelphia chromosome though, K562 cells exhibit a second reciprocal 
translocation between the long arm of chromosome 15 with chromosome 17 (Lozzio and Lozzio, 
1975).  
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• HEL92.1.7: cells are derived from a 30-year-old male Caucasian and express ß-2 microglobulin 
and Ia antigen often used in the study of erythroid cell differentiation and globin gene expression. 
They are nalogous to friend cell leukaemia in mice and have similar characteristics to K562 cells. 
These cells differentiate spontaneously into erythroblast-like cells. Macrophage-like differentiation 
may be induced with phorbol esters like TPA (12-O-tetradecanoyl-phorbol-13-acetate) and PMA 
(phorbol myristic acid). 
 
• KU-812: cells are a chronic myelogenous leukaemia cell line in which the cells are morphologically 
characteristic of basophils (Fc receptors, basophilic granules, histamine production), and are 
negative for lymphoid markers. These cells contain at least one Ph1 (Philadelphia) chromosome 
and have some characteristics of basophilic leukocytes (Fc receptors, basophilic granules, histamine 
production), along with being negative for lymphoid markers.  
 
2.2 Instruments and materials 
Instruments and materials that were used in this study were: Beckman coullier, a plate reader 
(Miltenyibiotec), a fluorescence-activated cell sorting (FACS) machine (Lebtech), a Nanodrop 
spectrophotometer ND-1000, Stratagene Mx 3005P, cytospin 4, a fluorescent microscope, and an 
eppendorf centrifuge 5415R. Cloned AMV first-strand synthesis kit, glutamine, foetal bovine serum 
and IMDM medium were obtained from Invitrogen, Paisley. SYBR green jumpstat Taq ready mix, 
penicillin-streptomycin solution and RPMI-1640 were all supplied by Sigma, Dorset. RNeasy mini kit 
was obtained from Qiagen, (West Sussex). Primers were supplied by Eurgentec (Belgium).  
 
2.3 Cell culture 
All cell lines were cultured in their appropriate media Table 2.2, which were made using the relevant 
reagents from Table 2.3. All cells were incubated in a Forma Steri-Cycle CO2 incubator (Thermo 
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Scientific, UK) at 37°C with 5% CO2 and 25% O2. Cells were regularly passaged and weren’t allowed 
to pass 90% confluency. Media was changed every 3-5 days or as required. When cells were passaged, 
cells were centrifuged at 690g for 3 minutes, the media was removed and the cell pellet was then re-
suspended and washed with Hanks to remove any FBS. The cell solution was then re- centrifuged again 
at 690g for 3 minutes and the supernatant was removed. Once cells had been centrifuged down, fresh 
media containing foetal calf serum was added and the cell pellet was then re-suspended in the 
appropriate media and then split into the required dilutions and required flasks. All work was carried 
out in a sterile environment provided by a laminar flow hood with a double filter.  
 
Cell line  Source  Disease  Culure media  References  
  
KG-1  Human  Erythroleukaemia  IMDM, 20% FBS, P/S  (Koeffler and 
Golde 1978)  





HL-60  Human  APML  IMDM, 20% FBS, P/S  (Collins, Ruscetti 
et al. 1978)  
KU812F  Human  CML in blast crisis  RPMI, 10% FBS, P/S and L-glutamine  (Kishi 1985)  
K562  Human  CML in blast crisis  RPMI, 10% FBS, P/S and L-glutamine  (Lozzio and 
Lozzio 1975)  
Table 2.1 A table listing cell lines used in this study. This table shows sources and diseases that cell 
lines were derived from. All cell lines were cultured at 37°C, 5% CO2 and split 3 times a week or as 
required. 
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2.4 Patients, controls and ethics 
Blood samples obtained from normal healthy donors at the Royal Surrey County Hospital (Guildford, 
UK). Ethics for this work covered by a pre-existing multi-project approval. Of these, 143 healthy donor 
samples were analyzed in this study, between the ages of 18 and 86. These samples were collected in 
November 2011, where peripheral blood mononuclear cell isolation was undertaken.
 
Cells were 
transferred into a 25ml universal tube and centrifuged at 690g for 3 minutes. The supernatant was 
removed and cell pellets were re-suspended in 1ml RPMI, supplemented with 10% (v/v) dimethyl 
sulphoxide DMSO (Sigma-Aldrich, UK) and 10% (v/v) FBS. The cell suspension was then transferred 
into 1.8ml cryovials. Cells were stored in cryovials and initially frozen overnight using a Mr Frosty 
Freezing Container (Thermo Scientific, UK) which has a temperature drop of 1°C/minute overnight 
before being transferred to the -80°C for storage. The collection of tissue and blood from AML patients 
and patients with other hematological disorders was approved by the local research ethics committee 
(REC no: 15/EM/0537).  Suitable patients were identified at St. George’s Hospital Haematology and 
Oncology. Patients were and asked to sign a written consent form. In total, ethics requested 100 patients, 
73 of which were used in this study from patients with AML or other various haematological 
malignancies. 
 
2.5 Cryopreservation of cell stocks  
After calculating the cell density, a volume of media containing 5x10
6 
cells were transferred into a 
25ml universal tube and centrifuged at 690g for 3 minutes. Then, supernatant was removed and cell 
pellets were re-suspended in 1ml storage medium, which was full growth medium supplemented with 
10% (v/v) dimethyl sulphoxide (DMSO). The cell suspension was then transferred into 1.8ml cryovials. 
Cryovials were initially frozen overnight using a Mr. Frosty Freezing Container (Thermo Scientific, 
UK) which has a temperature drop of 1°C/minute. The following day the cells were transferred to liquid 
nitrogen storage 
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2.6 Revitalisation of cryopreserved cells  
Cryopreserved cells were thawed rapidly by incubating in a 37°C water bath for 2 minutes. Then, cells 
were transferred to 10ml of pre-warmed FBS and centrifuged at 690g for 3 minutes. The supernatant 
was discarded to remove DMSO traces and cell pellets were re-suspended in 10ml full growth medium 
in a T-25 sterile cell culture flask and cultured at 37°C in a humidified environment containing 5% 
CO2. After cell growth had resumed, cells were transferred to a T-75 flask and used for experiments. 
To maintain stock of all cell lines used, and provide varying passage numbers, cells were regularly 
cryopreserved. Cells in log phase of growth were centrifuged at 690g for 3 minutes to form a cell pellet. 
The pellet was then re-suspended at 106-107 cell/ml in appropriate complete media, with the addition of 
10% DMSO (Sigma-Aldrich, UK). Cells were then transferred into 1ml aliquots, under sterile 
conditions, into labelled cryovials. Cryovials were frozen overnight. Rapid thawing at 37°C was used 
to revive cells from liquid nitrogen storage. 
 
2.7 PBMC isolation  
PBMCs were isolated from 10-15ml of human blood collected in EDTA tubes from normal healthy 
donors and patients. Blood was diluted in 10ml PBS and layered carefully onto 15ml of Ficoll before 
being centrifuged at room temperature for 25 minutes at 690g. PBMC’s were harvested from the 
interface (buffy coat/ring) and placed in separate tubes, washed with 50ml of ice cold PBS before being 
centrifuged at 4°C for 5 minutes at 690g. The supernatant was aspirated without disturbing the cells and 
incubated for 10 minutes with 20ml ice-cold Red Blood Cell lysis buffer and centrifuged down at 4°C 
for 5 minutes at 690g. Isolated PBMCs were then re-suspended in 1ml of storage media [RPMI-1640 




2.8 RNA extraction 
Cells were centrifuged down at 690g for 3 minutes, the media was removed, and the cell pellet was then 
re-suspended and washed with HBSS to remove any FBS. The cell solution was then re- centrifuged 
again at 1500rpm for 3 minutes and the supernatant was removed. The cell pellet was then lysed using 
600μl of Lysis Buffer RLT (Qiagen, UK) with 6μl (10%) of β-mercaptoethanol (Sigma-Aldrich, UK). 
RLT and β-mercaptoethanol amounts used varied upon the size of the cell pellet. Complete RLT mix 
was then transferred to a gDNA eliminator spin column (Qiagen, UK) placed in a 2ml collecting tube 
and centrifuged for 30 seconds at 10,000rpm. The spin column was discarded 70% ethanol was added 
at a 1:1 ratio and mixed. The 1:1 mixture was then transferred to an RNeasy MinElute spin column 
(Qiagen, UK) placed in a 2ml collecting tube and centrifuged for 30 seconds at 10,000rpm. The 
collecting tube containing the flow through was discarded and replaced with a fresh 2ml collecting tube. 
700μl of Buffer RW1 (Qiagen, UK) was added to the RNeasy MinElute spin column and centrifuged 
at 10,000rpm for 30 seconds. The collecting tube with flow through was discarded and again replaced 
with a new 2ml collecting tube. Then 500μl of complete Buffer RPE (Qiagen, UK), with ethanol added, 
was added to the RNeasy MinElute spin column and centrifuged at 10,000rpm for 30 seconds. The 
collecting tube was discarded and replaced before an additional 500μl of complete Buffer RPE was 
added to the RNeasy MinElute spin column and centrifuged at 10,000rpm for 2 minutes. Again, the 
collecting tube was discarded and replaced before the RNeasy MinElute spin column was centrifuged 
at 10,000rpm for 1 minute. The RNeasy MinElute spin column was then placed in a new 1.5ml 
collecting eppendorf with 30μl of RNase-free water (Qiagen, UK) added to the RNeasy MinElute spin 
column. This was left for 1 minute at room temperature before being centrifuged at 10,000rpm for 1 
minute. The RNeasy MinElute spin column was discarded, and the collecting Eppendorf kept. RNA 
was quantified using a NanoDrop spectrophotometer ND-1000 (NanoDrop Technologies, USA). 
Samples were stored at -80°C for later use. All products used during the RNA extraction from Qiagen 




During gel preparation 550μL of RNA gel matrix was pipetted into a spin filter and spun at 1500g for 
10 minutes at room temperature. 65μl filtered gel was aliquoted into 0.5 mL RNase-free micro 
centrifuge tubes. Preparing the Gel-Dye Mix: The RNA dye concentrate was left to equilibrate to room 
temperature for 30 minutes. RNA dye concentrate was then spun for 10 seconds. 1μl of dye was added 
into a 65μl aliquot of filtered gel. This solution was vortexed well and centrifuged at 13000g for 10 
minutes at room temperature. During loading, put a new RNA chip on the chip priming station, 9μl of 
gel-dye mix was pipetted into the appropriate wells, waiting for exactly 30 seconds the clip was released 
before waiting a further 5 seconds. The plunger was slowly pulled back to the 1mL position. The chip 
priming station was opened and 9μl of gel-dye mix was added to the wells marked before discarding 
the remaining gel- dye mix. Loading the Marker 1: 5μl of RNA marker was loaded into all sample 
wells and in the wells of interest, accordingly marked. When loading the ladder and samples 1μl of 
prepared ladder was added to the wells marked. 1μl of sample was pipetted into each of the sample 
wells.  1μl of RNA Marker was added into each unused sample well. The chip was put horizontally 
into the IKA vortexer and vortexed for 1 min at 2400rpm before being analysed in the Agilent 2100 
Bioanalyzer instrument within 5 minutes of preparation. 
 
 
Figure 2.1 The quality control run on RNA extracted from peripheral mononuclear blood cells that was 
used throughout the study. RNA was run on 2% agarose Egel when determining RNA integrity with RIN 
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scores being obtained from running each sample on an agilent 2100 bioanalyser. Any RNA with a RIN 
score <7 was discarded. 
 
2.10 Complementary DNA synthesis 
RNA was reverse transcribed by mixing 1μg of RNA in a total volume of 20μl with final concentrations 
of 0.1M DTT (Invitrogen, UK), 10mM of deoxynucleotide triphosphate mix (dNTP) (Invitrogen, UK), 
50μM Oligo (dT)20 primers (Invitrogen, UK), 15 U/μl of Cloned AMV reverse transcriptase (Invitrogen, 
UK) and 40 U/μl of RNaseOut (Invitrogen, UK). RNase-free water was added to make up the volume 
to 20μl. This mixture was incubated at 50°C for 45 minutes. The cDNA synthesis reaction was 
terminated by incubating the sample at 85°C for 10 minutes. The cDNA samples were stored at a total 
volume of 500μl (2ng/μl) at 20°C. Total volume was made up by adding Nuclease-free water. All 
products used during the cDNA synthesis from Invitrogen were supplied in the Cloned AMV First-
Strand Synthesis Kit (Invitrogen, UK). One sample of total RNA from normal human adult brain 
(Clontech Laboratories, UK) purchased for cDNA synthesis was stored at -80°C. 
 
Well Reagent Well Reaction Volume 
cDNA 2μl (4ng/μl) 
Primers (Forward and Reverse) 5μl 
SYBR Green JumpStart Taq ReadyMix 12.5μl 
Reference Dye 0.25μl 
Nuclease-free water 5.25μl 




2.11 Quantitative reverse transcription polymerase chain reaction 
A Quantitative Reverse Transcription Polymerase Chain Reaction (QRT-PCR) was performed using 
the Stratagene Mx3005P (Agilent Technologies, UK) real time PCR machine. The Stratagene Mx3005P 
machine measures PCR product accumulation during the exponential phase of the reaction by SYBR 
green fluorescence (Sigma-Aldrich, UK). The qRT-PCR master mix was prepared using 625μl SYBR 
Green JumpStart Taq ReadyMix (Sigma-Aldrich, UK), 12.5μl Reference Dye (ROX) (Sigma-Aldrich, 
UK), 262.5μl nuclease-free water and 100μl of 2ng cDNA. A primer master mix was also prepared by 
mixing 20μl each of relevant forward and reverse primers with 160μl of RNase-free water. Table 2.4 
shows a breakdown of reagents and reaction volumes of an individual well. β-actin and GAPDH were 
used as housekeeper genes and thus the internal controls. Details of primers can be seen in the 
Appendix. Each experimental well was loaded with 20μl of qRT-PCR master mix and 5μl of appropriate 
primer master mix. Reaction conditions used were 1 cycle at 95°C for 10 minutes, followed by 40 cycles 
of 30 seconds at 95°C, 1 minute at 60°C and 1 minute at 72°C. The final cycle was 1 cycle of 1 minute 
at 95°C, 30 seconds at 55°C and 30 seconds at 95°C. The thermal profile can be seen in Figure 2.3. 
Results were analysed using the calculation derived from Livak’s comparative Ct calculation method 
(Livak and Schmittgen, 2001). Cycle threshold (CT) is defined as the number of cycles required for the 
fluorescent signal to cross the threshold to be detected. Below is the calculation used:  
Relative Expression =   2
(-𝚫𝚫𝐂𝐓)
 x 10,000 
 
 
2.12 Calculations (qPCR)  
There are two common methods used to analyse real-time PCR data: absolute quantification and relative 
quantification. Absolute quantification is known as the input copy number, which relates the PCR signal 
to a standard curve. Relative quantification on the other hand relates the PCR signal of a target transcript 
in a treatment group to the PCR signal of another sample just like an untreated control. The 2
(-𝚫𝚫𝐂𝐓) 
method is an extremely useful way of analysing relative changes in gene expression from real-time 
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quantitative PCR experiments. Normalizing to an endogenous reference allows us to use a method for 
correcting results with differing quantities of input RNA. The 2
(-𝚫𝚫𝐂𝐓) 
method is useful in that it uses 
data, which is already generated as part of the real-time PCR experiment that can perform this 
normalization function. This is a huge positive when it is not practical to measure the exact amount of 
input RNA.  As mentioned, results were calculated by first normalizing internally to B-actin or GAPDH 
before dividing against the gene of interest (HOXA9) for a relative comparison. This calculation is 
derived from Livak’s PCR calculation method (Livak and Schmittgen, 2001). Cycle threshold (CT) is 
defined as the number of cycles required for the fluorescent signal to cross the threshold and be detected. 
Calculations for the quantification of gene expression was done using the Livak formula. It is important 
that we are able to amulate where threshold is consistent or where the gradient is similar if we are to 
compare and contrast there values. 
 
2.13 CT Values for qPCR: 
 
 
 HL60 K562 KG-1 
HOXA9 177.09 359.57 906.66 
PBX1 0.42 21.57 3.96 
PBX2 3.93 32.33 2.28 
PBX3 179.82 20.30 160.63 
PBX4 2.16 4.09 1.83 
MEIS1 214.73 41.91 186.51 
MEIS2 11.98 291.37 21.48 
MEIS3 0.76 15.96 1.59 
 
 
Table 2.3 A table of the CT values used for qPCR. Values were calculated by first normalizing 
internally to B-actin before dividing against the gene of interest for a relative comparison. This 
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calculation is derived from Livak’s PCR calculation method:  Relative Expression =   2
(-𝚫𝚫𝐂𝐓)
(Livak 




2.14 Preparation of cell lysate for western blotting 
Western blotting is a very common technique in cell and molecular biology that is used to separate and 
identify proteins. A mixture of proteins is separated based on molecular weight and type, as the 
antibodies only bind to the protein of interest, through gel electrophoresis where the thickness of the 
band corresponds to the amount of protein present only one band should be visible (Mahmood and 
Yang, 2012). Cells were harvested then centrifuged at 720g for 3 minutes to aspirate the supernatant. 
After adding 600µl of RLT buffer (Qiagen) to disrupt the cells, the lysate was pipetted into QIAshredder 
spin columns placed in 2ml collection tubes and centrifuged for 2 minutes at full speed. This step was 
followed by transferring the homogenized lysate to AllPrep DNA spin columns that were placed in 2ml 
collection tubes and centrifuge for 30 seconds at full speed. The flow-through was then used for RNA 
purification by adding 400µl of 100% ethanol. The samples including any precipitate were then 
transferred to an RNeasy spin column placed in a 2ml collection tube and centrifuged for 15 seconds at 
full speed. The resulting flow-through was mixed vigorously with 1ml of buffer APP (Qiagen) and 
incubated for 10 minutes at room temperature to precipitate the protein. Afterwards this was centrifuged 
at full speed for 10 minutes and then 500µl of 70% of ethanol was added to the protein pellet and 
centrifuged at full speed for 1 minute. The supernatant was removed and the protein pellet was dried 
for 5-10 minutes at room temperature as incomplete drying may lead to problems when loading the 
protein onto the gel due to residual ethanol. 100µl of buffer ALO (Qiagen) was added and mixed 
vigorously to dissolve the protein pellet and then incubated for 5 minutes at 95°C to completely dissolve 
and denature the protein. The sample was cooled at room temperature and centrifuged for 1 minute at 
full speed. The resulted supernatant was used later in western blotting. The protein concentration in cell 
lysates was determined using a bicinchonic acid (BCA) assay.  
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2.15 Measuring protein concentrations by BCA  
This assay was used to measure protein concentrations in cell lysates. It is based on reduction 
of copper Cu
2+ 




then chelates with two molecules of BCA 
to form a purple-coloured product that can be detected by a 96-well plate reader at 562nm. The 
intensity of the formed colour increases linearly with increasing protein concentrations 
allowing protein concentrations to be calculated using a standard curve made of bovine serum 
albumin (BSA). This assay was performed as follows: 25μl of samples were added in duplicate 
in 96-well flat-bottom plates. Additionally, each plate contained a BSA series dilution added 
in duplicate. To each sample and standard well, 200μl of BCA working reagent, a combination 
of reagents A (1000mL (containing sodium carbonate, sodium bicarbonate, bicinchoninic acid 
and sodium tartrate in 0.1M sodium hydroxide) and B (25mL, containing 4% cupric sulfate) in 
a ratio 50:1, was added. The plates were gently agitated on a plate shaker and incubated for 30 
minutes at 37°C. After the incubation, the plates were left at room temperature for 5 minutes in the 
dark before reading the absorbance on a plate reader. The absorbance means for the duplicate repeats 
of each sample and standard were calculated. The standard curve was then generated by the absorbance 
means of BSA series dilutions and their corresponding concentrations using Microsoft Excel. Finally, 




2.16 Western Blot 
After preparing, the resolving gel solution was poured between the glass plates and left for 20 minutes 
until the gel was solidified. 10% stacking gel solution was prepared and the gel plate filled to the edge 
of the glass plate. The comb was inserted to ensure no air bubbles. Butanol was added on top of the 
resolving gel and washed with ddH2O. The running buffer was poured into the electrophorator to cover 
the gel completely. The ladder (Bio-Rad protein ladder) (1µl) and protein sample (15µl) was loaded 
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into each well of the gel carefully and the gel was run for 1 hour at 200V until the dye front reached the 
end of the gel. A transfer sandwich was created with 3 pieces of filter paper, nitrocellulose membrane 
and then the gel, which had been removed from the glass plates followed by 3 pieces of the filter paper. 
These were all immersed in transfer buffer before creating the sandwich. The sandwich was placed on 
the transfer apparatus and run at 45V for 1 hour 30 minutes. After transfer, the membrane was coated 
with Ponceau S stain to visualize transfer efficiency and then washed thoroughly. 
 
Running Buffer: 20x 
Tricine (free base) 71.7g 
Tris (free base) 72.6g 
SDS 10g 
Sodium Bisulphite 2.5g 
Table 2.4 A table showing the preparation of 20x running buffer. 
 
 
Transfer Buffer: 10x 
Tricine (free base) 15.2g 
Glycine 72.1g 
SDS 5g 






2.17 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE) for protein separation  
 
SDS-Page resolving gel: 10% Stacking gel 
H2O 4.00ml 3.4ml 
1.5M Tris PH 8.8 2.50ml - 
1M Tris PH 6.8 - 630µl 
30% Protogel acrylimide 3.34ml 750µl 
10% SDS 100µl 50µl 
10% APS 80µl 50µl 
TEMED 8µl 8µl 
Table 2.6 A table showing the preparation of 10% resolving gel and stacking gel 
 
 
2.18 Electrophoresis  
10% SDS PAGE Running buffer 
Tris base 30.3g 
Glycine  144.1g 
10% SDS 100mL 
DdH2O 1L 






2.19 Transferring proteins to poly-vinylidene fluoride (PVDF) membranes  
Transfer buffer 
Tris  3g 
Glycine  15g 
Methanol  200mL 
DdH2O 1L 




















2.20 Detection of proteins by antibodies  
After transferring proteins, PVDF membranes were blocked in 5% blocking buffer (5% (w/v) dried 
non-fat milk powder, 0.1% (v/v) Tween-20) with gentle rocking for 2 hours at room temperature. Then, 
the membranes were incubated with primary antibodies, 10µl of primary antibody (Rabbit polyclonal 
to HOXA9, Goat polyclonal to MEIS1) (Abcam, UK) was appropriately diluted in 10ml of TBST and 
added to the membrane with gentle rocking overnight at 4°C. After overnight incubation, the 
membranes were washed 4 times with 0.1% Tween PBS solution for 10 minutes at room temperature 
with gentle rocking to remove unbound antibodies. Then, the membranes were incubated with 
secondary antibodies (anti-Rabbit for HOXA9 and anti-Goat for MEIS1) and (Abcam, UK) diluted for 
2 hours at room temperature with gentle rocking; the antibodies used in western blots (Table 2.9). After 
2 hours incubation, membranes were washed 3 times, as above. The membranes were exposed to 
superSignal
® 
West Pico Chemiluminescent substrate according to the manufacturer's recommendation. 




light film for 3 minutes to visualise the 
chemiluminescence. Films were developed and then fixed using developer and fixer, respectively.  
 




Cat # Supplier 
Primary anti-HOXA9 Polyclonal Rabbit IgG 30 1/100 ab83480 
Abcam Primary anti-PBX1 Polyclonal Rabbit IgG 47 1/100 ab97994 
Secondary for anti-Rabbit Polyclonal Goat IgG 32 1/2000 ab205718 




2.21 HXR9 and CXR9 peptide synthesis  
The synthesis of the HXR9 and CXR9 peptides have been previously described (Morgan, Pirard et al. 
2007). HXR9 is a short peptide of 18 amino acids, that is comprised of a hexapeptide sequence and nine 
C-terminal arginine residues (R9) enabling cell penetration. The HXR9 hexapeptide mimics the 
hexapeptide sequence of HOX proteins of paralogs 1-10, this sequence functions as a competitive 
inhibitor of HOX/PBX. CXR9 is the control peptide that does not have the functional domain but has 
the R9 region. The stability of the peptides was increased using D-isomers NH2- and COOH- terminals. 
The half-life of these peptides is approximately 12 hours in the serum (Morgan, Pirard et al. 2007). A 
conventional column-based technique was used to synthesise HXR9 and CXR9 which were purified to 
at least 80% (Biosynthesis Inc., Lewisville, TX, USA). Sequences for both peptides are as follows:  
 
HXR9: WYPWMKKHHRRRRRRRRR (2700.06 Da)  
CXR9: WYPAMKKHHRRRRRRRRR (2604.14 Da)  
 
2.22 Statistical analysis 
Student t-tests or one-way anovas were used for data analysis on all assays using GraphPad Prism 
software. Apart from the age related analysis where healthy volunteer mRNA expression levels were 
calculated using Livak’s PCR calculation method (Livak and Schmittgen, 2001) and then grouped into 
decades of age, as in Morgan; 2005, where the graph depicts decades from 20’s to 80’s as a graph 
constructed using GraphPad accounted for and represented on the GraphPad prism package. This was 
used in statistical calculations where data was further analysed with t-test using GraphPad statistical 
software (GraphPad software Inc., San Diego, CA USA) and by Mann-Whitney-Test using unpaired 
Wilcoxon rank sum test from R. All results are expressed as the mean of three separate experiments 
performed in duplicate with error bars to show the SEM. Statistical significance was also determined 
by comparing the different conditions in each assay with each other [p < 0.05 (*), p < 0.01 (**), or p < 
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0.001 (***) or p < 0.0001 (****)]. Calcusyn software was used to determine the IC50 of the HXR9 
treatment for the different cell lines. 
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Chapter 3: The role of HOXA9 and 
its co-factors in-vitro 
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3.1.1 The importance of HOXA9 
The HOX genes are a family of transcription factors responsible for the identity of tissues in early 
embryonic development that subsequently play several roles in regulating adult processes involved in 
cell renewal. As highlighted, HOXA9 is one of the most intensively studied examples of these genes, 
which is a key regulator of adult haematopoiesis. The dysregulation of HOX genes and HOXA9 is 
common to many haematological malignancies, including AML (Ferrando et al., 2003), and solid 
malignancies including renal (Shears et al., 2008), ovarian (Cheng et al., 2005, Morgan et al., 2010), 
lung (Abe et al., 2006, Plowright et al., 2009) and other cancers. Over-expression of HOXA9 in AML 
is well documented and has been shown as a poor prognostic factor (Golub et al., 1999), with down-
regulation of HOX genes being a favourable prognostic factor (Andreeff et al., 2008, Zangenberg et al., 
2009). HOX genes have been identified as playing an oncogenic role in leukaemia (Eklund, 2007) and 
their over-expression in some cancers, for example in melanoma, maintains cell survival, through 
preventing c-Fos transcription (Morgan et al., 2007), for this and many other reasons c-Fos becomes a 
gene of interest in the HOXA9 death pathway. 
 
3.1.2 Co-factors of HOX  
DNA binding site studies over the last number of decades have suggested that HOX proteins have 
limited selectivity and specificity, and therefore need co-factor interactions to increase both (Phelan et 
al., 1995, Moens and Selleri, 2006, Mann et al., 2009). The most commonly studied HOX co-factors 
are the TALE family of proteins, which are compromised of the PBX and MEIS families (Moens and 
Selleri, 2006, Mann et al., 2009). These co-factors have been identified in playing crucial roles in 
development and haematopoiesis (Thorsteinsdottir et al., 2001). PBX1 null mice die during the 
embryonic stage due to severe hematopoietic defects and suffer severe anaemia (DiMartino et al., 
2001). Mice that were deficient in MEIS1 failed to generate megakaryocytes, expressed severe 
haemorrhaging and also died during the embryonic stage (Figure 3.1) (Hisa et al., 2004). MEIS1 and 
PBX contribute to the inhibition of myelopoiesis and in the production of erythropoietic cells (Pillay et 
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al., 2010). MEIS1 has been shown over recent years to contribute to leukemic transformation (Kroon 
et al., 1998). Almost as a rule, HOX proteins (HOX 1-10) generally bind with PBX1 (Shen et al., 1996), 
whereas the paralog groups 9-13 are shown to bind with MEIS1 (Shen et al., 1997). This has been 
challenged in recent years although no definitive studies have managed to confirm this. 
 
 
Figure 3.1 A schematic diagram depicting the morphology of MEIS1-deficient embryos compared to 
the wild-type (Hisa T 2004). 
 
3.1.3 Translocation of HOXA9 
Trying to underpin the mechanisms by which HOXA9 and its co-factors interact, and function has been 
widely studied over the last decade. Research has tried to gather more information about the localization 
of HOXA9 but also the localisation of its co-factors and use these findings for future studies. Significant 
advances over the last few years has been in nucleoporin Nup98 associating with HOXA9 binding and 
its localization not only to the NPC and intranuclear bodies that can be characterized by both 
deconvolution and electron microscopy (Griffis et al., 2004). The prevalence of these bodies can vary 
between cell lines and uncovered information on the whereabouts of HOXA9 and its movements in and 
out of the nucleus. For example, in Xu et all, 2010, it was shown that in nearly all Nup98 leukemogenic 
translocations, an N-terminal half of the Nup98 protein containing the FG and GLFG repeats, is retained 
in the leukemic fusion protein suggesting that Nup98 leukemic fusion proteins may also be associated 
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with GLFG bodies as well as an endogenous Nup98 or with a distinct intranuclear compartment. Nup98 
fusion proteins are valuable to the cell and are most frequently detected in AML patients that have been 
linked to HOXA9. Probably the most common of these is the Nup98/HOXA9 fusion protein, which 
consists of the amino acids 1-469 of Nup98 joined to amino acids 163-271 of HOXA9. Other studies 
aimed at gathering more information about localization used GFP-tagged proteins visualized in HeLa 
cells after transient transfection (Griffis et al., 2004), with both the GFP-tagged Nup98 GLFG domain 
and the full-length protein present in intranuclear bodies. 
Furthermore, the localization and regulation of transcription factor activity has in recent years been 
shown to play a pivotal role in various biological processes. Different mechanisms regulate 
transcription factor activity, as in post-translational modifications, expression level and protein stability. 
Since a transcription factor exerts transcriptional regulation in the nucleus, the control of nuclear 
localization plays a crucial role in this regulation (Stevens and Mann, 2007). For this reason, proteins 
like PBX1, MEIS1 and PREP1 (transcription factors) in the nucleus of cells is for the regulation of the 
appropriate target genes. Recent studies have shown that PBX1 (co-factor for HOXA9) 
nuclear/cytoplasmic distribution is very tightly regulated through other mechanisms (Laurent et al., 
2009). As for the role of MEIS/PREP and PBX interactions and their nuclear translocation (Figure 3.3) 
for this interaction, the PBC-A domain of PBX1 (Chang et al., 1997, Knoepfler et al., 1997), and the 
HR1 and HR2 domains of the MEIS1/PREP1 are required. The LFPLL motif of HR1 is essential for 
PBX1 binding (Diaz-Blanco et al., 2007). It has been shown that PBX1 and MEIS1/PREP1 bind co-
operatively to DNA, however they interact efficiently in the absence of DNA as well (Knoepfler et al., 
1997, Berthelsen et al., 1998). These interactions in the absence of DNA can regulate the subcellular 
localization (Jaw et al., 2000, Berthelsen et al., 1998, Berthelsen et al., 1999) and the stability (Jaw et 
al., 2000, Longobardi and Blasi, 2003) of PBX proteins. PBX1 has a very dynamic subcellular 
localization. It contains two co-operative NLS (nuclear localization signal) (Saleh et al., 2000) and two 
independent NES (nuclear export signal) ((Kilstrup‐Nielsen et al., 2003). The first NLS is situated in 
the N-terminal arm of the HD (amino acids 234-239) and contains the consensus RRKRR sequence. 
The second and less conserved domain (KRIRYKKNI), is situated within the helix 3 (amino acids: 
285–294) (Saleh et al., 2000). The two NES are situated within the PBC- A domain spanning amino 
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acids 45-72 and 73-90 respectively ((Kilstrup‐Nielsen et al., 2003). The two NES are able to mask and 
inhibit the NLS via an intramolecular interaction between the N-terminus and homeodomain of PBX1. 
This conformational change of PBX1 due to the interaction with MEIS/PREP exposes the PBX1 NLS, 
causing nuclear translocation (Saleh et al., 2000). The NES of PBX1 has been shown to mediate the 
interaction with the nuclear export receptor Crm1 responsible for exporting PBX from the nucleus. 
Importantly, two NES are located within the domains responsible for the interaction with MEIS/PREP 
and the deletion of either of the NES can impair this interaction. The contact domains for Crm1 and 
MEIS/PREP overlap, therefore the interaction of PBX1 with MEIS/PREP masks the NES and can 
facilitate PBX-MEIS/PREP to stay in the nucleus as heterodimers (Stevens and Mann, 2007, Kilstrup‐
Nielsen et al., 2003). Importantly, PBX1 nuclear localization is not only dependent on the MEIS/PREP 
interaction but various other mechanisms that regulate its subcellular distribution (Figure 3.2).  
 
 
Figure 3.2 A schematic diagram depicting PBX1 and PREP1 interaction and their subsequent 
translocation into the nucleus. PBX also interacts with MEIS through a similar domain and this 
complex then translocates into the nucleus as shown in this figure (Stevens and Mann, 2007, Kilstrup‐
Nielsen et al., 2003). 
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Although a lot of this previous work gives some indication about the whereabouts of these proteins and 
their mechanisms of action very little to date has been done to try and analyse the localization of these 
proteins in AML cell lines. This poses the question whether HOXA9 would have the same reaction with 
or without PBX1 and other co-factors implicated in HOXA9 binding. Gathering a better understanding 
about these interactions and where in the cell these interactions occur along with the mechanism of 
action by which the cells transcribes these genes either in normal cells or in leukemic cells will outline 
the future of drug development (Figure 3.3). 
 
Figure 3.3 A schematic depicting the VMD of the HOXA9-PBX DNA complex. HOXA9 is shown here 
in green and PBX1 is depicted in purple. The linker portion as well as the hexapeptide of HOXA9 spans 
the minor groove of the complex and the conserved tryptophan is inserted into the PBX1 binding pocket.   
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Aims 
To analyse the expression of HOX genes, mainly HOXA9 and its co-factors in AML derived cell lines 
and asses their importance and the role they may play in the development of AML, related 




Materials & Methods 
3.2.1 Fixation and permeabilization of cell lines 
A cell suspension of 106 cells was transferred from the flask into a micro-centrifuge tube and centrifuged 
at 690g for 3 minutes. These were then re-suspended in 1ml PBS and centrifuged at 690g for 3 minute. 
The supernatant was discarded and 160µl of PBS was added to 20µl cells to re-suspend them. Cells 
were fixed with 20µl 4% paraformaldehyde (PFA) solution at 37°C for 15 minutes then centrifuged at 
690g for 3 minutes. PFA was freshly prepared in a fume hood due to its toxicity and was handled 
appropriately. A washing step was performed twice by using 1ml PBS and centrifuging at 690g for 3 
minutes. This step was carried out after all the steps of this technique. Cells were then permeabilized to 
allow free access of the antibody to its antigen, since HOXA9 and its co-factors (MEIS and PBX) are 
expressed inside the cells. 0.3% Triton X-100 in PBS was added to the cells before being centrifuged 
at 690g for 3 minutes. This step was also followed by washing with 1 ml PBS and centrifuging at 690g 
for 3 minutes. 
 
3.2.2 Immunofluorescence labelling of HOXA9 and PBX1 
Before labelling the cells with antibodies, cells were blocked to minimize the adsorption of nonspecific 
antibody sites followed by incubation of cells with 5% PBSA, which was prepared by dissolving 5µg 
of bovine serum albumin (BSA) (Sigma-Aldrich, UK), in 1ml PBS, for 1 hour at room temperature. 
Cells were centrifuged at 690g for 3 minutes and the PBSA was aspirated. 1µl of the primary antibody 
(Rabbit polyclonal to HOXA9 and Rabbit polyclonal to PBX1) (Abcam, UK) was appropriately diluted 
in 200µl of PBS; Afterwards cells were incubated with 200µl antibody at room temperature for 2 hours. 
This step was followed by two washing steps with 1ml PBS to remove unbound antibody and 
centrifuged at 690g for 3 minutes. 1µl of the secondary fluorochrome antibody, (Donkey polyclonal 
Secondary Antibody to Rabbit IgG - H&L, Alexa Fluor 488) (Abcam, UK), was diluted in 200µl, and 
added to the cells. Cells were incubated at room temperature for 1 hour followed by the centrifuging at 
690g for 3 minutes and washing with 1ml PBS. 
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Cat # Supplier 
Primary anti-HOXA9 Polyclonal Rabbit IgG 30 1/200 ab83480 
Abcam Primary anti-PBX1 Polyclonal Rabbit IgG 47 1/200 ab97994 
Secondary for anti-Rabbit Polyclonal Goat IgG / 1/2000 ab150077 
Table 3.1 A table listing the antibodies used during immunofluorescence.  
 
3.2.3 Preparations for microscopy  
Cells were counterstained with DAPI (4′,6-diamidino-2-phenylindole) by adding 2 drops to 100µl of 
PBS to the cells and then being left for 5 minutes. Afterwards cells were centrifuged at 690g for 3 
minutes, washed with 1ml PBS and mounted on a glass microscope slide to be analysed using a Floyd 
microscope. A very small drop of clear acrylic nail varnish was applied to each of the 4 corners of an 
18 x 18mm, 0 thickness (0.5um), borosilicate glass coverslip (BDH, Poole, UK) thereby preventing the 
cells from being damaged (squashed) when the slide is covered. The 0.5um thickness coverslip was 
used to maximize the depth of focus during confocal analysis. Vectashield anti fade reagent (Vector 
Laboratories Ltd, Peterborough, UK) 20ul, was applied to the centre of the coverslip and 40ul to the 
middle of the slide. The slide was inverted and lowered over the cover slip to rest onto the coverslip. It 
was carefully lowered allowing the two drops of antifade reagent to meet, the effect being to draw the 
cover slip rapidly up towards the slide. The slide was then rapidly turned over preventing movement of 
the cover slip (which would result in drawing cells from the slide) and placed to one side allowing the 
cover slip to settle on the nail varnish mounts for 1 minute. Using clear acrylic nail varnish, a line was 
painted along four edges of the cover slip, applying minimal pressure so as to not crush the cells and 
creating a sealed chamber. Slides were analysed within two days of staining and stored at 4°C in a 
blacked-out slide box.  
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3.2.4 Confocal laser scanning microscopy 
Confocal laser scanning microscopy (CLSM) provides a technique for optically sectioning fluorescent 
labelled whole cells or tissue, restricting out of focus light using a confocal imaging aperture (pinhole) 
within the optical system (Amos et al., 1987). The CLSM system also typically uses high numerical 
aperture objective lenses to focus the excitation laser light and reduce background fluorescence 
(Zemanová et al., 2003). Laser light is used, for excitation of the fluorescent probes or conjugated 
antibodies (Dunn et al., 1994). The CLSM used throughout this project (Zeiss LSM 4.10) provided two 
different laser light sources for fluorescent excitation; low powered argon ion and helium neon 
producing two different wavelengths of laser light, 488nm and 543nm respectively, making it possible 
to undertake multi-fluorescent analysis. As for the EPF microscopy, this requires the use of specialized 
filters, ideally permitting fluorescent signals from only one fluorochrome to be detected when more 
than one fluorochrome is present within the specimen. The excitation light is reflected by a dichroic 
mirror and focused onto the specimen by the objective lens. The fluorescent and refracted light is then 
collected by the same objective lens. The dichroic mirror splits the fluorescent and refracted light, only 
allowing the fluorescent light to pass and removing the refracted light from the final image. Filters are 
also employed to ensure that reflected laser light is not allowed to reach the confocal aperture and 
contribute to the final image. The emitted fluorescent light is then focused onto the confocal imaging 
aperture. The focal point of the aperture and specimen are on the conjugated lanes restricting light from 
above and below the focal plane and resulting in high axial resolution free from stray light (Wilson and 
Pawley, 1995). The depth of focus is dependent on the size of the confocal aperture, with a smaller 
aperture producing a thinner focal plane, forming an image of an individual slice through a region of 
the cell.Additional advantages are obtained through the ability of the CLSM system to record only in 
focus light. It creates the possibility for the microscope to act as if there were an infinite depth of field 
compared to an extremely limited one of approximately 10im for ELM. By using an automated 
microscope stage, the depth of the focal plane can also be adjusted whilst undertaking simultaneous x, 
y scanning to create an axial z scan. A complete in focus representation of the specimen throughout the 
z-axis, z-scan slices can be achieved (Sheppard and Shotton, 1997). CLSM optics also enables the 
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observation of cells that are adherent whilst minimising the interference from cells floating within the 
mounting medium and free fluorochromes or non-specific fluorescent debris also above the cell layer 





3.3.1 HOX gene expression in a whole panel of 39 HOX genes measured in 
leukemic cell lines 
 
The expression of all HOX genes were assessed by qPCR in the five AML derived cell lines HL-60, 
KG-1, HEL92.1.7, KU812F and K562 (Figure R3.1). This analysis revealed substantial differences in 
HOX gene expression, whereby HOXA and HOXB cluster genes were far more highly expressed than 
those of HOXC and HOXD clusters. Importantly, many HOXA cluster were seen to be highly expressed 
in KG-1 cells including HOXA5, HOXA6, HOXA9 and HOXA10. Noticeably, HOXA9 and HOXA10 
were also highly expressed in KU812F cells, whereas HOXB9 on the other hand was the most highly 
expressed gene in K562 and HEL92.1.7 cells. HL-60 cells show very little HOX expression.  
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Figure R3.1 HOX gene expression in KG-1, HEL92.1.7, KU812F, K562 and HL-60 cell lines. A) The 
most expressed HOXA genes in the KG-1 cell line appeared to be HOXA5, HOXA6, HOXA9 and 
HOXA10, with HOXA9 and HOXA10 being the most highly expressed in KU812F. B) HOXB9 was the 
most expressed HOX gene in HEL92.1.7 and K562. C) HOXC and D) HOXD genes showed very low 
expression in comparison in AML derived cell lines. The expression of these HOX genes are represented 
as the logarithm of the ratio of the expression of HOX genes to the housekeeping gene β-actin (×1000). 
The mean of three independent experiments are shown and error bars show the SEM in these graphs.  
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3.3.2 Identifying HOX genes heavily linked to cancer in leukemic cell lines 
 
To assess the variation in expression of HOX genes in leukemic cell lines, several HOX genes of most 
interest were selected based on previous literature: HOXA5, HOXA6, HOXA7, HOXA9, HOXA10, 
HOXB4, HOXB9, HOXC4, HOXC9 and HOXD9 (Figure R3.2). Mononuclear cells isolated from the 
peripheral blood of healthy volunteers were used as a control where n=3. As expected, expression varies 
between cell lines, qPCR was used to analyse 3 separate AML derived cell lines: HL-60, KG-1 and 
K562. HOX genes are generally of low expression in mononuclear cells isolated from the peripheral 
blood of healthy adults whereas gene expression varies significantly between cell lines. In terms of 
HOXA9, HL60 and KG-1 cells express this gene at a much higher level than K562, which is supported 
by previous studies as they are being both myeloid cell lines, with K562 being a CML-derived cell line. 
Other noticeable genes of higher expression include: HOXA5, HOXA6, HOXA10, HOXB4 and HOXC9 
in HL60, HOXB9 HOXC4 and HOXC9 in K562 cells and HOXA5, HOXA6, HOXA7, HOXA10, HOXB4 




Figure R3.2 Variation in expression of HOX genes heavily linked to cancer in mononuclear cells 
isolated from the peripheral blood of healthy adults against the HL60, K562 and KG-1 leukaemic cell 
lines. The expression of these HOX genes are represented as the logarithm of the ratio of the expression 
of HOX genes to the housekeeping gene, β-actin (×1000). The mean of three independent experiments 






































































































































3.3.3 PBX and MEIS are important co-factors of HOXA9 in 
leukemic cell lines 
 
To determine the expression of HOXA9 and its possible co-factor genes (MEIS1, MEIS2, MEIS3, PBX1, 
PBX2 and PBX3) and how their expression may vary between cell lines, qPCR was used to analyse 3 
separate AML derived cell lines: HL-60, KG-1 and K562 (Figure R3.3). As already seen, there are 
substantial differences in global HOX gene expression (Figure R3.1), whereby expression changed 
between cell lines, as expected. HL60 and KG-1 cell lines show similarity in most genes, both being 
primary derived AML cell lines. The only exception to this rule is in HOXA9 expression with HL60 
expressing much low levels.  Both however express very low levels of PBX1 with K562 cells showing 
a change in comparison exhibiting a lower HOXA9 and a higher PBX1 expression level. Much of this 
change is due to HL60 and KG-1 being myeloid cell lines with K562 being a secondary leukaemic 
CML derived cell line. Morphologically K562 cells differ to both HL60 and KG-1 cells, expressing 
positivity for the BCR-ABL gene. What was most interesting however, was that in almost every gene 
analysed K562 stood out and appeared to have an inverse relationship with the other two cell lines for 
each gene not just in HOXA9. 
This analysis gives us a better understanding of the relative expression of HOXA9 in healthy donors 
compared to that of leukemic cell lines, allowing us to quantify the variation in HOXA9 expression as 
well as highlighting co-factor expression in the healthy volunteers. Most noticeable in this analysis was 
the variation in expression between the healthy volunteers and the leukemic cell lines in terms of 
HOXA9 expression, however, it was observed in Figure R3.3, that HOXA9 expression in each cell line 
as well as in the mononuclear cells isolated from peripheral blood differs to that of PBX1. This 
significance will be touched on in a little more detail when discussing HXR9 and the strong interactions 
between PBX1 and HOXA9. 
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Gene Expression in PBMCs and AML Derived Cell Lines  
 
Figure R3.3 Variation in gene expression of HOXA9 and its potential co-factors in mononuclear cells 
isolated from the peripheral blood of healthy adults (HVM Low HOXA9 expression, HVM High HOXA9 
expression) against the HL60, K562 and KG-1 leukaemic cell lines (see appendix for CT values). The 
expression of these genes are represented by the ratio of the expression of HOX genes to the 
housekeeping gene β-actin (×1000). The mean of three independent experiments are shown and error 













































































































































































































































































































































































































































3.3.4 HOXA9 is present in leukemic cell lines and appears to translocate to 
the nucleus 
 
Immunofluorescence was used to validate HOXA9 expression but also to observe localization in the 
cell. Immunofluorescent images of KG-1, HL60 and K562 and cells show a very similar pattern to that 
of the HOXA9 gene expression analysed via qPCR in Figure R3.3 with the highest presence of positive 
antibody for HOXA9 in KG-1, and K562 and HL60 showing a lower expression rate respectively. The 
is significance in variation of expression between the healthy volunteers and the leukemic cell lines in 
terms of HOXA9 expression, however, it was observed in Figure R3.3, that HOXA9 expression in each 
cell line as well as in the mononuclear cells isolated from peripheral blood. This is significant and will 
touch on this in a little more detail when discussing HXR9 and the strong interactions between PBX1 
and HOXA9.  
Localization of these proteins is important, with HOXA9 appearing almost entirely within the nuclear 
envelope (Figure R3.4). The true mechanisms by which these proteins get chaperoned into the nucleus 
for transcription is currently unknown however our current hypothesis is that HOX-PBX binding 
facilitates the translocation of these proteins into the nucleus. 
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HOXA9 Localisation in AML-Derived Cell Lines  
(A)  




 (C)  
Figure R3.4 Representative immunofluorescence images of (a) HL60 cells (b) K562 and (C) KG-1 cells 
stained with DAPI and HOXA9 respectively (scale bar shown, 100m). All images were taken using an 






In summary, the expression of all the 39 HOX genes were analysed in the five main AML-derived cell 
lines: HOX expression analysed concurred with previous studies (Figure R3.1), with the myeloid origin 
cell line KU812F highly expressing both HOXA9 and HOXA10 genes and the erythroid cell line 
HEL92.1.7 highly expressing the HOXB9 gene, consistent with previous studies (Giampaolo et al., 
1994, Kawagoe et al., 1999, Pineault et al., 2002). K562 as we know, originated from a CML patient 
in blast crisis, however, here we saw that the cell line highly expresses the HOXB9 gene, supporting 
previous studies that have suggesting that K562 is in fact a human erythroleukaemia cell line 
(Andersson et al., 1979). Interestingly, KG-1 expresses high levels of HOXA5, HOXA6, HOXA9 and 
HOXA10 even though it is an erythroid cell line. Previously, studies have shown that KG-1 cells express 
high levels of HOXA9 and HOXA10 and it is hypothesized that this increased expression is due to the 
presence of a trisomy 8 mutation (Kok et al., 2010). At present, the associating mechanism 
underpinning the up regulation of some of these HOXA genes and trisomy 8 is unclear. The APML cell 
line HL-60 expresses very little HOX which is seen across the board in all HOX families, concurrent 
with previous studies, APML was found to be characterized by a global down-regulation of HOX genes 
(Thompson et al., 2003). It is worth noting at this point, however, that the most expressed subset of 
HOX genes in this cell line were posterior (6-13) HOX genes. Possibly most important of all is that the 
KG-1 cell line is CD34+, which is very often characterized by a poor response to most current 
conventional chemotherapies, and happens to strongly express HOX genes compared to the CD34
- 
cell 
line HL60 that represents AML with a more favourable prognosis (Ahmed et al., 1999, Marone, 
Scambia et al. 2002; Dores, Devesa et al., 2012). This difference in prognosis suggests a link with the 
expression of HOX genes, as high and low expression of HOX genes has recently been shown to 
correspond with a poor or favourable prognosis, respectively (Golub et al., 1999, Andreeff et al., 2008, 
Zangenberg et al., 2009). A good comparison between KG-1 and HL-60 in terms of HOX expression is 
as mentioned, consistent with previous studies showing that HOX genes are highly expressed in CD34
+ 
cells although they appear to show little or no expression in CD34
- 
cells (Sauvageau et al., 1994a, 
Pineault et al., 2002). Although this is true, it is important to note here that the biggest limitation when 
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assessing the expression of HOX genes is to note the lack of normal CD34
+ 
cells which should be 
addressed in future studies. A potential explanation for the up-regulation in AML cell lines may be their 
ability to interrupt haematopoietic differentiation (Pineault et al., 2004). The evaluation of the 
expression of HOX genes in all AML lines is important for us to get a basic understanding of the role 
HOX genes play in AML and other cancers and therefore identify the role HOXA9 may play in these 
malignancies. These results, in general, are consistent with the already established hypothesis that HOX 
genes are expressed in a lineage-restricted manner with HOXA and HOXB genes being expressed in 
myeloid and erythroid cells, respectively (Giampaolo et al., 1994, Kawagoe et al., 1999, Pineault et al., 
2002).  
The expression of HOX genes in leukemic cell lines were compared to that of healthy volunteer 
mononuclear cells isolated from the peripheral blood of adults. As we would expect, HOX genes are 
generally low expressed in mononuclear cells isolated from the peripheral blood of healthy adults. Gene 
expression varies between cell lines, although in terms of HOXA9, HL60 and KG-1 cells express this 
gene at a much higher level than in K562 cells which as we know are myeloid cell lines (Figure R.3.2). 
K562 on the other hand is a CML-derived cell line and differs from both HL60 and KG-1 cells (Figure 
3.2). It is noteworthy that much like many HOX genes, HOXA9 positively regulates the transcription of 
other HOX genes including HOXA7 and HOXA10 as well as its co-factors PBX3 and MEIS1 
(Thorsteinsdottir et al., 2001). This was supported by our findings (Figure R3.2) with HOXA7 and 
HOXA10 resembling HOXA9 expression to some degree and being noticeably expressed at high levels 
in both HL60 and KG-1 cells opposed to K562 cells, which exhibited a significantly lower level of 
HOXA9, which is in turn unable to positively upregulate HOXA7 and HOX10. HOX gene expression 
may also contribute to tumorigenesis through activating anti-apoptotic pathways. This was first 
discovered in breast cancer with deficient p53 expression in breast cancer cell lines and primary tumours 
that has also been shown to correlate with the methylation of the HOXA5 promoter and loss of HOXA5 
expression. HOXA5 binding sites have been found in the promoter region of the TP53 tumour 
suppressor gene, and transient transfection of HOXA5 activated the p53 expression in the breast cancer 
cell lines, MCF-7 and ZR75.1, which in turn led to an increased rate of apoptosis (Raman et al., 2000). 
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HOXA5 is also known to induce apoptosis independently of p53 pathways, with activation of caspase-
2 and caspase-8 mediated apoptosis (Chen et al., 2004) supported by our observations of high HOXA5 
expression levels in both HL60 and KG-1 cells (Figure R3.2). HOXA10 is also increased in these cell 
lines with high HOXA5 expression, which supports studies that have already shown HOXA10 to play a 
similar role to HOXA5 by activating p53 expression in breast cancer cells. The most logical explanation 
for this is through oestrogen-HOX signalling as oestrogen can upregulate the expression of HOXA10 in 
these ER+ breast cancer cells (Chu et al., 2004).  
Analysing potential co-factors revealed substantial differences in gene expression between cell lines, 
whereby expression changed as would be expected when delving deeper into their morphology. HL60 
and KG-1 cell lines are most similar to K562 cells showing a change in overall HOX gene profile 
expression. As mentioned previously, HOXA9 positively regulates the transcription of its co-factors 
PBX3 and MEIS1 (Thorsteinsdottir et al., 2001), in which cell lines expressing a higher level of HOXA9 
also have a high level of MEIS1 and PBX3 in comparison to cell lines like K562, which has a lower 
level of all three genes. It is important to note at this point that low expression of HOXA4 and MEIS1 
are also favourable predictors for AML patient outcome (Zangenberg et al., 2009) supporting our 
findings (Figures R3.2, Figure R3.3) with high expression levels of MEIS1 being demonstrated in HL60 
and KG-1 cells, a lower expression level shown in K562 cells before observing an almost zero 
expression shown in healthy volunteer mononuclear cells isolated from the peripheral blood of adults 
with varying HOXA9 expression (Figure R3.3). The signature up-regulation of HOXA6, HOXA9 and 
PBX3 shown here has been demonstrated as a poor prognostic marker in some forms of AML over the 
last decade, with a simultaneous knockdown of both HOXA6 and HOXA9 increasing cell death and 
increased sensitivity of AML cell lines to cytarabine (Dickson et al., 2013) with studies also showing 
that a high expression of HOXA7, HOXA9 and HOXA11 as well as PBX3 (a co-factor) are independent 
prognostic markers of adverse overall survival in abnormal karyotype AML (Li et al., 2012) (Figures 
R3.2, Figure R3.3). 
Immunofluorescence helped validate the presence of HOXA9 and PBX1 (Figure R3.4). The presence of 
HOXA9 and PBX reflects almost identically previous analysis and data obtained from the qPCR analysis 
of the genes at the mRNA level (Figure R3.2). This is not always the case for several reasons including 
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post-translational modifications being the most prevalent. Localization on the other hand, gives us a 
better indication of the mechanism by which HOXA9 interacts with other proteins and its possible role 
in cell death and oncogenesis. Current understanding or hypotheses based on the literature and our 
findings, is that HOX proteins, HOXA9 in our case, binds to its co-factors (PBX1) and is then transported 
into the nucleus where it functions as a transcription factor and facilitates the transcription of genes that 
are heavily implicated in haematopoiesis (Figure R3.4) 
This in vitro data is a good foundation; however, it is also important to assess whether primary cells 
have or express similar characteristics to these cell lines, which is not always the case. For this, it is 
essential to analyse the above in primary cells, in aged matched healthy donors but also in patients with 
AML and other haematological disorders.  
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4.1.1 HOXA9 and AML 
Acute myeloid leukaemia is a heterogeneous group of genetically and phenotypically aggressive 
disorders whereby the differentiation of hematopoietic progenitor cells is increasingly blocked, which 
in turn increases their self-renewal ability and disturbing the normal regulation of proliferation 
(Fröhling et al., 2005). In the UK, AML is the most frequent acute leukaemia in adults, accounting for 
just over 75% of cases. The median age at presentation of disease is 68-69 years and the male: female 
ratio is about 5:4. In this age group, AML has a very poor outcome with less than 5% of the patients 
surviving 5 years after the initial diagnosis of the disease, compared to 35-40% in the younger age 
groups.  
Not only this, lower rates of complete remission (CR) in the elderly (40–50% vs 60–70% in the young) 
and a short duration seen in patients who are eligible for treatment strongly suggests there is a different 
disease biology in this age group. From a clinical standpoint, it is far more frequent that elderly patients 
have already received previous cytotoxic treatment or radiotherapy or perhaps they already have 
antecedent hematologic diseases, such as myelodysplastic (MDS) or myeloproliferative neoplasms, (see 
Chapter 5).  
AML is commonly classified by either the French-American-British (FAB) system, or the World Health 
Organization (WHO). The former is based on morphology and the maturation stage that classifies AML 
into eight groups (M0-M7). The latter is also based on morphology, but includes immunophenotyping, 
genetics and clinical manifestations and classifies AML into four main groups: AML with recurrent 
genetic abnormalities, AML with myelodysplasia-related changes, therapy-related AML and MDS, or 
AML that does not fit into any of these groups. Non-random chromosomal alterations, such as balanced 
translocations, monosomies, trisomies, inversion and deletions have been found in the leukemic cells 
of almost 55% of AML patients, and until recently they were the most crucial prognostic factors for 
complete remission (CR) and higher probability of relapse and survival (Estey and Döhner, 2006, 
Mrózek et al., 2007). Recent advances in molecular diagnosis have resulted in both gene alterations and 
the dysregulation of specific genes becoming increasingly important as prognostic elements in AML. 
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This has helped to clarify the numerous heterogeneities of AML subsets, particularly AML subsets 
showing normal karyotype (NK-AML)(Bullinger et al., 2008) and furthered understanding of the 
molecular mechanisms of leukaemogenesis. 
 
4.1.2 HOXA9 and aging 
It has been suggested previously that HOXA9 expression levels remain relatively constant throughout 
adult life until the age of about 50-55 (Morgan 2005). At this age, HOXA9 begins to increase in many 
individuals averaging a 2.5-fold increase compared to normal HOXA9. The effect this change in gene 
expression may have on normal haematopoiesis is to date relatively unclear. However, age-related 
changes to HOXA9 expression during later decades may support its association with increased incidence 
of AML. Until now, many studies carried out on the HOX cluster genes and aging has focused primarily 
on embryogenesis. There does appear to be a strong correlation. between HOX gene expression levels 
and the development of AML and an increased incidence of AML with age but very little to date has 
been done to investigate the relationship between HOX expression, AML and its subtypes and ageing 
together in the same study. In this chapter, we aim to examine this and analyse some outliers (high HOX 
expression) in depth, to assess if chronic inflammation is responsible in the elevated gene expression 
of HOXA9 or if this elevated expression is increasing with age. 
Younger age brackets also have a risk of developing AML, when breaking down the subtypes of AML. 
HOXA9 expression has been detected in 63% of 52 bone marrow samples taken from 46 AL children 
(Jia et al 2013). The positive HOXA9 expression rate in the AML group was significantly higher than 
in the ALL and control groups (86% vs 35% and 13%. Among these children with AML, those with 
M5 AML had the highest HOXA9 mRNA levels, shortly followed by children with M4 AML and 
children with M1 and/or M2 AML. Similarly, when analysing HOXA9 levels especially when looking 
at healthy volunteers, patients with AML but also those with pre-leukemic disorders that may 
potentially go on to develop AML to ascertain which of these subtypes may lead to a worse prognosis 
dependent on HOXA9 expression. However, HOXA9 expression was not detected in children with 
 104 
M3 AML at all. The treatment subgroup had significantly higher positivity for HOXA9 expression 
and HOXA9 mRNA levels than the remission subgroup and the control group, with no significant 
differences between the latter two groups. As expected, the non-remission subgroup had significantly 
higher HOXA9 expression than the remission subgroup and control group and the high-risk subgroup 
of AML children had relatively high levels of HOXA9 expression. 
In summary, HOXA9 is associated with the occurrence of AL, and its expression level is significantly 
higher in children who suffer from AML than in those who suffer from ALL. It has been widely 
suggested that there is a positive correlation between the expression level of HOXA9 and the risk of 
childhood leukaemia, with a high expression of HOXA9 suggesting a poor prognosis (Jia et al., 2013).  
Despite previous studies into the changes in gene expression in an aged population, relatively little is 
known about the expression of HOX genes in the mature blood lineages and their activation efficiency. 
This becomes hugely important when dealing with the elderly or age-specific peripheral blood, whereby 
many these “healthy” donors may in fact have underlying abnormalities in relation to inflammation. 
Recent studies have purified different cell populations from human peripheral blood based on their 
expression of the surface markers and used this analysis to gather a better understanding of the 
activation of specific cell populations (Morgan and Whiting, 2008).   
 
4.1.3 Important CD markers 
Often distinguishing what type of tumour being looked at under the microscope is difficult. However, 
in this case with acute leukaemia, most cases have distinctive features, auer rods for example, which 
can tell what kind of leukaemia being looked at; other cases have no such clues and can be difficult to 
distinguish. In these cases where indications are minimal, in hematopoietic or lymphoid neoplasms, 
flow cytometry can give us a better understanding and observing what markers are on the surface of the 
cells is a great start. Flow cytometry involves fluorescent antibodies that tag molecules on the surface 
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of cells. The flow cytometer has a small tube that allows the cells to flow one at a time past a laser beam 
(Figure 4.1). In addition to showing what kinds of markers a cell has, we may also sort cells by other 
parameters like size and complexity. It’s an incredibly useful technique that can be used for various 
purposes, one of the most common is to find out which markers are on the surface of specific cells. 
Important CD markers in AML are CD13, CD33 and CD117. The “CD” in the names of these markers, 
stands for “cluster differentiation.” An important way of referring to different molecules on the surface 
of cells. There are over 350 CD markers. Sometimes, however, it’s the absence of a marker that helps 
with diagnosis rather than the presence of one.  
 
Figure 4.1 A schematic diagram depicting how flow cytometry can be successfully used to identify cells, 
involving fluorescent antibodies that tag molecules on the surface of cells and the small tube that allows 




CD33: is a 67-kDa glycoprotein expressed on the surface. Of early multi-lineage hematopoietic 
progenitors, myelomonocytic precursors and generally to more mature myeloid cells, being absent from 
normal pluripotent hematopoietic stem cells. Almost 85–90% of AML cases have been shown to 
express the CD33 antigen. CD33 has also gained clinical importance as a suitable tumour-associated 
antigen and an important target for monoclonal antibody-based AML therapies (Harrington et al., 
2014). 
 
CD117: is a transmembrane protein receptor encoded by the c-kit proto-oncogene. The CD117 ligand 
is a stem cell factor and an important hematopoietic regulator. CD117 is present on just over 4-5% of 
normal bone marrow mononuclear cells and is extremely common in AML and CML in myeloid blast 
crisis but found rarely in ALL which makes CD117 an important marker when isolating AML and ALL. 
Initially CD117 was used as a primitive myeloid marker and has since been identified in all FAB 
subtypes of AML thought to predict a poor outcome. CD117 has been seen on most leukemic blasts of 
myeloid origin where 87% of AML, 80% of MPD-myeloid BC, and 75% of MDS. Although CD117 is 
a receptor for stem cell factor, its expression does not appear to correlate with CD34 positivity (Wells 
et al., 1996). 
 
4.1.4 Cellular activation  
Activation of specific cells is thought to affect the cells’ probability of becoming cancerous. However, 
are genes expressed differently in cells based on activation or inflammation? Comprehensive analysis 
of HOX gene expression in activated leukocyte populations showed a unique pattern of HOX 
expression that may define cellular identity (Morgan and Whiting, 2008). The magnitude of these 
changes is striking, with activated T-cell subsets exhibiting virtually a complete loss of expression of 
many HOX genes. This is most prevalent in the more posterior members of the groups like HOXA10, 
HOXC13, and HOXD12. Conversely, activated monocytic and B-lymphocyte cells exhibit a large 
increase in expression of the same genes. Given the regulatory roles of HOX genes it is extremely likely 
that some of these changes in expression begin to facilitate the cellular changes associated with 
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activation. Of these the most noticeable seems to be increased proliferation, a response that is known 
to be mediated by HOX genes in several hematopoietic lineages.   
CD14: is a myeloid differentiation marker primarily found on monocytes and macrophages, although 
low levels can also be found on neutrophils. In recent years, CD14 has been viewed simply as a useful 
marker molecule for both monocytes and macrophages. The function of CD14, its expression in 
different cell types, its regulation of expression have been described, and the diagnostic value of CD14 
in various diseases was first discussed in detail in Ziegler-Heitbrock 1993. Upon cell activation, CD14 
surface expression seems to decrease on monocytes and CD14 is released (Shive, 2015). 
CD11b: is an integrin family member that pairs with CD18 to form the CR3 heterodimer. CD11b is 
expressed on the surface of leukocytes including monocytes, neutrophils, natural killer cells, 
granulocytes and macrophages, as well as on nearly 9% of spleen cells and almost 45% of bone marrow 
cells. Functionally, CD11b is known to regulate leukocyte adhesion and migration to mediate the 
inflammatory response. For this reason, it can be of benefit when assessing inflammation and/or 
activation of specific white blood cells.  
The relevance of cellular activation in relation to gene expression was of great significance when 
looking at HOXA9. The hypothesis was that if these cells were chronically inflamed or activated, this 
may alter gene expression and therefore give a false positive which need to be addressed. Not only this 
but investigating the effects that activation/inflammation may have on the development of disease is of 
particular interest.  
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Aims 
To observe how the expression of HOXA9 changes with age in healthy donors and attempt to identify 
outliers in order to assess if chronic inflammation is responsible for the elevated gene expression of 
HOXA9 or if this elevated expression is really increasing with age.  
Observing if HOXA9 is expressed highly in myeloid cells that were also double positive for the AML 
markers CD33 and CD117 in peripheral mononuclear blood also helps us to understand the relationship 
between HOXA9 and disease progression. Analysis was also undertaken on HOXA9 expression in cells 





Materials & Methods 
4.2.1 Patients, controls and ethics 
Analysed blood samples for this section were obtained from 143 normal healthy donors (aged 18-86) 
collected from the Royal Surrey County Hospital (Guildford, UK).  
 
4.2.2 Decade grouping  
Healthy volunteer mRNA expression levels were calculated using Livak’s PCR calculation method 
(Livak et al., 2001) and then grouped into decades of age. As previously reported in (Morgan; 2005).  
  
4.2.3 LPS treatment 
A vial of 10-15ml of human blood was collected in EDTA tubes from three healthy donors following 
informed consent and left at room temperature; all samples were used within 4 hours of collection. Each 
blood sample was treated for 3 hours with 1ug/ml LPS. The cells were placed into 6 well plates and 
suspended in RPMI with 5% FBS serum, penicillin and streptomycin. Cells were either: untreated, 
treated for 3 hours or treated for 3 hours and left to recover for 24 hours in fresh media (RPMI with 5% 
FBS serum, penicillin and streptomycin). 
 
 
4.2.4 CRP ELISA 
Samples of high HOXA9 expression were selected and tested for chronic inflammation using CRP. 
Seven (7) outliers were selected and PBMCs were isolated as above. The Wash Buffer Concentrate 
(25x) was allowed to reach room temperature and mixed to re-dissolve any precipitated salts. This 
solution was diluted with 24 volumes of deionized water (e.g., 50 mL may be diluted up to 1.25 litres, 
100 mL may be diluted up to 2.5 litres) and labelled as Working Wash Buffer. This Working Wash 
Buffer was stored in the refrigerator and used within 14 days. 1x Streptavidin-HRP was prepared within 
15 minutes of usage. For each 8-well strip used in the assay, 10μL Streptavidin-HRP (100x) solution 
was take up (the pipette tip was wiped with a clean absorbent paper to remove any excess solution) and 
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dispensed into a tube containing 990μL of HRP Diluent and mixed thoroughly. The unused 
Streptavidin-HRP (100x) solution was returned to the refrigerator and stored. Hu CRP Standard was 
reconstituted to 8ng/mL with Standard Diluent Buffer. This was swirled to allow the contents to sit for 
10 minutes to ensure complete reconstitution. The standard was used within 15 minutes of 
reconstitution. 300μL of the reconstituted standard was added to a tube containing 1700μL Standard 
Diluent Buffer and mixed, labelled as 1200pg/ mL Hu CRP. 300μL of Standard Diluent Buffer was 
added to each of 7 tubes labelled as follows: 600, 300, 150, 75, 37.5, 18.75, and 0pg/mL of Hu CRP. 
Serial dilutions of the standards were made as described below. Human plasma required a 3000–fold 
dilution in the Standard Diluent Buffer. This was undertaken using a serial dilution of samples in a 
dilution series of 1:3000.  
 
This assay has been calibrated against the WHO reference preparation 85/506 (NIBSC, Hertfordshire, 
UK, EN6 3QG). One nanogram equals 0.98 International Units. Glass or plastic tubes were used for 
diluting standards. 100μL of Standard Diluent Buffer was added to the zero standard wells with wells 
reserved for the chromogen blank left empty. 100μL of each of the standards, diluted samples or 
controls were then added to the appropriate microtiter wells. The plate was then covered with the plate 
cover and incubated for 2 hours at 37°C. The solution was thoroughly aspirated, and wells were washed 
4 times with diluted Wash Buffer. 100μL of Hu CRP Biotin Conjugate solution was then added into 
each well except chromogen blanks before covering the plate with plate cover and incubated for 1 hour 
at room temperature. The solution was thoroughly aspirated, and wells were washed 4 times with diluted 
Wash Buffer. 100μL of 1x Streptavidin-HRP was added into each well except the chromogen blanks 
before the plate was covered with plate cover and incubated for 30 minutes at room temperature. The 
solution was thoroughly aspirated, and wells were washed 4 times with diluted Wash Buffer. 100μL of 
Stabilized Chromogen was added to each well for the substrate solution to begin to turn blue and 
incubated for 30 minutes at room temperature in the dark. 100μL of Stop Solution was added to each 
well and mixed gently until the solution in the wells changes from blue to yellow.  
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The absorbance was read at 450nm within 30 minutes after adding the Stop Solution. The curve-fitting 
software was used to generate the standard curve. This four-parameter algorithm provides the best 
standard curve fit. Optimally, the background absorbance was subtracted from all data points, including 
standards, unknowns and controls, prior to plotting. Concentrations for unknown samples and controls 
were read from the standard curve. The values obtained for the samples were multiplied by the 
appropriate factor to correct for the sample dilution and plotted on a graph using GraphPad Prism.  
 
 
4.2.5 Gating strategy 
 
 
Figure 4.2 Gating strategy for FACS. A) Isolated myeloid cells from PBMCs. B) Isolating CD33+ cells. 
C) Isolating CD117+ cells. D) Isolating HOXA9+ cells. E) Gating CD33+ and CD117+ cells that are 








4.2.6 FACS staining titrations  
Cells were titrated with the relevant antibody in ratios such as: 1:10, 1:20, 1:40, 1:80 and negative (no 
antibody) to get the final dilutions (Table 4.1). Antibody was made up in PBS with 1% BSA. These 
were then quenched with media, cells were centrifuged to remove the supernatant and suspended in 
500ul PBS and continued as below. 
 
 
Antibody  Type  Flourophore Isotype  Working 
concentration  
Supplier 
Primary anti-HOXA9 Monoclonal  Rabbit IgG 1/50 Abcam 
Primary anti-CD33 Monoclonal  Rabbit IgG  1/80 BioLegend 
Primary anti-CD117 Monoclonal  Mouse IgG 1/100 Millipore 
Primary anti-CD14 Monoclonal  Mouse IgG 1/50 BioLegend 
Primary anti-CD11b Monoclonal  Rat IgG 1/100 BioLegend 
Goat anti-Mouse Polyclonal  Goat IgG 1/200 Life Technologies 
Goat anti-Rabbit Polyclonal  Goat IgG 1/200 Life Technologies 
Goat anti-Rat Polyclonal  Goat IgG 1/200 Life Technologies 
Table 4.1 A table listing the antibodies used in during FACS.  
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4.2.7 Flow cytometry: CD33, CD117, CD14, CD11b  
Cells were harvested using a 5mM solution of EDTA before being washed with PBS (Thermo 
Scientific, UK). A total of 5x105 cells were re-suspended in 100µl of PBS plus 1% BSA (Sigma-
Aldrich, UK) and appropriate primary antibody in a flow cytometry tube. Primary antibody for each 
was used at the required dilution. Further details on antibodies used can be seen in Table 3.2. Cells were 
incubated for 30 minutes at room temperature. Cells were then centrifuged at 690g for 2 minutes and 
the supernatant was removed before the cell pellet was then re-suspended in 200µl of PBS. The cell 
solution was then centrifuged again at 690g for 2 minutes before the supernatant was removed and the 
cell pellet was re-suspended one last time with the secondary antibody diluted in 100µl of PBS 1% 
BSA. Secondary antibody was applied at a 1:200 dilution. This was incubated in the dark for 30 minutes 
at room temperature. Cells were then centrifuged at 2000rpm for 2 minutes. The supernatant was 
removed, and the cell pellet was then re-suspended in 200µl of PBS before being centrifuged again at 
690g for 2 minutes. The supernatant was again removed, and the cells were re-suspended in 200µl of 
PBS prior to being analysed on a MACS Quant Analyzer 10 (Miltenyi Biotec, UK). All tests were 
accompanied by a negative (no primary antibody) control. Primary antibody dilution was determined 
with a positive titre using isolated PBMCs. 
 
 
4.2.8 Flow cytometry (intracellular): HOXA9 
The cells used during the above extracellular staining step were re-suspended in 100µl of Fixation 
medium (Invitrogen, UK) in a flow cytometry tube and incubated for 15 minutes at room temperature. 
Cells were centrifuged at 690g for 2 minutes. The supernatant was removed, and the cell pellet was then 
re-suspended in 100µl of Permeabilization medium (Invitrogen, UK) with appropriate primary 
antibody. Primary antibody was then applied at the required dilution. Further details on antibodies used 
can be seen in Table 3.2. Cells were incubated for 20 minutes at room temperature before being 
centrifuged at 690g for 2 minutes. The supernatant was removed, and the cell pellet was then re-
suspended in 200µl of PBS before being centrifuged again at 690g for 2 minutes. The supernatant was 
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again removed and then the cell pellet was re-suspended with a secondary antibody diluted in 100µl of 
Permeabilization medium. Secondary antibody was applied at a 1:200 dilution. This was incubated in 
the dark for 30 minutes at room temperature. Cells were then centrifuged at 690g for 2 minutes. The 
supernatant was removed, and the cell pellet was then re-suspended in 200µl of PBS before being 
centrifuged again at 690g for 2 minutes. All tests were accompanied by a negative (no primary antibody) 
control. Primary antibody dilution was determined with a positive titre on the cell lines. 
All products used for intracellular staining from Invitrogen were provided in the FIX and PERM Cell 
Fixation and Permeabilization kit (Invitrogen, UK). Analyses were performed on a FACS-LSRII (BD 
Biosciences, UK) using the flow-Jo Software (Flow Jo, USA). 
 
 
4.2.9 FACS Fluorophores 
 
Antibody  Flourophore Working concentration  
CD11b PeCy7 1/100 
CD14 V450 1/100 
CD33 PE 1/80 
CD117 APC 1/100 
HOXA9 FITC 1/100 




4.3.1 HOXA9 expression increases with age in healthy volunteers 
 
Blood samples were taken from a randomized group of healthy donors aged between 20 and 86 (n = 
132), none of whom were known to be suffering from any haematological abnormality. The expression 
of HOXA9 and housekeeper gene, β-actin were quantified using qPCR. HOXA9 expression remains 
consistent throughout adult life until the age of c.55-56 (Figure R4.1). From this age onwards, there is 
a larger variation in HOXA9 expression. Some patients exhibit a low level of HOXA9 in these later 
decades, however the likelihood of outliers has drastically increased. By 55 to 60 years of age, the 
median expression of HOXA9 is significantly higher than previous decades, averaging 2.5-3-fold. This 
age-related change in HOXA9 expression is supported by Spearman regression analysis that shows there 
to be a positive correlation. HOXA9 expression levels of these healthy volunteers were quantified based 
on decades of age and plotted in the whisker plot as shown in Figure R4.1. Groups divided into decades 
of age, 20’s through to 80’s, with numbers of samples in each decade vary between 18 and 19, (Table 
4.1). Volunteer samples were analysed in duplicate and tested in experimental triplicate so that each 
individual sample was analysed six times. These results highlight HOXA9 expression increasing with 
age after 50, with an increased median value compared to those within the 20-40-decade groups. The 
most significant result being that the probability of outliers or the probability of an individual having 
an increased HOXA9 expression level increases with age. The lower bars reflect the lowest HOXA9 
expression which can generally be seen in most if not all decade groups.  
  
 116 
Changes in HOXA9 Expression with Age  
Figure R4.1 Variation in HOXA9 expression increases with age. Relative HOXA9 expression is 
represented by the ratio of the expression of HOX genes to the housekeeping gene β-actin (×1000) in 
mononuclear cells isolated from the peripheral blood of adults of different ages (horizontal axis). A: 
shows the data as a box and whisker plot. A central bar depicts the median, upper and lower bars 
represent the 75th and 25th percentiles, and whiskers represent minimum and maximum values. B: 
shows the data as a scatter dot plot. A central bar depicts the median, upper and lower bars represent 
the 75th and 25th percentiles. The numbers of samples in each decade are n= 18-19, Table 4.1 where 
the total n=132.  
 
Decades of Age 20s 30s 40s 50s 60s 70s 80s 
Number of 
Samples 
19 19 21 19 18 19 17 































































































4.3.2 Validating outliers for chronic inflammation responsible for the 
elevated gene expression of HOXA9 
 
To validate outliers and assess whether chronic inflammation is responsible for the elevated gene 
expression of HOXA9 or if this elevated expression is really increasing with age, whole blood was taken 
from healthy donors with high HOXA9 expression levels (outliers). From these outliers, 3 randomised 
samples were challenged with 1ug/ml of LPS for 3 hours and the expression of HOXA9 of the treated 
samples were compared against untreated samples and samples that were treated and left to recover for 
24 hours (Figure R4.2.1). As shown, the expression of HOXA9 in each of the 3 samples decreases 
significantly when challenged for 3 hours with LPS. Significantly the expression of HOXA9 in each 
sample appeared to stay low when left to recover for 24 hours. Western blots confirmed the QPCR 
findings (Figure R4.2.1). An ELISA was also used to validate and assess whether outliers were suffering 
from chronic inflammation where 5 outliers were analysed against a positive control. All 5 outliers were 
in the normal range and supported our LPS analysis where LPS is used in vitro to mimic chronic 
inflammation in cells (Figure R4.2.2). 
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Figure R4.2.1 A) variation in HOXA9 expression when challenged with LPS. Mononuclear cells were 
isolated from the whole blood of three healthy adult outliers with a higher than basal HOXA9 expression 
where cells have been challenged for 3 hours with 1ug/ml LPS.  A) The expression of HOXA9 is 
represented by the ratio of the expression of HOXA9 to the housekeeping gene β-actin (×1000). The 
mean of three independent experiments are shown and error bars show the SEM in these graphs. *p< 
.05, **p < .01. B) shows western blot analysis of HOXA9 protein levels in mononuclear cells isolated 
from the peripheral blood of adult outliers of a HOXA9 expression, after the same treatment.  
  











































Figure R4.2.2 Diagram showing huCRP levels in mononuclear cells isolated from the whole blood of 
healthy adult outliers with a higher than basal HOXA9 expression. These outliers were analyzed and 

























































Chronic Inflammation (huCRP) in Outliers with an 
Increased HOXA9 Expression
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4.3.3 HOXA9 is expressed extremely highly in myeloid cells, double positive 
for AML markers CD33 and CD117 in peripheral mononuclear blood  
 
FACS analysis was used to answer if the increase in HOXA9 expression in peripheral mononuclear 
blood taken from three outliers is due to an increase in the number of cells already expressing HOXA9 
or indeed an increase in the level of HOXA9 in these individual cells (n=3). In attempting to answer this 
question, on whether the elevated level of HOXA9 in these samples is due to either 1) elevated HOXA9 
expression within a restricted lineage or lineages of cells, and 2) an elevated level of HOXA9 within 
those cells already expressing HOXA9 or 3) is there an increase in number of specific cells expressing 
high levels of HOXA9. FACS analysis was undertaken on healthy volunteers with a higher than normal 
HOXA9 expression (outliers) using CD33 and CD117 to observe which cells appear to express HOXA9 
in primary samples (Figure R4.3). As the data shows, three separate peripheral mononuclear blood 
samples were gated positively for HOXA9 and many of these HOXA9 positive cells were double positive 
for both AML markers CD33 and CD117, 72.69%, 79.05% and 89.61% respectively (Table 4.2). As 
we have mentioned CD33 and CD117 are markers responsible for the clinical diagnoses of AML, 
therefore drawing a strong link between the levels of HOXA9 positive cells that are also double positive 




Figure R4.3 Representative flow cytometry surface staining data from three outliers where HOXA9 
positive peripheral mononuclear blood samples (having been intracellularly stained) were also stained 
with extracellular CD33 and CD117 performed in experimental triplicate (Gating strategy see 
appendix).  
 
 1 2 3 
HOXA9 positive cells double 







HOXA9 positive cells double 







Table 4.4 Representative table of data from three outliers where HOXA9 positive peripheral 
mononuclear blood samples (having been intracellularly stained) were also stained with extracellular 
CD33 and CD117 where n=3 performed in experimental triplicate. 
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4.3.4 HOXA9 is expressed highly in cells positive for the activation markers 
CD14 and CD11b.  
 
High HOXA9 expression was seen in cells that were double positive for both activation markers CD14 
and CD11b via FACS analysis on peripheral mononuclear blood taken from two donors with a higher 
than normal HOXA9 expression (n=2). Mononuclear cells were isolated and intracellularly stained for 
HOXA9 before being stained for the extracellular markers CD14 and CD11b (Figure R4.4). Noticeably 
cells that were activated (CD11b and CD14 positive) were also positive for HOXA9. Both patients 
exhibited 88.87% and 76.78% positive CD11b expression in their HOXA9 positive cells and 82.9% 
and 68.21% positive CD14 expression in their HOXA9 positive cells (Table 4.3). These results indicate 
a correlation between HOXA9 expression and cellular activation.  
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Figure R4.4 Representative flow cytometry surface staining data of HOXA9 positive peripheral 
mononuclear blood cells stained with the extracellular activation markers CD14 and CD11b and 
intracellularly with HOXA9 to analyse if there was a link between cellular activation and high HOXA9 
expression (Gating strategy see appendix). 
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Table 4.5 Representative table of data where normal peripheral mononuclear blood cells were stained 




Until recently there has been very little evidence for a direct molecular link between a person’s age and 
their risk of developing AML, several age-associated potential haematological factors have been 
identified. These include MDS and MPN, which like AML, are also classified by WHO and are an 
extremely heterogeneous group of haematological disorders. MDS and MPD are clonal haematological 
disorders characterized by ineffective haematopoiesis, bone marrow dysplasia in MDS or hyperplasia 
in MPN, frequently progressing to AML (15-52% and 7% respectively) and having a poor prognosis. 
In MPN, HSC dysregulation occurs due to failure of normal cytokine feedback or hypersensitivity. This 
results in the production of excessive blood cells and involves the 3 main myeloid lineages; erythroid, 
megakaryocytic/platelet and granulocytic, although predominantly affecting only one lineage. In MDS 
several factors are believed to contribute to the molecular pathology of this disorder, including increased 
HSC apoptosis, defective BM stroma, altered response to cytokines and chromosomal abnormalities 
including deletions of chromosome 5q31–q32. HOXA9 and HOXA7 are both often linked to the status 
of HSC underlying MDS and AML, either through over-expression or reciprocal translocations (the 
NUP98-HOXA9 fusion protein for example) although very little, if any profile of HOX expression has 
been explored for MPD.  
The importance of HOXA9 in homeostasis and disease has led us and others to investigate the way in 
which its expression changes in a mixed population with age in peripheral, mononuclear blood cells. 
Blood samples were taken from a randomized group of healthy donors aged between 20 and 86 (n = 
132), none of whom were known to be suffering from any haematological abnormality. As the results 
show, the variation and frequency of high HOXA9 expression increases in an aging population in 
support of previous findings (Morgan 2005). HOXA9 expression remains relatively consistent 
throughout adult life until the age of c.55-56 (Figure R4.1). From this age a larger variation in HOXA9 
expression is seen perhaps in part due to poorer transcriptional regulation. It is not unusual to see some 
patients with a low level of HOXA9 in these later decades, however the likelihood of outliers is 
drastically increased. By 55 to 60 years of age, the median expression of HOXA9 higher than previous 
decades, averaging 2.5-3-fold. HOXA9 expression increases with age after 50, where there is an 
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increased median value compared to those within the 20-40-decade groups.  
Developmental genes are active in the embryo and in most cases these genes switch off or decrease 
over time. At this point, highlighting these genes or mechanisms by which the cell reduces the 
expression of HOX genes after development, may pave the way for novel therapeutics or biomarkers of 
cancers, like AML, heavily implicated by the elevated expression of HOX genes. More research into 
this area could uncover proteins or co-factors as prognostic markers in later years for patients of AML 
and other haematological malignancies. 
Having observed how gene expression changes with age, the next step was to investigate outliers with 
an increased HOXA9 expression. This did not support the possibility of chronic inflammation skewing 
HOXA9 expression which has been previously shown to affect expression of developmental HOX 
genes. The expression of HOXA9 changed when challenged with LPS, however the results were not an 
increase of HOXA9 gene expression as first hypothesized, but rather a universal decrease in HOXA9 
expression (Figure R4.2.2). Having been challenged with LPS, cells were left to recover for 24 hours 
and the expression of HOXA9 remained low, relative to initial expression levels. This gene expression 
data was supported by western blot analysis using the same treatments and parameters. Although this 
supported the findings by qPCR that outliers express increased level of HOXA9 it poses many new 
questions. If inflammation and activation may affect HOXA9 gene expression in vitro, does this hold 
true in vitro? What if cells around an area of chronic inflammation or activation have altered gene 
expression based on the neighbouring micro-environment and then further effect important fundamental 
genes responsible for important cellular functions? And if these genes are heavily implicated in cancers 
as we now know, then what role may chronic inflammation play in the development of human cancer? 
In summary, having examined these outliers at the protein level using western blotting, we can safely 
say that chronic inflammation is not responsible for the elevated gene expression of HOXA9. 
Lineage committed FACS analysis was used to specifically determine which populations express 
elevated HOXA9 levels. Here we attempted to address the question, is the elevated level of HOXA9 in 
these samples due to elevated HOXA9 expression within a restricted lineage or lineages of cells. As we 
would expect, the cells that were positive for HOXA9 were also very clearly positive for myeloid 
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markers CD33 and CD117 in three healthy volunteer samples as: 72.69%, 79.05% and 89.6% 
respectively (Figure R4.3)(Table 4.2). Further work is required to address HOXA9 across different ages 
of AML patients and patients of haematological disorders. 
Mononuclear cells were isolated and intracellularly stained for HOXA9 before being stained for the 
extracellular activation markers CD14 and CD11b (Figure R4.4). Noticeably cells that were activated 
(CD11b and CD14 positive) were also positive for HOXA9 but more importantly very few of the 
negative cells were not activated at all and did not show any signs of expression for CD11b and CD14. 
Both patients exhibited 88.87% and 76.78% positive CD11b expression in their HOXA9 positive cells 
and 82.9% and 68.21% positive CD14 expression in their HOXA9 positive cells (Table 4.3). This 
suggests a possible link between the positivity of HOXA9 expression with CD14 and CD11b expression. 
The question remains, are activated cells expressing high levels of HOXA9 or maybe perhaps, high 
levels of HOXA9 are causing cells to be activated?  It is a difficult responsibility to try and make optimal 
use of scarce resources and achieve the best outcomes avoiding discrimination purely on grounds of 
age. To date, treatment options remain limited for these older adults with AML. Even as a bridge to 
transplant or by themselves, low-intensity approaches may help improve the outlook of elderly patients 
with AML. However, a limitation for these methods is that additional research on the impact of pre-
treatment geriatric assessment and other different therapeutic approaches, like HCT, on the quality-of-
life of the elderly, as well as higher social awareness of the huge resources concerned to improve the 
outcome of this elderly population soon, is urgently required. For all the above reasons, it is essential 
to tailor the choice of therapy to the patients’ condition and the disease characteristics as only a few 
patients benefit from aggressive approaches. Some novel agents hold promise; however, it is unlikely 
that they will achieve much benefit as single agents, hopefully, combinations may cover more ground 
in the future.  
In summary, having identified normal individuals with an increased HOXA9 expression future studies 
should look to progress onto isolating sub-populations where there is an increased HOXA9 expression, 
and being able to highlight or select individuals who may show a higher risk of developing 
haematological malignancies such as a myeloproliferative neoplasm or a myelodysplastic syndrome 
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and/or at a high risk of transforming to AML from these often less aggressive disorders and see if these 
principles hold true, as discussed and investigated in Chapter 5.  
  
 128 
Chapter 5: The role of HOXA9 in the 




5.1.1 HOX as a risk factor 
The main objective of this section is to determine HOXA9 gene expression in primary cells and its effect 
on AML and pre-leukemic malignancies like MPN and MDS. To get a better idea of the progression of 
AML, it is important not only to analyse AML patients, but also to look closely at other haematological 
disorders and pre-leukemic disease that may or are known to transform into AML. Importantly, it has 
been shown over the last decade that HOXA9 plays a key role and may be used as a risk factor in AML. 
This is a common finding in many recent studies, for example of 54 AML patients and 20 healthy 
individuals, HOXA9 expression was negative in 20 healthy individuals but positive in 22 of the 54 
(40.75%) of the AML patients. There was a complete remission (45.45%) for the patients who expressed 
HOXA9 which was significantly lower than the 71.86% of patients who did not express this gene after 
chemotherapy (Li et al., 2013). This supports the now well suggested hypothesis that HOXA9 may be 
used as a biomarker for chemotherapy in these patients in the future, however very little is known about 
patients with pre-leukemic disorders who go on to develop AML. Does HOXA9 play a role in this 
progression? If so to what extent could HOXA9 be targeted in the future as a biomarker for disease but 
also an intervention therapeutic to prevent the progression to AML from pre-leukemic malignancies 
like MDS and MPN? 
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5.1.2 HOX genes and cancer 
HOX gene expression can affect various pathways that promote tumorigenesis and metastasis.  
a) Differentiation: the expression of HOX genes involved in the terminal differentiation of normal tissue 
changes in malignant tissues, resulting in a failure of cellular differentiation, which suggests that the 
cells maintain an embryonic state. HOXC8 is a good example it is not usually expressed in prostate 
tissues but may be upregulated in prostate cancer (Miller et al., 2003). This overexpression in prostate 
cancer cell lines and primary cancer specimens may correlate with a loss of differentiation (Waltregny 
et al., 2002).   
b) Apoptosis: HOX gene expression may also contribute to tumorigenesis through activating anti-
apoptotic pathways. This was first discovered in breast cancer where it was shown that deficient p53 
expression in breast cancer cell lines and primary tumours correlated with the methylation of the 
HOXA5 promoter and loss of HOXA5 expression. HOXA5 binding sites have been found in the promoter 
region of the TP53 tumour suppressor gene, with transient transfection of HOXA5 activating the p53 
expression in the breast cancer cell lines, MCF-7 and ZR75.1, leading to an increased rate of apoptosis 
(Raman et al., 2000). HOXA5 has also been shown to induce apoptosis independently of p53 pathways, 
activating caspase-2 and caspase-8 mediated apoptosis (Chen et al., 2004). HOXA10 has been found in 
recent years to play a very similar role to HOXA5 by activating p53 expression in breast cancer cells. 
The most logical explanation for this is through oestrogen-HOX signalling, whereby oestrogen can 
upregulate the expression of HOXA10 in ER+ breast cancer cells (Chu et al., 2004).  
c) Proliferation: HOX genes are known to induce cellular proliferation of cancer cells. In human 
mammary carcinoma cells, the increased expression of human growth hormone (hGH) also increases 
the expression of HOXA1 resulting in a decreased apoptotic response, increased proliferation and 
metastatic potential (Zhang et al., 2003). HOX activity appears to show tissue specificity, for example, 
downregulation of HOXD10 in breast cancer (Carrio et al., 2005) and HOXB13 in colorectal cancer 
(Jung et al., 2005) have both been shown to increase proliferation. Upregulation of HOXC9 and 
HOXD10 in lung cancers is also linked with increased proliferation (Plowright et al., 2009).  
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d) Invasion: HOX genes have been implicated as factors of the invasive properties of cancer cells. 
HOXB7 is found to be overexpressed in bone metastasis and some primary breast tumours, and cells 
transfected with HOXB7 gained features of EMT. Included in this was the loss of adhesion molecules 
and changes in cell morphology and cytoskeleton arrangement (Hu et al., 2009). EMT is a biological 
process of the morphogenesis of various tissues that occur during embryogenesis, where polarized 
epithelial cells undergo multiple biochemical changes that enable them to assume a mesenchymal cell 
phenotype and facilitate migration through the ECM. It has been hypothesized that cancer cells undergo 
an EMT-like process to promote ECM invasion and distant metastasis (Thiery, 2009). In breast cancer 
cells however, HOXB9 was shown to trans-activate the production of transforming growth factor- β 
(TGF-β), ErbB ligands and several other angiogenic factors that may lead to EMT, invasion, and 
angiogenesis (Hayashida et al., 2010).  
It has been almost three quarters of a century since the discovered the primary function of HOX genes, 
however to date, their role in malignance is yet to be fully unveiled. Recent gene expression studies are 
slowly decoding the genetic antagonists in cancers and have highlighted and identified key molecular 
targets of which HOX genes are one. HOX genes have been shown to possess the ability to act as both 
oncogenes and tumour suppressors, with some possessing both abilities (Morgan et al., 2012). HOX 
deregulation has been observed in numerous cancers including bladder, kidney, non-small cell lung, 
thyroid, melanoma, myeloma, lung, prostate, breast, colon, ovarian cancer and more importantly in 
various types of leukaemia. In these cancers HOX genes have been shown to influence an increase in 
proliferation, invasion, metastasis, angiogenesis and help in DNA repair. Abate-Shen has proposed 
three mechanisms of action for the deregulation of HOX in cancer (Abate-Shen, 2012). Firstly, 
temporospatial deregulation, whereby HOX gene expression in malignant cells is different to its normal 
counterpart. Secondly, the mechanism of gene dominance, whereby HOX genes are overexpressed in 
malignant tissue compared to their adjacent normal parent tissue. Thirdly, the mechanism of epigenetic 
deregulation, such as methylation, whereby HOX genes often present in healthy tissue differ on a 
molecular level in comparison to their cancer counterpart.  
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5.1.3 Focusing on HOXA9   
HOX gene expression over the years has become an important prognostic factor in AML with over-
expression of HOX genes associated with an intermediate/unfavourable cytogenetic subset of AML. 
Among 6817 genes investigated in AML patients, the single gene correlated with the worst outcome 
and relapse of disease with short survival was HOXA9 (Golub, Slonim et al., 1999). Equally, high 
expression of HOXA9 is associated with a low CR rate (Li, Li et al. 2013). On the other hand, low 
HOXA9 expression was found to correlate with some of the best outcomes and responses to therapy 
(Andreeff, Ruvolo et al., 2008). It is also important to note that low expression of both HOXA4 and 
MEIS1 are favourable predictors for AML patient outcome (Zangenberg, Grubach et al., 2009). 
Additionally, a signature of up-regulation of HOXA6, HOXA9 and PBX3 combined with a low 
expression of MEIS1 is an independent poor prognostic marker in some forms of AML like NK-AML. 
Simultaneous knockdown of HOXA6 and HOXA9 causes cell death and AML cell lines to become 
significantly more sensitive to cytarabine (Dickson, Liberante et al., 2013). Higher expression of the 
HOXA7, HOXA9 and HOXA11 genes along with the cofactor PBX3 is a strong independent prognosis 
marker of adverse OS in abnormal karyotype AML (Li, Huang et al., 2012). The global HOX expression 
levels, also seems to mirror the outcome of disease, possibly mirroring the functional redundancy 
exhibited by many of the HOX genes. For this reason, the highest levels of HOX genes are seen in FLT3 
mutation cases, which often have unfavourable outcomes, and generally the HOX genes are expressed 
only at a very low level in favourable subsets of AML. It seems clear that the best biomarker that would 
assist in finding novel therapeutics for AML and pre-leukaemic malignancies would be HOXA9 and its 




Figure 5.1 A schematic diagram depicting HOXA9 regulation in normal haematopoiesis and HOXA9 
regulation in leukaemia due to upstream genetic alterations or the effects of proteins like NUP98 
(Collins and Hess, 2016). 
 
Recent studies have established the importance of HOX genes in the development of AML, although it 
is still not clear exactly what the functions of some of these genes are beyond general inhibition of 
differentiation and a significant increase in cell proliferation. There is a large void around the precise 
mechanistic knowledge for individual HOX genes which may also be owing to the functional 
redundancy showed by many members of this family, making knockdown of single HOX genes 
extremely difficult to interpret, and may also explain the contrast in gene knock-in and knock-out 
results. In myeloma and some solid malignancies, it has been investigated by targeting HOX proteins 
by antagonizing their interactions with the PBX cofactor using the peptide inhibitor HXR9 (Morgan, 
Pirard et al., 2007; Shears, Plowright et al., 2008; Plowright, Harrington et al., 2009; Daniels, Neacato 
et al., 2010; Morgan, Plowright et al. 2010).  As already mentioned, PBX binds to the PBX motif in the 
HOX paralogous group 1-10. HOX-PBX dimers have a higher binding affinity and specificity for target 
DNA sequences than the HOX monomer by itself. HOX-PBX dimers however, are strictly involved in 
the interaction of PBX to the conserved hexapeptide sequence WYPWMK found in the N terminal to 
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the homeodomain of HOX proteins from paralogous groups 1-10 for cooperative DNA binding by PBX 
and HOX partners (Chang, Shen et al., 1995; Shen, Rozenfeld et al., 1997; Medina-Martinez and 
Ramirez-Solis 2003). The HXR9 peptide inhibitor contains a hexapeptide sequence which mimics the 
HOX protein sequences responsible for binding to PBX and interferes with the DNA binding of HOX-
PBX. HXR9 is extremely cytotoxic to cells, predominantly through the induction of apoptosis in some 
cancers, which has been shown to depend upon a rapid increase in expression of c-Fos (Morgan, Pirard 
et al., 2007; Shears, Plowright et al., 2008; Espinosa, Shinohara et al., 2009; Plowright, Harrington et 
al., 2009; Daniels, Neacato et al., 2010). A similar approach may be useful in AML for addressing 




To observe the expression of HOXA9 in patients of AML and other related pre-leukemic and 
haematological malignancies and the role HOXA9 may play in the development of these diseases as 
well as the molecular mechanisms underpinning the progression from pre-leukemic disorders to AML. 
Examining the relationship between HOXA9 expression, the cells expressing HOXA9 and the way 
these may change in peripheral mononuclear cells of patients of various haematological malignancies. 
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Materials & Methods 
To observe the expression of various HOX genes in patients with AML and other haematological 
malignancies, mononuclear cells were isolated from the peripheral blood (Figure R5.1), shown as a 
ratio to β-actin where n=3 shown by error bars where each patient was analysed in three independent 
experiments. To assess the variation in expression of HOX genes in leukemic patients, several HOX 
genes of most interest were selected based on previous literature: HOXA5, HOXA6, HOXA9, HOXA10, 
HOXB4, HOXC4, HOXC9 and HOXD9. Blood was taken from patients on the ward or those who 
appeared in clinic for regular check-ups. FACS analysis was undertaken on the peripheral mononuclear 
cells isolated from patients selected, who were either suffering from AML or a host of other 
haematological malignancies using CD33 and CD117 to observe which cells appear to express HOXA9 
in primary cells and to validate the apparent increased expression of HOXA9 with the progression of 
AML. Having isolated peripheral mononuclear blood cells from patients of either active AML (n=3), 
MDS transforming into AML (n=3), MPN (n=2) and AML patients in remission (n=2) can observe 
from the data that many HOXA9 positive cells were also double positive for both AML markers, CD33 
and CD117 (Figure R5.3). In active AML and MDS transforming into AML, we see an average of 
90.16% and 82.01% of HOXA9 positive cells also being positive for the AML markers CD33 and 
CD117 respectively. On the other hand, we can see the percentage of HOXA9 positive cells being 
positive for the AML markers CD33 and CD117 in both MPN patients suffering from both 
myelofibrosis and polycythemia vera was lower at 61.08% and 54.29% respectively. Most notably, few 
cells from patients in remission were positive for HOXA9 let alone positive for HOXA9 and double 
positive for CD33 and CD117 (4.08% and 10.88%). As would be expected, the number of HOXA9 
positive cells decreases as we can see from the percentage of cells that are HOXA9 relative to the total 
cell number, but we also see a huge drop off in these cells that are double positive for the myeloid 




5.3.1 Identifying cancer related HOX genes in patients suffering from AML 
and other haematological malignancies 
HOX genes are generally low expressed in mononuclear cells isolated from the peripheral blood of 
healthy adults, however, gene expression increases significantly in patients suffering from AML and 
other haematological malignancies. The expression of HOX genes changes with the progression of 
AML (Chapter 6), with most AML patients expressing HOXA9 at a much higher level than other HOX 
genes and a much higher level than those of other haematological disorders, also supported by previous 
studies whereby AML patients had a 4.57 or a 1.71 times increase in HOXA9 expression compared to 
patients with myelofibrosis (MF) and myelodysplastic syndrome (MDS) respectively. Other noticeable 
with disease progression include: HOXA5, HOXA10 and HOXB4 which are present in the clear majority 
of patient samples, especially those samples who have progressed towards AML. Samples from patients 
who are in remission from AML show a very low HOX gene expression profile, which is to be expected 




Figure R5.1 Expression profiling of cancer related HOX genes in mononuclear cells isolated from the 
peripheral blood of patients with acute myeloid leukaemia and other haematological disorders. The 
expression of HOX genes is represented by the ratio of the expression of the HOX genes to the 
housekeeping gene β-actin (×1000). The mean of three independent experiments are shown and error 
bars show the SEM in these graphs, normal PBMCs were n=3. *p< .05, **p < .01, ***p <.001 and 



















































































































































5.3.2 HOXA9 expression increases in AML from other haematological 
malignancies 
 
The expression of HOXA9 was analysed in AML patients and patients with other related pre-leukemic 
and haematological malignancies. As expected, HOXA9 expression varies between patient with a 
significant increase in HOXA9 expression between patients with mild haematological malignancies 
such as MPN’s like ET and PRV compared to those diagnosed with MDS and AML. Some AML 
patients express low levels of HOXA9 though the probability of higher HOXA9 expression is increased, 
likely due to discrepancies between differences in AML subtypes which may not express HOXA9 at all, 
along with patients who may have had a bone marrow transplant or are currently in remission. When 
analysing the data, 9 out of the 10 lowest HOXA9 expression levels analysed were seen in the patients 
with the mildest haematological disorders suffering from malignancies like ET and PRV or mild 
anaemia (Figure R5.2.1), on the contrary however, 7 of the 10 highest HOXA9 expression levels were 
seen in active AML patients. HOXA9 has been shown to be necessary for maintaining leukemic 
transformation; however, the molecular mechanisms through which it promotes leukaemogenesis 
remain poorly understood. HOXA9 expression between the individual cohorts changes drastically with 
AML patients exhibiting an increase of 3.78 and 5.32 times greater HOXA9 expression than MDS and 
CML respectively. High expression of HOXA9 is well associated with low CR rate (Li, Li et al. 2013), 
while low HOXA9 expression found to correlate with some of the best outcomes and responses to 
therapy (Andreeff, Ruvolo et al., 2008). 
When analysing AML patients’ HOXA9 expression, the 22 AML patients were separated either by those 




Figure R5.2.1 Variation in HOXA9 expression in mononuclear cells isolated from whole blood of patients 
with acute myeloid leukaemia and other haematological disorders. The expression of HOXA9 is 
represented by the ratio of the expression of HOXA9 to the housekeeping gene β-actin (×1000). The 
values of seventy-three separate patients were plotted where each patient was analysed in three 
independent experiments with the SEM for each patient used in this graph. The mean of three 
independent experiments are shown and error bars show the SEM in these graphs, normal PBMCs 




Figure R5.2.2 Variation in HOXA9 expression of mononuclear cells isolated from the whole blood of 22 
patients either with various degrees of active acute myeloid leukaemia (grey) or in active acute myeloid 
leukaemia in remission (black). The expression of HOXA9 is represented by the ratio of the expression 
of HOXA9 to the housekeeping gene β-actin (×1000). The mean of three independent experiments are 
shown and error bars show the SEM in these graphs. The mean of three independent experiments are 
shown and error bars show the SEM in these graphs, normal PBMCs were n=3. *p< .05, **p < .01, 
***p <.001 and ****p <.0001. 
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5.3.3 The relationship between HOXA9 expression, the cells expressing 
HOXA9 and the way these may change in peripheral mononuclear cells of 
patients with haematological malignancies 
 
FACS analysis was undertaken on peripheral mononuclear cells isolated from AML patients and other 
haematological malignancies using CD33 and CD117 to observe which cells appear to express HOXA9 
in primary cells and to examine the increased expression of HOXA9 with the progression of AML. RNA 
was isolated from peripheral mononuclear blood cells of patients with either active AML (n=3), MDS 
transforming into AML (n=3), MPN (n=2) or AML patients in remission (n=2). We could see from the 
data (Figure R5.3). Many HOXA9 positive cells were also double positive for both AML markers CD33 
and CD117. Active AML and MDS that transform into AML had an average of 90.16% and 82.01% of 
HOXA9 positive cells also being positive for the AML markers CD33 and CD117 respectively (Table 
5.4). Conversely, the percentage of HOXA9 positive cells also being positive for the AML markers 
CD33 and CD117 in MPN patients suffering from both myelofibrosis and polycythemia vera was 
61.08% and 54.29% respectively. Of particular interest, very few cells from patients in remission were 
positive for HOXA9 let alone positive for HOXA9 and double positive for CD33 and CD117: 4.08% 
and 10.88% (Table 5.4). 
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Figure R5.3 Representative flow cytometry surface staining data of peripheral mononuclear blood cells 
isolated from patients with a) active AML, b) MDS transforming into AML, c) MPN and d) AML 
currently in remission stained with extracellular CD33 and CD117 and intracellular HOXA9 
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Figure 5.4 A table listing surface staining data of peripheral mononuclear blood cells isolated from 
patients with a) active AML, b) MDS transforming into AML, c) MPN and d) AML currently in 













AML MDS-AML MPN AML (rem)






Stained Cells 1 2 3 
AML HOXA9 positive cells double 
positive for CD33 and CD117 
92.73% 92.94% 84.81% 
MDS-AML HOXA9 positive cells double 
positive for CD33 and CD117 
85.23% 71.98% 88.86% 
MPN HOXA9 positive cells double 
positive for CD33 and CD117 
61.08% 54.29% 
AML in Rem HOXA9 positive cells double 
positive for CD33 and CD117 
4.08% 10.88% 
Table 5.1 A table listing surface staining data of peripheral mononuclear blood cells isolated from 
patients with a) active AML, b) MDS transforming into AML, c) MPN and d) AML currently in 
remission stained with extracellular CD33 and CD117 and intracellular HOXA9 antibodies. 
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5.3.4 HOXA9 expression changes over time in patients suffering from AML 
and other haematological malignancies and appears to correlate with 
progression of disease 
 
To observe the potential change in HOXA9 expression over time in mononuclear cells isolated from the 
peripheral blood of patients with various haematological malignancies, blood was taken before and after 
a 9-month period and gene expression of HOXA9 was analysed in thirteen separate patients. Evidently, 
expression of HOXA9 changes measurably between individuals but we managed to observe a significant 
change when grouping patients based on their disease progression. High HOXA9 expression levels were seen 
in “active” AML patients 27 and 21 which remained significantly high throughout the 9-month period, both 
patients have a very poor clinical prognosis of AML, one of which has transformed from MDS over the last 
few years. A low HOXA9 expression was exhibited in patient 45, 50, 58 and 14, all of which were AML 
patients in remission or who had received a bone marrow transplant and this expression didn’t change hugely 
over this 9-month period.  Most interestingly, HOXA9 expression increased significantly over time in both 
patients 29 and 27, who have subsequently transformed from MF and MDS respectively into AML during 




Figure R5.5 The change (before and after) in HOXA9 expression of mononuclear cells isolated from the 
whole blood of patients with acute myeloid leukaemia and other haematological disorders over time. 
Patients were broken up into either: progressing AML, active AML, recovering AML or AML patients in 
remission based on their clinical diagnosis. The expression of HOXA9 is represented by the ratio of the 
expression of HOXA9 to the housekeeping gene β-actin (×1000). The values of thirteen separate 
patients were plotted where each patient was analysed in three independent experiments with the SEM 
for each patient used in this graph. The mean of three independent experiments are shown and error 
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Table 5.2 A table listing all important data from AML and MDS patients whose HOXA9 expression was 




Investigating HOXA9 gene expression in primary cells and its role in acute myeloid leukaemia (AML), 
myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS) and other pre-leukaemic 
malignancies will expand on the progression of disease from these disorders towards AML and other 
haematological cancers. For this reason, it is important not only to analyse AML patients, but also to 
look closely at other haematological malignancies and pre-leukemic disorders that are thought to, or are 
known to, transform into AML. It has been shown over the last decade the importance of HOXA9 and 
may be used as a prognostic factor in AML. This is a common finding in many recent studies, for 
example of 54 AML patients and 20 healthy individuals, HOXA9 expression was negative in 20 healthy 
individuals but positive in 22 of the 54 (40.75%) of the AML patients. There was a complete remission 
rate (45.45%) of the patients who expressed HOXA9 which was significantly lower than the 71.86% of 
patients who did not express this gene after chemotherapy (Li et al., 2013). Does HOXA9 play a role in 
this progression? If so to what extent could HOXA9 be used in the future as a biomarker for disease but 
also be targeted with intervention therapy to prevent the progression to AML from pre-leukemic 
disorders like MDS and MPN. 
The expression of HOX genes linked to cancer were assessed in various patient groups. HOX genes 
selected were those based on previous literature: HOXA5, HOXA6, HOXA9, HOXA10, HOXB4, 
HOXC4, HOXC9 and HOXD9 and analysed in these various cohorts. As we have seen in previous 
chapters and in the literature thus far, we would normally expect HOX genes to be of low expression in 
mononuclear cells isolated from the peripheral blood of healthy adults. Gene expression vary between 
individuals, however in terms of HOXA9, almost all AML patients analysed express this gene at a much 
higher level than that of healthy aged matched donors with other mild haematological disorders, which 
as we know is supported by previous studies. Other noticeable stand-out genes with disease progression 
include: HOXA5, HOXA10 and HOXB4 which are present in the clear majority of patient samples 
especially those samples which have progressed towards AML. Interestingly however, patients who are 
in remission from AML showed a very low HOX gene expression profile, which is to be expected. 
Some of these patients have had a bone marrow transplant which would suggest a low or almost normal 
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HOX gene expression profile. HOXA9 positively regulates the transcription of other HOX genes 
including HOXA7 and HOXA10 and its co-factors PBX3 and MEIS1 (Thorsteinsdottir et al., 2001) 
although the effect this may have on the global expression of HOX genes currently remains elusive. 
HOXA10 resembles HOXA9 expression to some degree in almost all cohorts of patients and is expressed 
at high levels simultaneously whereas this was not the case in the mild haematological disorders (Figure 
R5.1). The HOX genes most important for the maintenance of progenitor or stem cell status and promote 
their proliferation are HOXA9 and HOXB4. The former is the most preferentially expressed HOX gene 
in early hematopoietic progenitors and CD34b HSCs and is downregulated during differentiation 
(Thorsteinsdottir et al., 2001) and both are expressed highly in most samples analysed (Figure R5.1). 
HOX gene expression may also contribute to tumorigenesis through activating anti-apoptotic pathways. 
It was first discovered in breast cancer with deficient p53 expression in breast cancer cell lines and 
primary tumours and has also shown to correlate with the methylation of the HOXA5 promoter and loss 
of HOXA5 expression. HOXA5 binding sites have over recent years been found in the promoter region 
of the TP53 tumour suppressor gene, and the transient transfection of HOXA5 activating the p53 
expression has been seen in the breast cancer cell lines, MCF-7 and ZR75.1, leading to an increased 
rate of apoptosis (Raman et al., 2000). Recently HOXA5 has been shown to induce apoptosis 
independently of p53 pathways, with activation of both caspase-2 and caspase-8 mediated apoptosis 
(Chen et al., 2004). These findings have huge significance and was supported by our observations of 
high HOXA5 expression levels in cohorts suffering from AML who also express HOXA9 at high levels 
(Figure R5.1). Notably, as we have discussed HOXA10 is also increased in these cohorts however, the 
link between HOXA10 and that of high HOXA5 expression is relevant. This supports studies that have 
already shown HOXA10 to play a similar role to HOXA5 by activating p53 expression in breast cancer 
cells. The most logical explanation for this is through oestrogen-HOX signalling where oestrogen can 
upregulate the expression of HOXA10 in these ER+ breast cancer cells (Chu et al., 2004).  
To date the relationship between the potentially increased HOXA9 expression of pre-leukemic disorders 
and the increased HOXA9 expression in many AML patients remains elusive. Looking into the 
expression of HOXA9 in AML patients at various stages of disease progression and how HOXA9 
changes between AML and pre-leukemic disease such as MDS and MPD will allow us to understand 
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the molecular roles some genes may have in relation to disease. Not surprisingly we found that there 
was a significant increase in HOXA9 expression in patients with AML or some MDS patients especially 
those close to transforming into AML compared to those who have been diagnosed with very mild 
haematological disorders such as MPN’s like ET and PRV or normal patients. It is important to note, 
however that there are still various AML patients who express low levels of HOXA9. There are several 
reasons for this, with differences in AML subtypes and the cytogenetic differences between subtypes, 
it makes it a little more difficult to uncover the exact genes involved. However, we have also found that 
many of these low level HOXA9 patents have had a bone marrow transplant or are in remission, which 
makes things interesting. Having analysed the data, 9 out of the 10 lowest HOXA9 expression levels 
were seen in mild haematological disorder patients suffering from malignancies like ET and PRV or 
mild anaemia (Figure R5.2.1). Most significant for us in this study was that in contrast, 7 of the 10 
highest HOXA9 expression levels were seen in active AML patients.  
Attempting to underpin the role HOXA9 may play in MPN and MPD that results in AML remains 
elusive, however, recent studies have used haemopoietic chimeras acted as a mouse model for NUP98-
HOXA9 induced leukaemia to reproduce phenotypes observed in human disease. Mice that were 
transplanted with marrow cells known to be expressing NUP98-HOXA9 through retroviral transduction 
went on to develop MPN and eventually succumbed to acute myeloid leukaemia AML. It was the 
NUP98 section of this fusion protein that was shown to be responsible for the transformation of a 
clinically silent pre-leukemic phase into a chronic stem cell derived MPN. Interestingly it was found 
that the co-expression of this fusion protein as well as MEIS1 (one of the co-factors highlighted in 
previous chapters) accelerated this transformation of MPN into AML which highlights an already 
established genetic interaction between both HOXA9 and MEIS1 (Kroon et al., 2001).This was the first 
study that not only highlighted this but was actually able to demonstrate an overlapping yet distinct 
molecular mechanism for both MPN and AML, highlighting the extreme complexity of leukemic 
transformations. These Philadelphia chromosomal negative (Ph-) chronic myeloproliferative neoplasms 
have an inherent tendency to transform into acute myelogenous leukaemia with the long-term rate of 
transformation in randomised unselected patients being studied extensively in well-defined populations 
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in Sweden and France. In these studies, a median observation time of 15 years, with 56 subjects of the 
total 795 (7%) with Ph- transformed from MPN to AML with a yearly incidence rate of 0.38% in PRV, 
0.37% in essential ET and almost 1.09% in idiopathic myelofibrosis IMF. The average survival time 
for these 56 MDS patients that went on to develop AML was 4.6 +-5.5 months and didn’t differ 
substantially to any of the three subtypes of pre-AML MPN. Interestingly 17 of the 18 patients with 
PRV that went on to develop AML were female as the gender ratio for this group was 146/171 (0.85) 
compared to ET and IMF showed a slight male dominance of 1.33 and 1.13 respectively. 
Looking at the possible progression of AML from pre-leukemic disorders over time and being able to 
look into each patient’s prognosis and clinical pathology with their corresponding HOXA9 expression 
change over time gives us a much better understanding of whether these changes are of any significance. 
Blood was taken before and after a 9-month period and gene expression of HOXA9 was analysed in 
thirteen of these patients with access to their medical records and diagnosis, cytogenetics, morphology 
and disease progression. Expression of HOXA9 changes between individuals but we managed to 
observe a significant change when grouping patients based on their disease progression. High HOXA9 
expression levels were seen in some AML patients which remained significantly high throughout the 
9-month period, these patients had a very poor clinical prognosis of AML, one of which has transformed 
from MDS over the last few years. As we know, MDS and MPN are clonal haematological disorders 
characterized by ineffective haematopoiesis, bone marrow dysplasia in MDS or hyperplasia in MPN, 
frequently progressing to AML 15-52% and 7% respectively, and incurring a poor prognosis so 
assessing those patients who may transform was of interest to us. Interestingly then, HOXA9 expression 
was increased significantly over time in both patients 29 and 27, who had subsequently transformed 
from MF and MDS respectively into AML during this 9-month period (Figure R5.4). On the other hand, 
however, a low HOXA9 expression was exhibited in patients 45, 50, 58 and 14, all of who were AML 
patients in remission or who had received a bone marrow transplant and this expression didn’t change 
hugely over this 9-month period. Drawing a link between the expression of HOXA9 and the progression 
of disease over time is something that has never been fully investigated. This data suggests to us that a 
much larger, thorough study would be of huge interest and bear fruit for the potential use of novel 
therapeutics could target patients suffering from AML and other pre-leukaemic malignancies.  
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Understanding the affects HOXA9 may have on AML and other haematological malignancies is of huge 
importance in the development of novel therapeutics in the future. The high levels of HOX gene 
dysregulation in cancers as we know makes HOXA9 and the other HOX genes perfect potential targets 
for therapeutic intervention in theory although it is not always that simple. Targeting of specific HOX 
genes is extremely problematic due to functional redundancy between proteins. However, it has been 
identified that targeting the HOX/PBX dimer is an effective way of impacting the function of multiple 
HOX genes. The logical method was to use a peptide that is responsible for disrupting the interaction 
between HOX proteins and its co-factor PBX, to block the functionality of PBX-dependent HOX 
functions. This idea led to the production of HXR9.  
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Chapter 6: HXR9 as a potential 




6.1.1 HXR9, the future? 
HXR9 is a small peptide that has been designed to mimic the hexapeptide sequence in HOX proteins 
of paralogue groups 1- 8 (Phelan et al., 1995, Chang et al., 1995, Shanmugam et al., 1997, Piper et al., 
1999, Morgan et al., 2000, Medina-Martínez and Ramírez-Solis, 2003), acting as an extremely specific 
competitive inhibitor of the HOX/PBX binding site. This peptide has a strong ability to prevent the 
formation of the HOX/PBX dimer and the subsequent binding to target DNA sequences, essentially 
inhibiting the transcription of target genes. For HXR9 to enter cells, a polyarginine (R9) sequence is 
linked to the hexapeptide that has been previously been shown as an extremely effective delivery system 
(Jiang et al., 2006). Previous studies have shown that HXR9 can block this important interaction not 
only in vitro but also in vivo (Morgan et al., 2007, Plowright et al., 2009, Morgan et al., 2010) and that 
antagonising the HOX/PBX interaction induces apoptosis (Morgan et al., 2007, Shears et al., 2008, 
Plowright et al., 2009, Morgan et al., 2010, Morgan et al., 2012). Therefore, investigating whether 
AML cell lines and patient samples were also sensitive to HXR9 was of keen interest. It is also useful 
to note that there may also be a similar effect when combining HXR9 with commonly used 
chemotherapies in AML treatment, MTX and DNR (Piccaluga et al., 2002, Fernandez, 2010, Larson et 
al., 2012). Molecular agents combined with conventional chemotherapies have given rise to more 
curative therapies and may provide a rational basis for the selection of a synergistic partner for HXR9, 





Figure 6.1 A schematic diagram depicting the blocking of the HOX/PBX dimerization with the small 
peptide HXR9. HXR9 is a peptide which mimics the hexapeptide sequence of HOX proteins and acts as 
a competitive inhibitor of HOX/PBX binding. This hexapeptide sequence is linked to nine arginine 
residues to allow cell membrane penetration (Morgan et al., 2014). 
 
6.1.2 The HXR9 death pathway 
Microarray analysis has revealed over twenty genes that seemed to have a significant increase in 
transcription levels, this has been confirmed by qPCR. Some of these upregulated genes were the 
oncogenes c-Fos and c-Jun (Morgan et al., 2007) in various cell lines. These oncogenes are transcription 
factors and members of the bZIP superfamily, that are characterised by a DNA-binding domain with a 
leucine zipper region (Hess et al., 2004). Jun proteins form homodimers or heterodimers with Fos 
proteins making the activating protein (AP-1) transcription factor. AP-1 mediates regulation of several 
genes controlling physiological functions including basic functions like cell proliferation and 
differentiation as well as apoptosis and neoplastic transformation (Ameyar et al., 2003, Eferl and 
Wagner, 2003, Jochum et al., 2001, Shaulian and Karin, 2001, Shaulian and Karin, 2002). 
The upregulation of c-Fos expression has been well documented in HXR9-mediated apoptosis. It is 
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currently unknown what the exact mechanism of AP-1 mediated apoptosis is, however, the AP-1 
complexes that contain c-Jun promotes the transcription of c-Fos ligand (FasL) which in turn promotes 
cell death via the FasL/Fas receptor pathway in lymphoid, fibroblast and neuronal cells (Eichhorst et 
al., 2000, Kasibhatla et al., 1998, Kolbus et al., 2000, Matsui et al., 2000). In some prostate cancer 
cells, c-Jun and c-Fos heterodimerisation has been seen to repress the transcription of cellular-FLICE-
inhibitory protein long isoform c-FLIP(L), which is well known as an anti-apoptotic molecule, that has 
resulted in the sensitisation of extremely resistant prostate cancer cells to tumour necrosis factor-related 
apoptosis-inducing ligand (TRAIL) induced apoptosis (Li et al., 2007, Zhang et al., 2007). 
Overexpression of c-Fos in hepatocytes has also been widely shown to induce apoptosis (Mikula et al., 
2003) and is required for Myc-induced cell death of hepatoma cells (Kalra and Kumar, 2004). However, 
c-Fos re-expression in several established tumour cell lines resulting in the activation of pro-apoptotic 
genes uses a different mechanism that does not involve Jun (Fleischmann et al., 2003). In these prostate 
cancer cell lines however, as well as c-Fos and c-Jun, other relevant genes were upregulated in response 
to HXR9 treatment: e.g. Dusp1, Aft3, Transcription factor Krüppel-like factor 4 (KLF4), Mad and 
Drak2. Dusp1 encodes dual specificity phosphate 1 which in turn dephosphorylates serine, threonine 
and tyrosine residues from a wide range of substrates, such as mitogen-activated protein kinases 
(MAPKs), for example which plays important roles in the signalling pathway of MAPK that tightly 
regulates cell division and cell growth. However, dephosphorylation of these kinases often leads to 
inactivation of this pathway (Ducruet et al., 2005). If AML derived cell lines/patients have an increased 
c-Fos and c-Jun expression, what about pre-leukemic diseases? Could this mechanism of cellular death 
help identify what exactly underpins the progression from pre-leukemic disease to AML? Could 
downstream proteins like c-Fos and c-Jun unlock the answers to HOXA9’s dysregulation? Not only 
this, what if the mode of cell death for AML derived cell lines is not apoptosis, then what role if any 




Figure 6.2 A schematic diagram depicting our currently hypothesised HXR9 Death Pathway including 
C-Fos, C-Jun (AP-1 complex), EGFR1 and downstream caspases once the HOX-PBX binding site is 
interrupted by HXR9. 
 
 
6.1.3 The importance of c-Fos  
Antagonism of the HOX/PBX interaction results in up-regulation in the expression of c-Fos in other 
cancers. This induction of c-Fos expression by HXR9 has been well documented and is thought to be 
responsible to some degree, for initiating cell death in human renal, lung, melanoma, ovarian, prostate 
and breast cancer cell lines (Morgan, Pirard et al., 2007; Shears, Plowright et al., 2008; Plowright, 
Harrington et al., 2009; Morgan, Plowright et al., 2010; Morgan, Boxall et al., 2012; Morgan, Boxall 
et al., 2014). It has also been shown that knocking down c-Fos expression has been able to rescue 
prostate and melanoma cancer cell lines from HXR9-induced apoptosis (Morgan, Pirard et al., 2007; 
Morgan, Boxall et al., 2014). The current literature has clearly shown that c-Fos is a key component of 
the AP-1 transcription activating complex, which dimerizes with Jun (its binding partner), to regulate 
cell proliferation and even cell cycle progression (Durchdewald et al., 2009). It has already been 
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suggested as a proto-oncogene in several human tumours, which include: bone, brain and skin (Gamberi 
et al., 1998, Silvestre et al., 2010, Guinea-Viniegra et al., 2012). It is worth noting that the reduction in 
c-Fos expression in epithelial ovarian carcinoma has shown some potential as an independent marker 
of overall survival (Mahner et al., 2008). It has also been discovered, that c-Fos over-expression may 
also have a pro-apoptotic function in vitro and may cause a delay in tumour growth and the metastasis 
of ovarian cancer cells (OvCa cells) in vivo. The mechanisms for c-Fos have been highlighted by a 
dysregulation of adhesion proteins (Oliveira-Ferrer et al., 2014), which has also be shown to have an 
involvement in the induction of the human ovarian carcinoma cell line A2780 in response to some 
fenrtinide treatment (Appierto et al., 2004). Interestingly, c-Fos has been subsequently shown to drive 
pro-apoptotic functions via repressing the anti-apoptotic gene cellular FLICE (FADD-like IL-1β-
converting enzyme)-inhibitory protein (L) (c-FLIP (L)) resulting in an increased sensitivity for prostate 
cells to the tumour necrosis-related apoptosis-inducing ligand protein (TRAIL) (Zhang, Zhang et al., 
2007). It has been hypothesized that c-Fos may induce human hepatoma Huh7 apoptosis by mediating 
c-Myc expression (Kalra and Kumar, 2004). The over-expression of c-Fos results in cell cycle arrest as 





 and suppresses rat sarcoma (Ras)-mediated malignancy eventually leading to 
apoptosis of murine epithelial hepatocytes (Mikula et al., 2003). A prolonged expression also 
suppresses cell cycle entry of murine BM cells (Okada et al., 1999). Studies have shown that c-Fos may 
also enhance hepatocyte apoptosis by directly up-regulating the major isoform of the BIM gene BIMEL 
(Kitamura, Ogawa et al., 2003). For these reasons, c-Fos is one of the more important genes in this 
pathway and its investigation is warranted for the HXR9 death pathway in AML and other 
haematological disorder. 
 
6.1.4 The importance of tumour suppressors 
Cells undergoing p53-dependant apoptosis demonstrated increased c-Fos transcription (Elkeles et al., 
1999). HXR9 does not alter the expression of p53 at the mRNA or at the protein level in breast cancer 
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cells that are p53-independent (Morgan et al., 2012). Not only this, but p53 protein interacts directly 
with anti-apoptotic members of the Bcl-2 family, Bcl-2 and Bcl-XL, therefore resulting in the release 
of pro-apoptotic members such as Bak and Bax. p53 has also been shown to up-regulate the 
transcription of, and physically interacts with, Bak, Bax and Bad therefore leading to mitochondrial 
apoptosis (Chipuk et al., 2003, Chipuk et al., 2004, Leu et al., 2004, Jiang et al., 2006, Pietsch et al., 
2007, Wenzel et al., 2012, Lee et al., 2008, Saha et al., 2014). Interestingly, neither cypD nor PARP1 
were seen to be involved in HXR9-induced AML necrosis. Together, these findings clearly suggest that 
HXR9-induces AML necrosis in a p53-independent manner (Vaseva et al., 2012, Montero et al., 2013, 
Pei et al., 2014).  
p21 is a member of the family of cyclin kinase inhibitors including p27 and p57 (Kwon et al., 2003, 
Masgras et al., 2012). It was originally reported to be a key regulator of the progression of the cell cycle 
(Harper et al., 1993). Interestingly, p21 also regulates several other cellular functions such as: apoptosis, 
cell proliferation and autophagy (Asada et al., 1999). Initially it was suggested that the regulation of 
p21 was totally dependent on p53, however, p21 can in fact be regulated by several transcription factors 
in a p53-independent manner (Liu and Huang et al., 2006; Lafarga, Cuadrado et al., 2009; Shin, Kim 
et al., 2011; Han, Kim et al., 2012; Masgras, Carrera et al., 2012). For example, early growth response-
1 protein has been shown to induce p21 transcription independently of p53 (Choi, Kim et al. 2008). The 
early growth response-1 gene is induced in lung cancer cells following HXR9 treatment (Plowright et 
al., 2009). p21 has also been shown to be involved in p53-independent necrotic cell death (Ussat et al., 
2002, Kwon et al., 2003). It is therefore suggested that the induction of p21 in response to HXR9 was 
p53-independent.  
As the expression of some of these tumour suppressor and pro-apoptotic genes increases after HXR9 
treatment in malignant cells, this suggests that some of the overexpressed HOX genes found may 
potentially inhibit intrinsic tumour suppressing pathways and therefore create a pro-tumour 
environment. Looking to target the HOX/PBX interaction is thus an important target in cancer therapy, 
with further investigation into HOX deregulation in cancers needed to determine whether HXR9 is a 
good potential treatment option.  
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Aims 
To observe the cytotoxicity of HXR9 on several AML cell lines along with observing the change in 
expression of HOX genes (HOXA9), co-factors of HOXA9 and important downstream genes in several 
AML cell lines, AML patients and patients with other haematological disorders when treated with 
HXR9 in attempt to answer: Does HXR9 treatment affect downstream genes responsible for cell death 
in leukemic cell lines? Is HXR9 induced cell death is independent of apoptosis? Does HXR9 treatment 





Materials & Methods 
6.2.1 HXR9 treatment  
HXR9/CXR9 powder was taken from -20°C freezer and left in a sterilised hood to slowly warm to room 
temperature. Once warmed to room temperature, 500mg of HXR9 was reconstituted in 1850μl of sterile 
water to make up a 100mM solution. CXR9 has almost the same molecular weight, so the same volume 
was added to make a 100mM solution. Once all the liquid was added it was left in the hood with the lid 
on for 10 minutes (ensuring not to mix or insert a pipette tip into the liquid once added as this could 
mean peptide is lost if stuck to the pipette tip). The powder was dissolved and lightly vortexed so the 
solution was a uniform colour (light yellow) and aliquoted out into 100μl aliquots before being stored 
at -80°C. 
 
6.2.2 Lactate dehydrogenase (LDH) assay  
Lactate Dehydrogenase (LDH) is present in the cytoplasm of cells and is released into culture medium 
through the membrane of the cell. The amount of this enzyme in culture gives a good indication of the 
integrity of the cell membrane and provides an estimation of cytotoxicity (Haslam et al., 2000). LDH 




. Having done this, diaphorase, (catalyst), transfers 2H from NADH/H
+ 
to a tetrazolium 
salt (INT) which results in the formation of red salt (formazan). Therefore, by using this we can gauge 
the amount of formazan formed and correlate it directly to the amount of LDH in the culture medium 
and to the number of damaged cells. The LDH cytotoxicity assay (Figure 6.5). LDH catalyses a 
reduction of NAD+ to NADH+/H+ by converting lactate to pyruvate. Diaphorase reduces yellow 
tetrazolium salt INT into the red formazan salt with the presence of NADH+/H+. During the process of 
HXR9 cytotoxicity determination, cells are treated with HXR9 or a negative control (CXR9) for 2 hours 
as seen in this study. This step is repeated six times. Plates were incubated in a humidified incubator at 
37°C, 5% CO2 for either 2 or 24 hours. After the treatment, plates were centrifuged at 1000rpm for 5 
minutes and 100μl of supernatant decanted from each well into a fresh, 96-well flat-bottom plate. The 
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same amount of LDH reagent is prepared to manufacturer's instructions, added to the supernatants for 
two minutes, and LDH enzymatic activity was then estimated by reading the absorbance at 492nm, with 
a plate reader.  
 
 
Figure 6.3 A schematic diagram depicting the mechanism of action of LDH cytotoxicity assay. LDH 
catalyses a reduction of NAD+ to NADH+/H+ through a conversion of lactate to pyruvate. Then, 
diaphorase reduces the yellow tetrazolium salt INT to the red formazan salt in the presence of 
NADH+/H+.  
 
6.2.3 LDH assay data analysis  
To assess the percentage of surviving cells, cytotoxicity percentage was calculated. An average 
absorbance of all six repeats were used and calculated. The average absorbance value of the background 
control is then subtracted from the HXR9 treated cells’ absorbance average value. Having done this, 
the cytotoxicity percentage was calculated according to the manufacturer's instructions as per:  
 
Cytotoxicity% = 
treated value−negative control 
× 100 
positive control−negative control  




The % of surviving cells was plotted on a X-Y scatter diagram using GraphPad Prism software 
(California, USA) after this, to create cytotoxicity curves for each cell line. The surviving fractions of 
the treated cells was compared to those of untreated cells. Not only this, but the cytotoxicity results of 
the different cell lines can also be compared. Every individual experiment undertaken was repeated 
three times (biological replicates) and the valid experimental curve should have a linear correlation 
coefficient (R
2
) ≥ 0.95. The cytotoxicity curves were generated using a mean %surviving cells at 
various drug concentrations. The SEM of each single dose was determined and then included with error 
bars on the cytotoxicity curves. IC50 was then determined by CalcuSyn software (Biosoft, Cambridge, 
UK) as described in the statistical analysis section. It is also important to note that PBX is not the 
solitary co-factor for many of these HOX proteins and therefore the inhibition of HOX/PBX interaction 
may cause alternative cofactors to be utilised.  
 
6.2.4 Inhibition of caspases activity by z-VAD-FMK  
Z-VAD-FMK is a cell permeable caspase inhibitor that can prevent the induction of apoptosis by 
irreversibly binding to caspase protease catalytic sites (Marcelli et al., 1999). Z-VAD-FMK was diluted 
in DMSO to 43mM before being stored at -20°C.  Some samples were pre-treated with 50μM z-VAD-
FMK. Cells were then suspended in 5% FBS supplemented culture media at a concentration of 1×10
6 
cell/ml, seeded in 96-well plates at a concentration of 1×10
5 
cells/well. Plates were incubated in a 
humidified incubator at 37°C, 5% CO2 for one hour. HXR9 and CXR9 were prepared as above, in 5% 
FBS media with or without 50μM z-VAD-FMK. After an hour pre-incubation, the cells were treated in 
triplicate with 100μl of HXR9 IC50, or with a CXR9 concentrations that were equivalent to double the 
IC50. Each plate had an untreated negative control cells and cells treated with Daunorubicin (DNR) as 
positive control cells. Plates were then incubated in a humidified incubator at 37°C, 5% CO2 for two 
hours. Having been treated for two hours, plates were centrifuged at 1000rpm for five minutes and 
supernatants discarded. Cell pellets were washed twice before RNA was extracted for analysis.  
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Results 
6.3.1 HXR9 is cytotoxic to all tested leukemic cell lines 
Five AML-derived cell lines including KG-1, HEL 92.1.7 and HL-60, derived from primary AML 
patients, with KU812F and K562 derived from secondary AML patients were challenged with titrations 
of HXR9 and its negative control CXR9 for two hours. The cytotoxic effect of HXR9 and CXR9 were 
subsequently measured by an LDH assay. HXR9 as expected had a large cytotoxic effect on all tested 
AML cell lines, while CXR9 which does not have a functional domain had no cytotoxicity (Figure 
R6.1). IC50 values were analysed by Calcusyn software and were 4.6μM, 7.2μM, 21.9μM, 9.6μM and 
11.4μM for KG-1, HEL 92.1.7, HL-60, KU812F and K562, respectively (Table 6.1). 
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Figure R6.1 LDH assay for HXR9 and CXR9 cytotoxicity on five AML-derived cell lines. Cell lines 
were challenged with titrations of HXR9 and CXR9 and LDH enzyme activity was measured in 
supernatants, indirectly reflecting cell survival. IC50s of HXR9 were then calculated using Calcusyn 
software. Graphs show the mean of three independent repeats that had R2 ≥ 0.95 where R2 = (0.956), 































































































































































































































































Cell Line Source IC50 of HXR9 (uM) SEM 
KG-1  
Primary AML patients 
4.6 +/- 0.322 
HEL 92.1.7 7.2 +/- 0.711 
HL-60 21.9 +/- 0.371 
KU812F  
Secondary AML patients 
9.6 +/ 1.676 
K562 11.4 +/- 0.267 
 
Table 6.1 A table listing the IC50 values for each of the five AML-derived cell lines that represent the 
mean IC50 of three experiments, conducted independently and their corresponding SEM. 
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6.3.2 HXR9 treatment affects downstream genes responsible for cell death 
in leukemic cell lines 
 
To analyse the effect HXR9 may have on downstream genes hypothesised in our proposed HXR9 
pathway, expression candidate genes was analysed in primary AML-derived cell lines HL60 and KG-
1 but also in the secondary AML-derived cell line K562, either challenged with titrations of HXR9 and 
its negative control CXR9 (Figure R6.2.1). HXR9 has an immediate effect on gene expression in genes 
analysed, varying between cell lines. HXR9 increases HOXA9 and PBX1 expression almost uniformly. 
Although HL60 expression was not what we had expected. This two-hour treatment with HXR9 resulted 
in a 1.93, 15.37, and 2.22-fold increase in c-Fos expression in KG-1, HL-60, and K562, respectively, 
compared to the negative control. A significant increase in both c-Fos, c-Jun and EGFR1 was noted 
especially in HL60 and K562 cells however virtually no, if any increased expression in either genes 
were noted in KG-1 cells. Interestingly, it was observed that none of the pro-apoptotic members of the 
Bcl-2 family including Bcl-XL, nor the anti-apoptotic member Bcl-2, which mediates mitochondrial 
cell death (Green and Kroemer, 2004), showed any transcriptional changes having been challenged with 
HXR9. The results obtained via qPCR on both HOXA9 and PBX1 were validated using western blotting 
which support the data with an increased expression of HOXA9 in all cell lines tested (Figure R6.2.2). 
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Figure R6.2.1 Gene expression of HOXA9, PBX1 and their downstream effector proteins in the primary 
leukaemic cell lines KG-1, HL60 and secondary leukaemic cell line K562 challenged with HXR9 and 
its control CXR9. Gene expression is represented by the ratio of the expression of genes to the 
housekeeping gene β-actin (×1000). The values of three separate experiments were plotted shown by 























































































































Protein Expression in AML Derived Cell Lines  




       
Figure R6.2.2 Western blot analysis of HOXA9 and PBX1 protein levels isolated from HL60, K562 and 
KG-1 cell line, where cell lines were challenged with titrations of HXR9 and CXR9, for two hours. 
   KG-1     HL60      K562 
 





6.3.3 HXR9 induced cell death is independent of apoptosis with no effect on 
caspase activity or the integrity of their nuclear membrane 
 
To gain a better understanding into the mechanism of cell death and to test the hypothesis, changes 
were assessed in caspase activity along with assessing nuclear morphology upon HXR9 treatment. KG-
1, K562 and HL-60 cells were pre-treated with or without the caspase inhibitor z-VAD-FMK using 
DNR (shown to activate caspases) as a positive control (Liu et al., 2002). Results showed that 50μM z-
VAD-FMK pre-treatment dramatically increased the percentage of viable cells in DNR-treated cells, p 
<0.0001, but saw no statistical difference in terms of the percentage of viable cells between z-VAD-
FMK non-treated or pre-treated cells. The percentage of viable cells was 64% and 63% for z-VAD-
FMK non- or pre-treated HL60 cells respectively and 65% and 61% for z-VAD-FMK non- or pre-
treated K562 cells respectively (Figure R6.3.1). 
When AML-derived cell lines were treated with the corresponding IC50s of HXR9, there were no 
significant changes to the nuclear morphology compared to the untreated cells in all cell lines (Figure 
R6.3.2). This suggests that HXR9-induces cell death in a nuclear fragmentation-independent pathway 
and therefore supports the hypothesis that HXR9 kills cells in a caspase-independent pathway.  
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Figure R6.3.1 The inhibition of caspase activity in HXR9 challenged AML cell lines KG-1, HL60 and 
K562 by the caspase inhibitor z-VAD-FMK. Cells were pre-treated either with/without 50μM z-VAD-
FMK for an hour, before the IC50, or 2xIC50 of HXR9 for two hours or with 17.5μM DNR for 24 hours, 
as a positive control. Data showed that there was no statistical difference in terms of sensitivity to 
HXR9 between pre-treated cells with or without 50μM z-VAD-FMK. The mean of three independent 
experiments are shown and error bars show the SEM in these graphs. *p< .05, **p < .01, ***p <.001 
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Changes in Cellular Morphology when Challenged with HXR9 
 
 
                                                                                                                           (scale 50m)  
Figure R6.3.2 DAPI staining of AML cell lines KG-1, HL60 and K562, upon HXR9 treatment. Cells 
were treated with the IC50 values of HXR9 for 2 hours. Cells were then harvested and fixed with 4% 
formaldehyde, and cytospan. Fixed cells were stained with DAPI for 5 minutes in the dark. Finally, 
stained cells were analysed by a fluorescent microscope at 20x magnification.  
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6.3.4 HXR9 treatment affects downstream genes responsible for cell death 
in patients of AML and other haematological disorders  
 
Gene expression was analysed in primary cells of healthy normal donors, MDS, AML or CML patients 
challenged with either titrations of HXR9 or its negative control CXR9 which did not have a functional 
domain for 2 hours, where n=3 plotted with error bars and each patient was analysed in three 
independent experiments (Figure R6.4). HXR9 has an immediate effect on gene expression in several 
genes analysed, which varies between cohorts. HXR9 increases HOXA9 and PBX1 expression almost 
uniformly throughout all groups, although this is seen more significantly in AML and MDS patients. A 
significant increase in both c-Fos, c-Jun and EGFR1 was noted especially in AML patients however 
there appeared virtually no expression of either genes in MDS patients. Antagonism of this HOX/PBX 
interaction has been seen to play a role in up-regulation in the expression of c-Fos in other cancers 
previously mentioned.  
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Gene Expression in Patients of AML and Other Haematological 




















































































































































































Figure R6.4 Gene expression of HOXA9, PBX1 and their downstream effector proteins in patients with 
acute myeloid leukaemia and other haematological disorders challenged with HXR9 and its control CXR9. 
Gene expression is represented by the ratio of the expression of genes to β-actin the housekeeping gene 
(×1000). The values of three separate patients were plotted shown by error bars where each patient 
was analysed in three independent experiments with the SEM for each patient used in this graph. *p< 




































































































































Here it has been confirmed that high expression of specific HOX genes could be used as a therapeutic 
target in AML and potentially in other haematological malignancies since targeting the HOX-PBX 
interaction with HXR9 causes significant cell death in our tested AML-derived cell lines (Figure R6.1). 
The IC50 of HXR9 for these treated AML cell lines ranged from 4.6μM to 21.9μM after treatment for 
two hours. The sensitivity of the tested cell lines to HXR9 can be directly correlated to the level of some 
HOX gene expression, for example, KG-1 cells that highly express HOXA5, HOXA6, HOXA9 and 
HOXA10 were most sensitive to HXR9 with an IC50 of 4.6μM after a two-hour treatment whereas HL-
60 cells, which show a global down-regulation of HOX genes were the least sensitive to HXR9, with 
an IC50 21.9μM after a two-hour treatment. However, there was very little difference in terms of HXR9 
sensitivity between the HEL92.1.7 cells derived from a primary AML patient and the KU812F and 
K562 cell lines, derived from CML patients in blast crisis (secondary AML) which may well be due to 
these cells expressing HOX genes at a much lower level.  Noticeably, the tested AML cell lines were 
far more sensitive to HXR9 than any of the other cell lines that were derived from solid malignancies 
e.g. melanoma, renal, ovarian and lung cancers (Shears, Plowright et al., 2008; Plowright, Harrington 
et al., 2009; Morgan, Plowright et al., 2010). This difference in sensitivity between AML cells and solid 
cancers may have something to do with the survival of AML cells depending on the HOX-PBX 
interaction, or because there is an abundance in expression of HOX genes in AML cells compared to 
solid cancers.  
Interestingly and most important to note, over recent years the expression of CD34 is thought to be a 
good marker of a poor prognosis, an adverse clinical course and a low CR rate of AML (Repp, Schaekel 
et al., 2003). Additionally, CD34
+ 
AML cells have been reported to be resistant to current 
chemotherapies, however CD34
+
 predicts high sensitivity to HXR9 since HOX genes are highly 
expressed in CD34
+ 
cells (Bailly, Muller et al. 1995; Bailly, Skladanowski et al., 1997). Gene 
expression profiling of these CD34
+ 
cells in some CML patients that are in a chronic phase has revealed 
a higher level of expression of HOXA9, suggesting that HXR9 could be used in combination with other 
 181 
drugs like imatinib, in first line treatment for CML, that target the BCR-ABL fusion protein (Diaz-
Blanco et al., 2007, Palandri et al., 2008, Hehlmann, 2012). As seen here, cell lines that express the 
BCR-ABL fusion like K562, are sensitive to HXR9. It has also been reported that BCR-ABL co-
operates with Nup98-HOX proteins that progresses to the ultimate phase of CML (blast crisis) (Mayotte 
et al., 2002, Ito et al., 2010, Di Giacomo et al., 2014). Sensitivity of Ph+ AML cells to HXR9 in recent 
studies also suggests that HXR9 could be used in a combination with imatinib to kill ALL cells that 
express both BCR-ABL fusion and HOX genes like HOXA9 (Redaelli et al., 2009).  
To determine what affect HXR9 has on the up-regulation of c-Fos and other important downstream 
genes in these AML-derived cell lines, the mRNA gene expression levels of important downstream 
genes were measured in untreated, CXR9 or HXR9 treated cells (Figure R6.2). HOXA9, PBX1, c-Fos, 
c-Jun, EGFR1, Bcl-Xl and Bcl-2 expression levels were measured under all 3 conditions, treated for 
two hours with the IC50 of HXR9 or equivalent concentrations of the negative control peptide CXR9 
which were 4.6μM, 7.2μM, 21.9μM, 9.6μM and 11.4μM for KG-1, HEL 92.1.7, HL-60, KU812F and 
K562, respectively (Table 6.1). This two-hour treatment with HXR9 resulted in a 1.93, 15.37, and 2.22-
fold increase in c-Fos expression in KG-1, HL-60, and K562, respectively, compared to untreated cells 





Figure 6.4 A schematic diagram depicting the current hypothesis of the interaction between the current 
DNR therapeutic and the newly discovered HXR9. DNR is a topoisomerase II inhibitor leading to the 
activation of the PKC/NF-kB survival pathway known for reducing necrosis by its ability to dampen c-
Fos activity. 
  
The primary hallmark of apoptosis is caspase activation; which was not found necessary in HXR9-
induced cell death (Figure R6.3.1). Recent data appears to be consistent with the likely mechanism of 
HXR9-induced cell death in renal cancer cell lines such as Caki-2 and 769-P, in malignant B cell lines 
and some prostate cell lines (Shears, Plowright et al., 2008; Daniels, Neacato et al., 2010; Morgan, 
Boxall et al., 2014). However, as seen here, the caspase inhibitor z-VAD-FMK had little or no 
significant effect on the viability of cells challenged with HXR9, nor did the integrity of the nuclear 
envelope change post treatment (Figure R6.3.2). The general inhibition of caspases in recent studies in 
other cancers has decreased the cytotoxicity of HXR9 on the tested renal, ovarian, breast and prostate 
cancer cell lines, although this decrease did not completely abrogate the effect of HXR9 (Shears, 
Plowright et al., 2008; Morgan, Plowright et al., 2010; Morgan, Boxall et al., 2014). The current 
hypothesis is that this may be due to the presence of other mediators of HXR9-induced cell death. 
Findings of recent studies also support this and suggest that mitochondrial apoptosis is not required for 
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HXR9-mediated cell death. The unchanged ratio found between the anti-apoptotic Bcl-2 and the pro-
apoptotic Bax and Bak1 (in previous studies) was supported here and could potentially reflect how 
intact the mitochondrial membranes is, as the presence of excess pro-apoptotic members of the Bcl-2 
family appears to enhance mitochondrial permeabilization (Martin et al., 2010). As we have mentioned, 
we observed that none of the pro-apoptotic members of the Bcl-2 family including Bcl-XL, nor the anti-
apoptotic member Bcl-2, which mediates mitochondrial cell death (Green and Kroemer, 2004), showed 
any major transcriptional changes having been treated with HXR9.  
This data ties in nicely with previous studies mentioned above that have also revealed that HXR9 did 
not cause transcriptional changes in the initiator caspase-9 and Apaf1 that together are known to form 
an apoptosome complex with cytochrome C (cyt C) which together start the intrinsic apoptosis pathway 
(Adrain and Martin, 2001). In addition to this, previous unpublished studies have shown that 
executioner caspases-3, -6 and -7, (key mediators of apoptosis) (Huerta et al., 2007) were not up-
regulated after HXR9 treatment. To summarise: HXR9 treatment of AML cells did not initiate nuclear 
fragmentation of apoptotic cells which results from the cleaving of the cytoskeletal protein lamin by 
caspase-3 or -6 (Kagawa, Go et al., 2001; Ruchaud, Korfali et al., 2002) suggesting an alternative to 
apoptosis. An alternative mode of cell death might explain the absence of nuclear fragmentation in 
HXR9-treated AML cell lines. These changes in nuclear morphology like chromatin condensation and 
nuclear fragmentation are important markers of late stage apoptosis (Collins et al., 1997, Ziegler and 
Groscurth, 2004, Huerta et al., 2007). The treatment of cells with HXR9 did not result in changes to the 
nuclear morphology after comparing these to untreated cells in all investigated cell lines. This suggests 
that HXR9-induces cell death in a nuclear fragmentation-independent pathway. The absence of 
apoptotic-hallmarks of activation, including caspase activation, Bcl-2 family involvement, chromatin 
condensation and nuclear fragmentation strongly suggests that HXR9 induces AML cell death via 
necrotic pathways.  
Analysing the effect HXR9 may have on primary cells and downstream genes involved in the proposed 
HXR9 pathway and the variation in these genes depending on the disease/progression of disease of the 
patient is of great importance. Gene expression was analysed in peripheral mononuclear cells of healthy 
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normal donors, MDS, AML or CML patients which were challenged with either HXR9 or the control 
CXR9 for 2 hours. HOXA9, PBX1, c-Fos, c-Jun, EGFR1, Bcl-Xl and Bcl-2 expression levels were 
measured under all 3 conditions, and it was very clear that the HXR9 peptide has an immediate effect 
on gene expression in many of these genes varies between cohorts. HXR9 increases HOXA9 and PBX1 
expression almost uniformly throughout all groups, although this is seen more significantly in AML 
and MDS patients (Figure R6.4). The significant increase in both c-Fos, c-Jun and EGFR1 was noted 
when challenged with HXR9 especially in AML patients however there appeared virtually no 
expression of either gene in MDS patients and suggests how effective this peptide may be in 
manipulating gene expression of crucial genes responsible for the progression of pathology. Most 
important seems to be c-Fos upregulation with the antagonism of this HOX/PBX interaction already 
highlighted as a key a role in up-regulation in the expression of c-Fos in other cancers and the induction 
of c-Fos expression by HXR9 thought to be responsible for initiating cell death in some human renal, 
lung, melanoma, ovarian, prostate and breast cancer cell lines (Morgan, Pirard et al., 2007; Shears, 
Plowright et al., 2008; Plowright, Harrington et al., 2009; Morgan, Plowright et al., 2010; Morgan, 
Boxall et al., 2012; Morgan, Boxall et al., 2014). Interestingly, it was observed that none of the pro-
apoptotic members of the Bcl-2 family including Bcl-XL, nor the anti-apoptotic member Bcl-2, 
responsible for the mediation of mitochondrial cell death (Green and Kroemer 2004), showed any 
transcriptional changes having been treated with HXR9. If this is the case, and taking into consideration 
that in AML-derived cell lines, it has already been shown (as have others) that apoptosis may not be 
the primary mode of cell death, then how might c-Fos play a role, in the progression to various forms 
of cell death other than by apoptosis? 
Future work aiming to look into the mitochondrial release of cyt C and analyse if this would ultimately 
lead to caspase activation would be of great benefit to this area of research. In addition to this, the 
cleavage and activation of Bid that is known to mediate mitochondrial apoptosis depends on the 
activation of caspase-8, which was not required for HXR9 cytotoxicity. HXR9 seems to induce cell 
death in a Bax- independent process, since Bax-dependent apoptosis involves either caspase-9 or p53 
activity, neither of which was needed for HXR9 mediated-cell killing (Janssen et al., 2007, Gogada et 
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al., 2011, Meng et al., 2012). CypD knockout studies over the last few years have demonstrated its 
crucial role in mitochondrial necrosis by Ca
2+ 
overload and oxidative stress, however it is not required 
for apoptosis (Li, Johnson et al., 2004; Baines, Kaiser et al., 2005; Nakagawa, Shimizu et al., 2005; 
Schinzel, Takeuchi et al., 2005). In addition, CypD is involved in Ca
2+
-independent, RIP3- and p53-
dependent mPTP necrosis (Lerch, Halangk et al., 2013; Tian, Xu et al., 2013; Pei, Shang et al., 2014). 
Accordingly, HXR9 might be a key regulator in mediating necrosis of AML in an mPTP-independent 
pathway, or at least via a CypD-independent mechanism. Recently published was data suggesting 
similarly that HXR9 leads to cell death through a necrotic pathway, at least in part, through RIP1 in 
HL-60 cells, however K562 cell death was RIP1-independent (Alharbi et al., 2017). It is possible 
however, that the effect of blocking RIP1 HXR9-induced HL-60 cell death may reflect a sub-effective 
dose of the RIP1 inhibitor, because Nec-1 has shown some toxic effects at higher doses. The latter is a 
good explanation that seems consistent with the fact that Nec-1 partially protected HL-60 cells from 
HXR9. On the other hand, some mediators in addition to RIP1 may be required in HXR9-induced cell 
death. It is important to note that a RIP1-independent cell death pathway does not rule out a potential 
role for necroptosis since it was reported that viral infection resulted in RIP3-dependent but RIP1-
independent necroptosis through TNF mediated necroptosis (Zhang, Shao et al., 2009; Upton, Kaiser 
et al., 2010), suggesting that the role of RIP3 in HXR9-induced K562 cell death requires further 
investigation and draws a very strong link between HXR9 and necroptosis. 
Looking closely into some of the downstream pathways strongly related to cell death ought to help 
understand the mechanism of actions involved when cells are challenged with HXR9. It has been 
recently suggested that the presence of ATP may also be crucial for caspase-dependent apoptosis as 
recent studies have suggested, but also for PARP1 hyper activation. In cases of caspase-dependent 
apoptosis, ATP involvement can be seen in the formation of the apoptosome complex. This apoptosome 
complex mediates apoptotic signalling by cleaving and activating various executioner caspases (Jochen, 
Richter et al., 2002). It has been reported that ATP depletion by fructose in some primary rat and mouse 
hepatocytes inhibits cyt C release and the activation of executioner caspases along with DNA 
fragmentation by TNF-mediated apoptosis as well this, these events were restored after ATP repletion 
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(Latta et al., 2000). Not only this but it is well established that ATP is essential for chromatin 
condensation and nuclear fragmentation (Tsujimoto, 1997). ATP depletion by fructose has been shown 
to prevent caspase activation and subsequently shifts cell death in the direction of necrosis in leukaemic 
Jurkat and K562 cells (Leist, Single et al., 1999; Verrax, Dejeans et al., 2011). Similarly, PARP1 
requires ATP during the transfer of poly (ADP-ribose) from NAD
+ 
(Devalaraja-Narashimha and 
Padanilam et al., 2009; Ethier, Tardif et al., 2012). Together, the depletion of this ATP initiates the role 
of caspases and PARP1 hyper-activation in HXR9-induced cell death of AML cells. It is well 
understood that at extremely high concentrations, fructose may trap intracellular ATP and maintain 
sufficient cytoplasmic concentrations that prevents cell necrosis (Latta et al., 2000, Latta et al., 2007, 
Speicher et al., 2012). The results of recent work like this has revealed that ATP depletion by a high 
concentration of fructose is unable to prevent HXR9-induced necrotic death on tested AML cells. This 
also supports a caspase- and PARP1- independent mechanism for HXR9-induced cell death.  
Despite a critical role in TNF-induced necrosis, PARP1 has been shown in TNF-mediating necroptosis 
(Xu et al., 2006). For this reason, TNF may activate necroptosis and necrosis in specific pathways, 
relevant to the results, although PARP1 has also been shown to be a downstream effector of the 
necrosome in TRAIL-induced necroptosis (Jouan-Lanhouet et al., 2012). Although the JNK pathway 
is heavily involved in PARP1-induced necrosis, HXR9-induces necrosis of AML cells is JNK-
independent (Degterev et al., 2005, Xu et al., 2006, Jog et al., 2009, Éthier et al., 2012). PARP1 is a 
key player in mPTP, and results of this PARP1 activation have supported a mitochondria-independent 
pathway for HXR9-induced necrosis (Abramov and Duchen, 2008) supporting the findings and 
highlights again that necrosis (necroptosis) is most likely the mode of cell death in this pathway. Further 
downstream of this however, the MAPK family of protein kinases is vital in a lot of key cellular 
processes. This family consists of four members; ERK, p38, JNK and the mitogen activated protein 
kinase. MAPK proteins are known to regulate various cellular pathways as mentioned above, including 
cell survival, proliferation and cell death (Chen and Sommer, 2009). Importantly, the JNK pathway has 
been reported to be a firm inducer of clonal evolution of Fanconi anaemia to AML (Li et al., 2007) and 
a sustained activation of the JNK pathway with AKT/FOXO signalling has been shown to maintain 
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AML cells in an undifferentiated state (Sykes et al., 2011). Of interest here, in FL15.12 cells (a 
haemopoietic pro-B cell line), IL-3 promotes cell survival by phosphorylating BAD through the JNK 
signalling pathway (Yu et al., 2004). Since this discovery, co-inhibition of the TNF-JNK pathway has 
been shown to increase sensitivity of primary human AML cells in vitro to NF-ĸB inhibitors (Volk et 
al., 2014), not only this but the JNK pathway promotes proliferation and metastasis in several cancers 
including liver and skin (Chen et al., 2001, Bettermann et al., 2010, Ebelt et al., 2013).  
 
Figure 6.5 Activation of RIP1-mediated necroptosis which clearly shows HXR9 (peptide of interest) 
inhibiting the interaction of PBX and HOX before the complex translocates into the nucleus and inhibits 




To summarise high expression of HOX genes could form the basis of individualised medicine in AML 
and progressive pre-leukaemic malignancies by antagonising the interaction between HOXA9 and its 
co-factor PBX with the integration of a small cell-permeable peptide, HXR9 resulting in cell death. A 
strong link between the susceptibility of the tested AML cell lines to HXR9 and their potential 
correlation with their expression levels of HOXA9 has also been seen. The most susceptible cell line 
KG-1 has been shown to highly express a set of HOX genes of great importance, while HL-60 has 
showed very low HOXA9 gene expression and has the lowest susceptibility to HXR9 as expected other 
than in a few experiments which go against previous literature. Although we have thoroughly analysed 
this discrepancy, further analysis should be undergone in the future to explore why this is the case.  
Finally, cell death was analysed and hypothesised by assessing changes in various cellular 
compartments after HXR9 treatment. The most obvious method of cell death in AML-derived cell lines 
would, on the above data, appear to through an apoptosis-independent pathway that involves 
programmed necrosis. Nuclear morphology was assessed using DAPI staining, with the only although 
significant limitation of this assay being the lack of a positive control for nuclear fragmentation. As 
mentioned already, the cytosolic changes have been previously studied by analysing changes in 
different proteins including the pro-apoptotic member of the Bcl-2 family, XIAP, Apaf1 and caspase 
activation. Over recent months, more studies have emerged that suggest the most obvious method of 
cell death in AML-derived cell lines is through an apoptosis-independent pathway that involves 
programmed necrosis and the results of this study support this theory. This is newly termed necroptosis. 
These in vitro results show that the HOX-PBX dimer in theory could be a potential therapeutic target 
in a subset of AML that over-express HOX genes. The comprehensive analysis of the mechanism of 
HXR9 cytotoxicity would guide us in the selection of the potential combination drugs. For example, 
avoiding agents that cause NOX, CaM, PKC activation ought to be avoided if possible. However, a 
proper in vivo systemic model should be used in future studies to assess the in vivo efficacy of HXR9 
cytotoxicity, as well as conducting more in vitro assays to investigate the mechanism of HXR9 to 
choose potential synergistic agents.  
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7.1 Discussion  
Microarray analysis has Acute myeloid leukaemia is well known as the most frequent acute leukaemia 
that affects adult patients around the globe. Generally, AML can be classified cytogenetically according 
to cell karyotypes in three main prognostic groups: which includes favourable prognostic groups 
t(8;21), inv(16) and t(15;17), adverse prognostic groups like complex karyotypes, trisomy 8 and CML-
blast crisis, and also in an intermediate prognostic group that includes other abnormalities but also NK-
AML (Roche et al., 2004). Noticeably, 50% of all AML cases exhibit normal karyotypes (Marcucci, 
Mrozek et al., 2005). The most standard treatment for any of these prognostic groups has not changed 
dramatically over the last few decades, other than for APML until the last few years. Current induction 
therapy is a combination therapy which consists of DNR for 3 days followed by cytarabine for a week. 
This treatment is termed the ''3+7 regimen''. This is strategic and usually achieves 72%-76% CR in 
young (< 60 years), and just over half (51%) CR in older patients. It seems very plausible then that a 
post-induction or consolidation regimen that consists of a high cytarabine dose or an allogeneic 
transplantation could significantly improve the outcome of these AML patients. However, 
unfortunately, the outcome is heterogonous and many of these patients relapse and die even if they have 
achieved clinical CR (Burnett, 2012; Patel and Levine, 2012). The significant heterogeneity in 
outcomes of these AML patients could be caused by various other factors. It would be important firstly, 
for us to address the current CR criteria, which as we know can be very broad, is very much dependent 
on a microscopic count of blast cells in the bone marrow and using this to determine whether these 
patients’ make-up the 5% of the cell population which has not changed measurably since 1956 
(Hourigan and Karp, 2013). Evidently this is a massive limitation and it is a hindrance that could be 
easily overcome by including the detection of AML-specific molecular stable targets such as HOXA9 
and various other biomarkers using some of the findings addressed in this study like PCR or flow 
cytometry in CR criteria. The detection of AML cells post chemotherapy, which are at levels under the 
sensitivity of microscopic detection have been coined minimal residual disease (MRD) (Ossenkoppele 
and Schuurhuis, 2013). There is a very low specificity of the current treatment regimen which is well 
known to play a large role in the heterogeneity of response. In overcoming this limitation, AML patients 
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may now be treated with drugs that are a lot more gene or cell specific as suggested here with HXR9. 
Finally, the heterogeneity of some AML cells in respect to treatment sensitivity can be of huge 
importance, and as we have seen, favourable prognostic groups often appear to respond better than poor 
prognostic groups to current therapeutics and chemotherapy.  
To date, current evaluation of relapse risk in AML, apart from APML patients, is based around the 
average clinical results of some large historical populations that have had the same pre-treatment, 
chromosomal and molecular abnormalities at the time of presentation (Mrózek et al., 2012, O'Donnell 
et al., 2012). However, this analytical assessment can lack evaluation and induction treatment efficiency 
due to patient-individualised-evaluation. There is no doubt however that this could be massively 
improved by including MRD detection with the ability to improve decisions when deciding on the most-
suitable post-induction treatment available. MRD is currently well known and is applicable in some 
cases for example in CML, where it can be used to detect BCR-ABL fusion proteins that present in 
virtually all CML cases (Cross et al., 2012, O'hare et al., 2012). Recently it has been shown that 
detection of the NPM1
mut 
MRD preceded haematological relapse by almost 8-9 weeks (Schnittger et 
al., 2009). Interestingly, therapeutic intervention often used after the detection of a molecular relapse 
by MRD is known and shown to significantly improve clinical outcomes (Rubnitz et al., 2010, Inaba et 
al., 2012). It is therefore of huge significance for us to bear in mind that HOX gene over-expression is 
quite common in many AML subtypes, now strongly associated with a poor prognosis as previously 
mentioned in the introduction, thus clearing potential targets in MRD as we have discussed with 
HOXA9. Future studies aimed at detecting which AML subtypes are more sensitive to HOX over-
expression in a larger widespread study ought to highlight the relationship between the various subtypes 
of AML and HOX genes like HOXA9. 
The heterogeneity of AML has been underpinned by the presence of various cytogenetic abnormalities 
in over half of AML cases that include numerical aberrations, structural aberrations and balanced 
translocations (Buccisano et al., 2012). Some studies have revealed a diversity of molecular markers 
that may be further sub-classified in many NK-AML patients (Marcucci, Mrozek et al., 2005) and more 
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recent discoveries of molecular markers in NK-AML strengthens the hypothesis that leukaemogenesis 
may result from an interaction of many mutations leading to either an increase in cell proliferation (class 
I mutations) or the block of cell differentiation (class II mutations), ultimately leading to AML (Döhner 
and Döhner, 2008b, Renneville et al., 2009, Betz and Hess, 2010). The ever advancing and ever-
increasing molecular understanding of diseases like AML will be extremely valuable, including further 
sub-classification of disease and being able to develop a more personal prognostic prediction that will 
hopefully form the cornerstone for future therapeutic procedures. The current literature seems to suggest 
that using all-trans retinoic acid (ATRA) is the only widely used molecularly targeted therapy in AML 
in the treatment of APML. APML is characterised by the presence of t(15;17)/PML-RARA. It is only 
by having a better understanding of this molecular mechanism, signalling pathways and co-operating 
mutations could now pave the way for new potential molecular drugs that will lead to more personalised 
treatment for patients of AML and pre-leukaemic malignancies in the future. 
Recently in-depth analysis of AML subtypes suggests that HOX genes can be one of the common 
denominators of a lot of the different cytogenetic and molecular aberrations involved in AML, however 
does this hold true for haematological malignancies that develop into AML? As we know, HOX gene 
over-expression has been universally reported in AML with chromosomal rearrangement that include 
MLL fusion proteins and an MYST3-CREBBP translocation (Ayton and Cleary, 2003, Camós et al., 
2006, Slany, 2009). The MLL fusion protein has been found to function in AML by collaborating with 
signal transduction protein pathways like Ras that are responsible for driving an over-expression of 
HOXA9 and activate Raf (Ono et al., 2009). HOX proteins also form fusion proteins with the NUP98 
protein and go on to mediate AML formation in combination with FLT3 (Borrow et al., 1996, Nakamura 
et al., 1996, Raza-Egilmez et al., 1998, Kroon et al., 1998, Fujino et al., 2002, Suzuki et al., 2002, 
Taketani et al., 2002b, Pineault et al., 2004, Palmqvist et al., 2006). In addition to this, the NUP98-
HOXA9 protein has been strongly linked with KRAS and Wilms' tumour gene 1 mutations (Chou et al., 
2009). HOX genes are regulated by the Cdx family in AML (Bansal et al., 2006, Thoene et al., 2008), 
with some gene profiling studies having shown strong association between FLT3 mutations and the 
HOX genes investigated in this study (HOXA7, HOXA9 and HOXA10 expression) (Roche et al., 2004, 
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Eklund, 2007). Over-expression of some of these HOX genes has also been seen in the presence of 
NPM1 mutations (Mullighan et al., 2007, Vassiliou et al., 2011). All-in-all, these studies point at HOX 
genes being key novel targets for molecular targeted therapies in various AML subtypes.  
In summary, our in vitro results have shown that the HOX-PBX dimer may be very useful when looking 
at potential therapeutic targets in subsets of AML and pre-leukaemic malignancies that over-express 
HOX genes and HOXA9 which would help the development of personalised medicine for patients 
suffering from AML diseases in the future. A more comprehensive analysis of the mechanism of action 
around HXR9 cytotoxicity may guide us in the selection of new potential combination drugs attempted 
here. Based on results and previous studies on the subject, perhaps some agents that cause NOX, CaM, 
PKC activation ought to be completely avoided with a more robust in vivo systemic model to be used 
in future, to assess in vivo efficacy of HXR9 cytotoxicity, as well as conducting significantly more in-
vitro assays that may further investigate the mechanism of HXR9. Combination therapy is becoming 
increasingly important in cancer treatment. These findings along with other studies reveal that HXR9 
could trigger necrosis of K562 and KU812F cells that express the BCR-ABL fusion protein; and HL-
60 that expresses PML-RARA. It is therefore extremely desirable in the future to assess some of these 
combination therapies with HXR9 and some other first line treatment drugs like imatinib and ATRA 
that are known to already target BCR-ABL and PML-RARA fusion proteins, respectively for not only 
patients of AML but CML as well.  
It would be logical that the resistance to cell killing by HXR9 may involve some anti-necrotic proteins, 
meaning that agents targeting these proteins are potential synergistic agents to HXR9. For example, 
tamoxifen and trifluoperazine, CaM antagonists, could also be used in combination with HXR9 (Ahn, 
Pan et al. 2003; Wang, Li et al. 2010). Equally, enzastaurin which was previously known to inhibit 
PKC activity and increase p21 levels in multiple myeloma cells may also have some potential 
synergistic effects with HXR9 (Raab, Breitkreutz et al. 2009). Arsenic trioxide has been shown in recent 
years to exert its cytotoxicity by inhibiting the JNK pathway and therefore increasing the activity of our 
gene of interest, c-Fos and the p21 protein which will also be valuable in assessing its combinatory 
effect with HXR9 (Huang et al., 2012, Liu et al., 2009). The recently suggested hypothesis of silencing 
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c-FLIP in combination with HXR9 treatment could also be an interesting combination, since c-FLIP is 
negatively regulated by c-Fos (Zhang, Zhang et al., 2007). In addition to this c-FLIP is a known 
downstream effector for CaM and PKC (Hwang et al., 2009, Kaunisto et al., 2009), thought to also 
inhibit apoptosis and/or necrosis by suppressing procaspase-8 and RIP1, respectively (Day, Huang et 
al. 2008; Wang, Du et al. 2008; He and He 2013).  
The mechanism of cell death by HXR9 of course requires further investigation in the future. A better 
understanding of how RIP1 activity may cause c-Fos over-expression after HXR9 treatment in HL-60 
cells for example may help, and the upstream regulators of c-Fos along with downstream effectors of 
RIP1 (like apoptosis signal-regulating kinase 1) could be involved in this mechanism (Liu, Nishitoh et 
al. 2000; Vanlangenakker, Vanden Berghe et al. 2012). Some of these investigations may also include 
c-Fos upstream regulators, with c-Fos related kinase or ribosomal S6 kinase 2 for example (Zhang, 
Zhang et al. 2007). Notably, p21 downstream effectors could also be examined. It is essential to 
highlight how important it is to assess the role of RIP3 in HXR9 cytotoxicity if necroptosis is involved, 
at least in HL-60 cells. AML cells may be co-cultured in direct or indirect contact with the stromal cells 
like human MS-5 cells to evaluate the influence of stromal cells and the secretome in the efficacy of 
HXR9. A systemic in vivo model is needed in the future however, to be able to assess the efficacy of 
HXR9 on AML disease. Recently, nude mice strains have been used, although growth rate was low, 
likely due to immune activity. Additionally, previous C57BL/6 and SCID flank models did not 
represent AML disease. For this reason, it is important to try and establish a systemic in vivo model in 
other mouse-mouse strains including NOG or NOD, known as the most common AML models, 
characterised by a lack of T and B lymphocytes, some impaired NK cells and antigen-presenting cells 




Figure 7.1: HOX protein such as HOXA6, HOXA7, HOXA9, HOXC9 and HOXD9 have been linked to 
increased proliferation rates as well as increased migration and invasion potentials. HXR9 is able to 
block HOX-PBX dimers, which in turn suppresses proliferation and invasion/migration.  
 
HOX genes have been shown to influence a variety of cellular functions including cell migration and 
proliferation in both normal and malignant cells (Morgan, 2014; Breau 2013). Our findings demonstrate 
that HXR9 has anti-proliferative and anti- migratory effects. As HXR9 targets multiple HOX and PBX 
proteins, it is not possible to establish which specific set or sets of HOX-PBX dimers are required for 
these activities, although the high level of functional redundancy amongst HOX proteins would indicate 
that a broad disruption of dimer formation is necessary. However, previous studies have shown that loss 
of HOXD9 expression reduces cellular proliferation, while suppression of HOXD10 causes an increase 
in invasion and migration (Tabuse, 2011). In addition, HOX genes HOXA6 and HOXA9 have been 
linked to increased invasion and migration, and HOXA7, HOXA9 and HOXC9 are all implicated in 
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cellular proliferation (Figure 7.1). Notably these are all targetable by HXR9 therapy. Further 
assessments of the mechanism behind HXR9’s anti- proliferative and migratory abilities are to be 
explored but the broad suppressive effects of HXR9 on HOX proteins, as well as their inherent 
functional redundancies, seriously hamper the likeliness of success.  
Investigations into HXR9’s anti-invasion potential resulted in a less than satisfactory outcome. This 
came as a surprise as HOX proteins have been implicated in the regulation of various MMPs. A potential 
explanation for this result is the short half-life HXR9. HXR9’s half-life in serum has been calculated to 
be 12 hours (Morgan, 2007). Though it must be noted that HXR9 incubated with cells will be actively 
ubiquitinated and degraded. Thus, the half-life on cells will be low. With this in mind the 12 hour time 
point for the migration assay will provide positive results as by the assay end point is reached less 
HXR9 would be degraded compared to invasion assay, 24 hours, which would have almost no HXR9 
left. This would mean that once HXR9 had been degraded, HOX suppression would be lowed allowing 
for cells to invade. Potential adding a second IC25 dose of HXR9 at the 12-hour time point for invasion 
assay might have resulted in more positive outcome, and is currently under investigation.  
HXR9 treatment was shown to induce expression of cleaved caspase 3, C-Fos and DUSP1 in parental 
and CSC tumours. This indicates that HXR9 induces apoptosis though caspase 3 activation, like that 
seen in vitro. In addition to this, results showed that C-Fos, DUSP1 and cleaved caspase 3 staining all 
correlated. This provided a strong indicator that the 3 aforementioned stains are interconnected, and 
that C-Fos and DUSP1 could have either a joint or apposing apoptotic effect on HXR9 treated cells 





Figure 7.2: HXR9 treatment causes an increase in C-Fos and DUSP1 protein levels. C-Fos and DUSP1 
activation and or suppression of caspase 3 ensue. In addition to this, C-Fos and DUSP1 transactivation 
and suppression is also possible.  
 
7.2 Future work 
This study has provided additional knowledge of HOX and TALE expression in healthy and malignant 
brains in adults and children. It has also proven that these interactions can be inhibited with potent 
cytostatic and cytotoxic results. However, there are still areas surrounding the body of work presented 
here which needs further investigating. Here we outline proposed future short- and long-term objectives 
we have currently set out to complete  
A major benefit of ICT9119 treatment over HXR9 and HTL00-1 is its increased half-life and thus 
sustained reactivity. The addition of amino acids to HXR9 and HTL00-1 can help increase the half-life, 
but cannot be larger enough to hinder peptide binding. Using the half-life prediction software ProtParam 
(Wilkins, 1999), which predicts that in mammalian cells, HXR9 and HTL00-1 have half-life’s of 2.8 
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hours. To improve this, we are currently trialling the use of a proline added to the N- terminus of HXR9 
and HTL00-1. This theoretically should increase peptide half- life to >20 hours. Initial results have 
shown no change in cytotoxicity with the added proline, with additional experiments using mass 
spectrometry planned.  
 
Figure 1.33 Unhindered HOX-PBX dimers are able to translocate and enter the nucleus, thus 
transcribing and repressing their target genes. Potential repressor targets are DUSP1, ATF3 and C-
Fos. HXR9 mediated inhibition of HOX-PBX causes an increase in DUSP1, ATF3 and C-Fos 
expression. The current consensus is that increased C-Fos protein levels activate Fas ligand (FasL) 
transcription. FasL protein in turn binds and activates Fas receptor (FasR) triggering the extrinsic 
apoptosis pathway. ATF blocks ubiquitination of p53, which promotes mitochondria mediated 
apoptosis and blocks proliferation through cell cycle arrest. DUSP1 dephosphorylates MEK and ERK, 
causing a loss of RAS mediated signalling (Morgan, 2017).  
 199 
The use of an additional N-terminus proline reduces proteasome activity. This again is seen as an 
important area of research. We currently plan on using proteasome activity assay that utilise 
fluorescently tagged peptides to see is peptide sensitivity correlated with proteasome activity. If positive 
results are obtained, the use of proteasome inhibitors in combination with HXR9 and HTL00- 1 will be 
explored. The importance of DUSP and MAPK activity in response to ICT9119 and RT treatment has 
been previously discussed in Chapter 5 Discussion. We plan to experimental test our hypothesis that 
DUSP1 and MAPK activity influences potential synergy of HOX-PBX inhibits with RT. This will be 
achieved with various knockdown and overexpression assays in combination with RT and ICT9119 
treatments. We also plan to explore the use of DUSP inhibitors with ICT9119-RT to rescue potential 
synergy between treatments in this sequence. Though HXR9 and HTL00-1 has been shown to have an 
identical death pathway to ICT919, their potential to replace ICT9119 in synergy treatments is 
questionable. This is mainly due to their shorter half-life, and the ability of ionising radiation to target 
and degrade them. Nonetheless additional therapeutic combination assays are planned to include HOX-
PBX inhibitors with TMZ. This will be evaluated both in vitro and in vivo.  
Work in this study has proved that CSCs express elevated levels of HOX and TALE genes compared 
to parental cells. This elevated expression equates to an increase in sensitivity to HOX-PBX inhibition. 
It must be noted that these CSC are enriched using growth factors and represent a unique type of GBM 
CSC. Hypoxic induced CSC’s express different genes compared to their growth factor counterparts, 
and also behave differently. We envision the use of a hypoxic chamber to enrich parental cell lines for 
hypoxic induced CSCs. We then plan to full HOX and TALE prolife to be able to compare their 
expression pattern to both parental and growth factor induced CSCs. These hypoxic CSCs will also be 
assessed for sensitivity to HOX-PBX inhibitors and compare results to that obtained from parental and 
growth factor CSCs.  
Peptide based therapies contain unique properties as they are based from naturally occurring molecules. 
These properties include high target specificity, low off-site binding, low toxicities and targeted 
degradation by proteasomes. As previously described the latter point means that half-life of peptide 
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therapies is low than that seen from inorganic compounds. This can be overcome by peptide 
modifications, modulation of the cell’s proteasome activity, or by providing patient’s with multiple 
drug doses. We propose that viral based drug delivery could provide a more enticing opportunity. The 
use of a virus such, as herpes simplex virus (HSV), can be genetically manipulated with exogenous 
genes inserted. This allows for a gene encoding HXR9 or HTL00-1 to be inserted into a virus. Once the 
virus enters the cancer cell, it shuts down cellular process, and ‘hijacks’ them for the production of new 
viral components. Once these are produced, the newly inserted HXR9 and HTL00-1 gene will be 
transcribed and translated. This thus allows newly formed peptides to target HOX-PBX dimers, causing 
cellular death (Figure 7.1).  
 
 
Figure 7.1: Genes encoding HXR9 or HTL00-1 can be inserted in virus vectors such as HSV. These 
modified viruses can then be used to transfect neoplastic cells. Once inside host cells, viruses utilised 
host’s cellular machinery to transcribe viral genes. HXR9/HTL00-1 molecule will be transcribed and 
translated, and then go on to target HOX-PBX dimers. If viral particles are able to full replicate before 
host cell death, they will be released and allowed to infect neighbouring cells.  
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HXR9 and HTL00-1 are encoded by relatively small gene allowing for individual viruses to be able to 
contain thousands and possible millions of copy numbers. Furthermore, it is possible to insert HXR9 or 
HTL00-1 genes into late cycle gene loci, allowing for virus particles to be able to fully replicate before 
transcribing peptide drugs. This would have the added benefit of continuing the viral cycle, allowing 
new viral particles to infect neighbouring neoplastic cells. Thus, starting a new cycle replicating 
additional viral particles and peptide agents. This concept is still under review, with preliminary tests 
commencing in the near future.  
Finally, we are currently investigating HOX-PBX inhibitors immunogenicity and inflammatory 
potential. Preliminary results show that HOX-PBX inhibitors do not induce inflammatory markers such 
as calreticulin, Fas ligand, Heat shock protein- 70KDa (HSP-70), Programmed death-ligand 1 (PD-L1), 
Cluster of differentiation 80 (CD80) and Human leucocyte antigen (HLA). Though these results are not 
definitive, if correct it proves that HOX-PBX inhibitors are non-inflammatory. This is a highly revered 
characteristic in brain tumour research, due to the adverse effects of inflammation and oedema. 
Inflammation and oedema cause an elevation in intracranial pressure of the brain, potential resulting in 
loss of cognitive functions, and even death. In addition to this, oedema causes an increase in hydrostatic 
pressure of the tumour causing an increase in drug efflux from the tumour site. These positive 
preliminary results are currently being followed up with additional in vitro experiments, with in vivo 
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Protoporphyrin IX  Sigma (Dorset, UK)  
 
Carestream® Kodak BioMax® light film  
Fixer and replenisher  
Developer and replenisher  
Cloned AMV first-strand synthesis kit  Invitrogen, Thermoscientific (Paisley, UK)  
 Glutamine  
FBS  
IMDM medium  
NuPAGE® LDS sample buffer  
BenchmarkTM prestained protein ladder  
NuPAGE novex 12% Bis Tris  
DMSO  
Pierce® RIPA buffer 
Protease inhibitor cocktail  
NuPAGE® sample reducing agent  
NuPAGE® MES SDS running buffer  
InvitrolonTM PVDF filter paper sandwich  
Novex cryoTubeTM vials  
SuperSignal® West Pico Chemiluminescent substrate  
Cytotoxicity detection kit  Roche (Mannheim, Germany)  
RNeasy mini kit and RBC lysis solution  Qiagen (West Sussex, UK)  
Gene Primers  Eurgentec (Seraing, Belgium)  
Mycoplasma detection kit  Lonza (Slough, UK)  
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Table A1: A table listing reagents that were used in this study and their suppliers. 
  
Reagent Supplier 
SYBR® green jumpstatTM Taq ready mixTM  Sigma (Dorset, UK)  
 Penicillin-streptomycin  
μI-1640  
DMEM  
Trypan blue  
HBSS 
Histopaque®-1077 Hybri-Max  
β-mercaptoethanol  





Media and Supplements Abbreviation Supplier 
Minimal Essential Medium Eagle (With Earle’s 
salts, non-essential amino acids and sodium 
bicarbonate) 
MEME Sigma-Aldrich 
Dulbecco's Modified Eagle's Medium (With 4500 
mg L-glucose, 110 mg L-sogium pyruvate, 
pyridoxine hydrochloride and sodium bicarbonate) 
DMEM Sigma-Aldrich 
RPMI-1640 Medium RPMI Sigma-Aldrich 
Foetal Bovine Serum  FBS Gibco 
Penicillin-Streptomycin (10,000 units of penicillin 
and 10 mg/ml streptomycin in 0.9% NACl) 
Pen/Strep Sigma-Aldrich 
L-Glutamine 200mM  L-Glu Sigma-Aldrich 
Minimal Essential Medium Non-Essential Amino 
Acids  
MEM NEAA Gibco 
Sodium Pyruvate 100mM NaP Sigma-Aldrich 
N-2 Supplement 100x N/A Gibco 
Heparin Salt Solution 0.2% Hep StemCell Technologies 
Epidermal Growth Factor 100μg EGF Invitrogen 
Basic Fibroblast Growth Factor 50μg bFGF Gibco 
Hanks Balanced Salt Solution HBSS Sigma-Aldrich 





RT-qPCR Primer Design, Sequences and Validation  
Forward and reverse primers were designed using the Primer3web software version 4.0 or Primer-
BLAST, both of which are web-based software. Primer sequences can be seen in Table A.3. The 
following parameters were used, when possible, to design primers:  
1. A PCR product size of between 100 to 400 base pairs  
2. A primer melting temperature between 55°C to 65°C  
3. Primers that span exon-exon junctions  
4. A primer length between 20 to 30 bases  
5. A primer with a GC% of >55%  
6. Self-complementarity between 2 to 6  
7. Self 3’ complementarity between 0 to 3  
All primers were purchased from Sigma-Aldrich, UK and were provided at a concentration of 100μM 
and desalted. Prior to delivery all primers are quality control checked by electrospray ionization mass 
spectrometry. Diluted and undiluted primers were stored at -20°C. All primers were assessed to prove 
single product amplification via melt curve analysis. In addition to this a ‘no template (cDNA) control’ 
was performed for all sets of primers to identify the possibility of primer dimer formation. Any primers 




Gene Target Forward and Reverse Primer Sequences  Supplier 
HOX A1 
U10421; 511 to 663; 153bp 
F: 5’ CTGGCCCTGGCTACGTATAA 3’ 
R: 5’ TCCAACTTTCCCTGTTTTGG 3’ 
 
Eurogentec, Belgium  
HOX A2 
NM_006735; 1027 to 1202; 176bp 
F: 5’ TTCAGCAAAATGCCCTCTCT 3’ 




NM_030661; 1525 to 1751; 227bp 
F: 5’ ACCTGTGATAGTGGGCTTGG 3’ 




NM_002141; 633 to 903; 271bp 
F: 5’ CCCTGGATGAAGAAGATCCA 3’ 




NM_019102; 796 to 988; 193bp 
F: 5’ CCGGAGAATGAAGTGGAAAA 3’ 




NM_024014; 361 to 518; 158bp 
F: 5’ AAAGCACTCCATGACGAAGG 3’ 




NM_006896; 38 to 322; 285bp 
F: 5’ TGGTGTAAATCTGGGGGTGT 3’ 
R: 5’ TCTGATAAAGGGGGCTGTTG 3’ 
 
Eurogentec, Belgium 
HOX A9 NM_152739; 653 to 855; 203bp 
F: 5’ AATAACCCAGCAGCCAACTG 3’ 





NM_018951; 1040 to 1198; 159bp 
F: 5’ ACACTGGAGCTGGAGAAGGA 3’ 




NM_005523; 800 to 1078; 279bp 
F: 5’ CGCTGCCCCTATACCAAGTA 3’ 




NM_000522; 1061 to 1236; 176bp 
F: 5’ GGATATCAGCCACGACGAAT 3’ 




NM_002144; 176 to 332; 157bp 
F: 5’ TTCAGCAGAACTCCGGCTAT 3’ 




NM_002145; 9 to 267; 259bp 
F: 5’ CTCCCAAAATCGCTCCATTA 3’ 




NM_002146; 1970 to 2268; 299bp 
F: 5’ TATGGCCTCAACCACCTTTC 3’ 




NM_024015; 593 to 747; 155bp 
F: 5’ TCTTGGAGCTGGAGAAGGAA 3’ 




NM_002147; 1543 to 1731; 189bp 
F: 5’ AAGGCCTGGTCTGGGAGTAT 3’ 





NM_156037; 151 to 334; 184bp 
F: 5’ ATTTCCTTCTGGCCCTCACT 3’ 
R: 5’ GGAAGGTGGAGTTCACGAAA 3’ 
Eurogentec, Belgium 
HOX B7 
NM_004502; 143 to 391; 249bp 
F: 5’ CAGCCTCAAGTTCGGTTTTC 3’ 
R: 5’ CGGAGAGGTTCTGCTCAAAG 3’ 
Eurogentec, Belgium 
HOX B8 
NM_024016; 964 to 1228; 265bp 
F: 5’ GTAGGCTTCAGCTGGGACTG 3’ 




NM_024017; 533 to 730; 198bp 
F: 5’ TAATCAAAGACCCGGCTACG 3’ 




NM_006361; 154 to 387; 234bp 
F: 5’ CTTGGATGGAGCCAAGGATA 3’ 




NM_014620; 1121 to 1396; 276bp 
F: 5’ CGCTCGAGGACAGCCTATAC 3’ 




NM_019953; 555 to 822; 268bp 
F: 5’ CAGTTACACGCGCTACCAGA 3’ 
R: 5’ AGAGAGGAAAGGCGAAAAGG 3’ 
Eurogentec, Belgium 
HOX C6 
NM_004503; 774 to 963; 190bp 
F: 5’ AAGAGGAAAAGCGGGAAGAG 3’ 




NM_022658; 390 to 539; 150bp 
F: 5’ CTCAGGCTACCAGCAGAACC 3’ 





NM_006897; 704 to 893; 190bp 
F: 5’ AGACGCTGGAACTGGAGAAG 3’ 




NM_017409; 982 to 1270; 289bp 
F: 5’ CGCCTGGAGATTAGCAAGAC 3’ 
R: 5’ GGTCCCTTGGAAGGAGAGTC 3’ 
Eurogentec, Belgium 
HOX C11 
NM_014212; 353 to 538; 186bp 
F: 5’ CGGAACAGCTACTCCTCCTG 3’ 




NM_173860; 654 to 833; 180bp 
F: 5’ CAAGCCCTATTCGAAGTTGC 3’ 




NM_017416; 1840 to 2009; 170bp 
F: 5’ GTGGAAATCCAAGGAGGACA 3’ 




NM_024501; 929 to 1160; 232bp 
F: 5’ TTCAGCACCAAGCAACTGAC 3’ 




NM_006898; 492 to 667; 176bp 
F: 5’ CAGCCTCCTGGTCTGAACTC 3’ 




NM_014621; 23 to 195; 173bp 
F: 5’ TCAAATGTGCCATAGCAAGC 3’ 
R: 5’ TCCATAGGGCCCTCCTACTT 3’ 
Eurogentec, Belgium 
HOX D8 
NM_019558; 1167 to 1456; 290bp 
F: 5’ TCAAATGTTTCCGTGGATGA 3’ 





NM_014213; 1803 to 2038; 236bp 
F: 5’ TCCCCCATGTTTCTGAAAAG 3’ 




NM_002148; 364 to 517; 154bp 
F: 5’ GCTCCTTCACCACCAACATT 3’ 
R: 5’ AAATATCCAGGGACGGGAAC 3’ 
Eurogentec, Belgium 
HOX D11 
NM_021192; 302 to 554; 253bp 
F: 5’ GGGGCTACGCTCCCTACTAC 3’ 




NM_021193; 113 to 313; 201bp 
F: 5’ CGCTTCCCCCTATCTCCTAC 3’ 




NM_000523; 868 to 1132; 265bp 
F: 5’ GGGGATGTGGCTCTAAATCA 3’ 
R: 5’ AACCTGGACCACATCAGGAG 3’ 
 
Eurogentec, Belgium 
β-Actin F: 5’ ATGTACCCTGGCATTGCCG 3’ 
R: 5’ GACTCGTCATACTCCTGCTTG 3’  
Sigma-Aldrich, UK 
Table A3: Forward and reverse primer sequences for all GoI quantified by RT-qPCR and their National 




Grouped HOXA9 Expression: 
 
 
Figure A1: Variation of HOXA9 expression in mononuclear cells isolated from the peripheral blood 
of patients of various hematological disorders grouped and shown as a ratio of beta-actin to the gene 
of interest signal (vertical axis) the expression of which is represented of the ratio of the expression of 
the gene of interest to the housekeeping gene to β-actin (×10 000). The variation of expression between 
patients is shown by error bars in this graph. *p< .05, **p < .01, ***p <.001 and ****p <.0001. 
 
E
T/
P
R
V
M
D
S
A
M
L
A
M
L 
R
em
 
C
M
L
0
1000
2000
3000
Patient Cohort
H
O
X
A
9
 E
x
p
re
s
s
io
n
(r
 r
a
ti
o
 x
 1
0
0
0
)
HOXA9 Expression
